Immediate (type-1) hypersensitivity and Haemophilus Somnus by Ruby, Kevin William
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1999
Immediate (type-1) hypersensitivity and
Haemophilus Somnus
Kevin William Ruby
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Immunology and Infectious Disease Commons, Medical Immunology Commons,
Microbiology Commons, and the Veterinary Medicine Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Ruby, Kevin William, "Immediate (type-1) hypersensitivity and Haemophilus Somnus " (1999). Retrospective Theses and Dissertations.
12479.
https://lib.dr.iastate.edu/rtd/12479
INFORMATION TO USERS 
This manuscript has been reproduced from the microfilm master. UMI films the 
text directly from the original or copy submitted. Thus, some thesis and 
dissertation copies are in typewriter face, while others may be from any type of 
computer printer. 
The quality of this reproduction is dependent upon the quality of the copy 
submitted. Broken or indistinct print, colored or poor quality illustrations and 
photographs, print bleedthrough, substandard margins, and improper alignment 
can adversely affect reproduction. 
In the unlikely event that the author did not send UMI a complete manuscript and 
there are missing pages, these will t)e noted. Also, if unauthorized copyright 
material had to be removed, a note will indicate the deletion. 
Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning 
the original, beginning at the upper left-hand comer and continuing from left to 
right in equal sections with small overiaps. 
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9° black and white photographic 
prints are available for any photographs or illustrations appearing in this copy for 
an additional charge. Contact UMI directiy to order. 
Bell & Howell Information and Leaming 
300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 
UIVQ 
800-521-0600 

Immediate (type-1) hypersensitivity and Haemophilus somtms 
by 
Kevin William Ruby 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
Major: Immunobiology 
Major Professor: Ronald W. Griffith 
Iowa State University 
Ames, Iowa 
1999 
Copyright © Kevin William Ruby, 1999. All rights reserved. 
UMI Number 9950115 
I® UMI 
UMI Microfomfi9950115 
Copyright 2000 by Bell & Howell Infomiation and Learning Company. 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code. 
Bell & Howell information and Learning Company 
300 North Zeeb Road 
P.O. 80x1346 
Ann AriDor, Ml 48106-1346 
ii 
Graduate College 
Iowa State University 
This is to certify that the doctoral dissertation of 
Kevin William Ruby 
has met the dissertation requirements of Iowa State University 
Major essor 
For the Major Program 
For the Graduate College 
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
iii 
TABLE OF CONTENTS 
ABSTRACT v 
CHAPTER L GENERAL INTRODUCTION 1 
Dissertation Organization 1 
Introduction 2 
Literature Review 4 
References 39 
CHAPTER 2. BOVINE TYPE-1 HYPERSENSmVITY I; 
HAEMOPHILUS SOMNUS 59 
Abstract 59 
Introduction 60 
Materials and Methods 60 
Results 67 
Discussion 68 
References 71 
CHAPTER 3. BOVINE HYPERSENSITIVITY H; ENHANCED TYPE-1 
HYPERSENSITIVITY WITH ANTIGEN SUSPENDED IN ALUMINUM 
HYDROXIDE ADJUVANT 78 
Abstract 78 
Introduction 79 
Materials and Methods 80 
Results 83 
Discussion 84 
References 85 
CHAPTER 4. HAEMOPHILUS SOMNUS-INDUCED IgE IN CALVES 
VACCINATED WITH COMMERCIAL MONOVALENT HAEMOPHILUS 
SOMNUS 88 
Abstract 88 
Introduction 89 
Materials and Methods 91 
Results 97 
Discussion 99 
References 102 
iv 
CHAPTER 5. VIRAL VACCINATION ALTERS PLASMA EICOSANOIDS IN 
CALVES PREVIOUSLY VACCINATEDWITH HAEMOPHILUS SOMNUS 
BACTERINS 121 
Abstract 121 
Introduction 122 
Materials and Methods 124 
Results 126 
Discussion 128 
References 135 
CHAPTER 6. HAEMOPHILUS SOMNUS BACTERINS AND BRSV VACCINE 
SYNERGIZE TO INCREASE PLASMA EICOSANOIDS ASSOCIATED WITH 
LATE-PHASE ALLERGIC REACTIONS 142 
Abstract 142 
Introduction 143 
Materials and Methods 144 
Results 147 
Discussion 150 
References 152 
CHAPTER 7. HISTAMINE PRODUCTION BY HAEMOPHILUS SOMNUS 159 
Abstract 159 
Introduction 160 
Materials and Methods 161 
Results 164 
Discussion 165 
References 168 
CHAPTER 8. GENERAL CONCLUSION 173 
General Discussion 173 
References 180 
ACKNOWLEDGEMENTS 183 
V 
ABSTRACT 
Induction of respiratory allergy has not been extensively studied in cattle. The 
potential for involvement of a type-1 hypersensitivity component in bovine respiratory disease 
caused by Haemophilus sommis was investigated. The hypothesis was that many of the acute, 
fatal pneumonias that develop in young calves may have a type-1 (immediate) hypersensitivity 
component and that vaccination with H. sotnmis and viral vaccines may contribute to 
respiratory disease. 
The first two studies were attempts to sensitize a small number of calves to various 
antigens. In the first study, calves were sensitized to and subsequently challenged with 
Micropolyspora faeni (positive control) and washed, live H. somnus organisms. Results of 
the first study indicated that 8-week-old Holstein calves had detectable levels of anti-M faeni 
IgG and no anti-//. somnus IgG. By the fourth week of sensitization, detectable levels of anti-
M faeni and anti-//. somnus IgE antibodies were noted in all calves, including non-sensitized 
controls. Highest anti-//. somnus lg£ antibody levels were noted in H. 5-o/nA?7/i-sensitized 
calves. Regardless of challenge, all calves exhibited mild tachypnea and dyspnea 0.5 h post-
challenge. Non-sensitized control calves continued to experience dyspnea for two days 
following an H. somnus challenge, but did not require intervention. The first study suggested 
that many nonvaccinated calves may have anti-//. somrms IgE antibodies. Micropolyspora 
faeni proved to be unsuitable as a positive control for immediate hypersensitivity. 
In the second study, calves were sensitized to and subsequently challenged with non­
viable antigens with and without aluminum hydroxide adjuvant. Calves immunized with 
ovalbumin suspended in 20% (v/v) aluminum hydroxide or H. somnus bacterins exhibited 
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dramatic clinical signs of anaphylaxis after a homologous intravenous challenge 7-10 days 
after the last immunization. Within 30 seconds of challenge with the homologous antigen, 
these calves collapsed and had an unsteady gait followed by tachypnea, abdominal bloating, 
excessive lacrimation and salivation, and were recumbent. Epinephrine and diphenhydramine 
effectively reversed the clinical signs. Intravenous sensitization with ovalbumin or equine sera 
produced mild clinical signs of anaphylaxis following intravenous challenge. Results of this 
study indicate that calves can become sensitized to non-viable antigen after a single exposure 
and that the presence of aluminum hydroxide may enhance this process Results suggest those 
H. somnus bacterins may be involved in allergic responses in vaccinated calves 
The next three studies utilized a large number of calves. The objective of the third 
study was to examine the ability of commercial H. somnus bacterins to induce an IgE response 
in calves. Groups of calves were vaccinated on Days 0 and 14 with one of four commercial 
monovalent H. somnus bacterins according to label recommendations. Commercial 
H. somnus bacterins apparently induce a significant IgE response that is detectable as early as 
14 days after the primary injection and as late as 45 days after the primary injection. This 
study also suggests that H. 5om//7/-v-specific IgE antibodies can be found in serum of some 
cattle, possibly induced by existing or previous sensitization. 
The objective of the fourth study was to quantitate various plasma eicosanoids 
associated with type-1 hypersensitivity induced by commercial H. somnus bacterins and 
bovine viral vaccines. Calves were vaccinated on Days 0 and 14 with one of four commercial 
H. somnus bacterins according to label recommendations. On Day 25 all calves, including 
controls, were vaccinated with a commercial modified live BRSV vaccine. Each of four 
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commercial H. sommis bacterins induced production of eicosanoids associated with 
bronchoconstriction (PGF,^ and TXB2,) and edema formation (6-k:etoPGF,(j and LTB^) 
detected as early as 14 days after the pnmar>' injection. Data also indicated that subsequent 
vaccination with modified live BRSV can alter these eicosanoid levels and white blood cell 
populations in calves previously vaccinated with H. sommis bacterins. 
The purpose of the fifth study was to examine the effect of allergen challenge in calves 
previously vaccinated with commercial H. sommis and BRSV vaccines Forty-five days after 
the initial H. sommis vaccination, calves were challenged by intratracheal injection with 
washed, live H. sommis organisms with or without modified live BRSV. Regardless of 
challenge, plasma concentrations of leukcrriene (LT) B^, LTC^, prostaglandin (PG) E,. and b-
ketoPGFjjj were significantly increased 15 minutes post-challenge. Significantly higher plasma 
thromboxane (Tx) B, concentrations were noted 15 minutes post-challenge with H. 
sc)mmis-rBRS\/ as compared with calves challenged with H. sommis alone. There were more 
calves that had tachypnea and dyspnea after challenge with H. sommis-^BKSW than after H. 
sommis challenge alone. Vaccination with H. sommis bacterins and modified live BRSV 
vaccines may adversely affect the calf by enhancing higher plasma concentrations of 
eicosanoids associated with development of a hypersensitized state and a late-phase asthmatic­
like bronchoconstriction. This was seen as early as 45 days after the primary H. sommis 
vaccination and 20 days after the BRSV vaccination. 
In the sixth study, isolates of H. sommis, Pasteiirella mvltocida. and various other 
bacterial cultures were examined for their ability to produce histamine. When grown in broth 
culture, nine of ten H. sommis isolates produced and secreted or released histamine in excess 
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of 35 ng/ml. Greater histamine production occurred at CO- concentrations of between 15% 
and 25% and varied with the length of incubation and strain. Other bacteria that had 
histamine levels in excess of 35 ng/ml included Bordetella hronchiseptica, Erysipeloihnx 
rhiisiopathiae. Salmonella diihlin, S. choleraesiiis. and S. typhimurlum. Production of 
histamine by H. sommis might contribute to inflammation, development of a type-1 
hypersensitivity, and airway hyperresponsiveness in bovine respiratory disease through 
interaction with histamine receptors and induction of IgE antibody 
1 
CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation begins with an abstract followed by a general introduction, six papers, 
and a general conclusion. The abstract provides a summary of the general objectives and 
conclusions. The general introduction includes the dissertation organization, an introduction, 
and a review of the literature. The literature review begins with bovine respiratory disease as 
a disease entity, the role of Haemophilus somttus in the BRDC, and mechanisms of 
pathogenicity. Next, a review of allergic reactions and immediate (type-1) hypersensitivity is 
presented covering the pathogenesis of immediate (type-1) hypersensitivity, regulation of IgE 
synthesis, mediators of allergy, and clinical manifestations of immediate hypersensitivities. 
The six papers are written in journal format for publication. The first two papers entitled 
"Bovine Type-1 Hypersensitivity I; Haemophilus somnu^'' and "Bovine Hypersensitivity II: 
Enhanced Type-1 Hypersensitivity With Antigen Suspended in Aluminum Hydroxide 
Adjuvant" have been submitted for publication in Comparative Immunology, Microbiology, 
and Infectious Diseases. The third paper entitled "Haemophilus 5om^7W5-specific IgE induced 
in calves vaccinated with commercial Haemophilus somnus bacterins" has been accepted for 
publication in Veterinary Microbiology. The fourth paper entitled "Viral Vaccination Alters 
Plasma Eicosanoids in Calves Previously vaccinated With Haemophilus somnus Bacterins" 
has been submitted for publication in the journal Biologicals. The fifth paper entitled 
"Haemophilus somnus bacterins and BRSV Vaccine Synergize to Increase Plasma 
Eicosanoids Associated With Late-Phase Allergic Reactions" has been submitted for 
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publication in the journal Vaccine. The sixth paper entitled "Histamine Production by 
Haemophilus sommt^'' has been submitted for publication in Veterinary Microbiology. 
The last chapter of the dissertation is a general discussion summarizing the results 
presented in the six papers and discusses conclusions drawn from them. A list of references 
cited is included at the end of each chapter. 
Introduction 
There is increasing concern that vaccination may trigger or exacerbate autoimmune 
diseases or allergies, especially in dogs and cats '. Vaccines may induce adverse reactions via 
hypersensitivity reactions (the focus of this research), induction of immunosuppression, and 
excessive induction of cytokine release for example. Allergic reactions due to type I 
hypersensitivity may occur as a result of the induction of IgE antibody to essentially any 
component of a vaccine ~ ^ including the disease agents themselves. For example, vaccination 
has been shown to augment production of IgE antibody to pollen in inbred atopic dogs "*• ^. 
These studies demonstrated that live attenuated distemper-hepatitis vaccine contributed to the 
development of ragweed pollen allergy in dogs. Immunization against bovine respiratory 
syncytial virus under experimental conditions was shown to induce IgE antibodies specific for 
BRSV which contributed to the development of clinical signs following aerosol challenge with 
BRSV ^. Various bacterial antigens have been shown to induce allergic responses '. 
Gershwin et al. demonstrated IgE antibodies specific for Micropolyspora faeni, and 
Mannheimia (Pasteurella) hemolytica " . 
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Bovine respiratory disease continues to be a major disease problem in all types of cattle 
operations . Although there are vaccines against many of the etiological agents, 
Haemophilus somrms biologicals have not always provided adequate protection against the 
pneumonic manifestation due to infection with this organism. Anecdotal evidence suggests 
that occasionally more severe clinical disease occurs in calves vaccinated wth H. somnus 
bacterins either alone or in combination with various viral vaccines. Vaccination with 
H. somnus bacterins in some cases may be contributory to the disease process in the lung. 
While the induction of respiratory allergy has not been extensively studied in cattle, it has 
received considerable attention in children and laboratory animals. The etiologic 
mechanism(s) is complex but centers on regulation of IgE production by T lymphocytes and 
various lymphokines " . Various intrinsic and extrinsic factors influence the T- cell regulatory 
process including genetic background, parasitism, viral infections and access to various 
allergens. Viruses are recognized for their role in affecting IgE immunoregulation . In 
children, measles virus, rhinoviruses, influenza virus as well as paramj^oviruses have been 
associated with asthmatic attacks . Viral infections can predispose to development of an 
allergic state and can exacerbate the clinical response to other allergens. Therefore, 
establishment of type-1 hypersensitivity to one allergen predisposes to induction of allergy to 
other agents. 
The basic objectives of this research were to induce type-1 hypersensitivity in calves to 
H. somnus and measure that response. Clinical signs (e.g., dyspnea, tachypnea, excessive 
lacrimation and salivation, abdominal bloating, unsteady gait, and collapse) were monitored as 
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physical measures of type-1 hypersensitivity reactions. Urinary, plasma, or serum 
concentrations of biochemical mediators of allergic hypersensitivity (e.g., IgE, eicosanoids, 
histamine, and serotonin) were also determined. Differential white blood cell counts were also 
determined. 
Literature Review 
Bovine Respiratory Disease 
The bovine respiratory disease has been extensively investigated. However, in spite of 
these studies, the pathogenesis and etiology is still poorly understood. Respiratory disease 
(also known as "shipping fever") is particularly prevalent after animals have been weaned, 
transported and placed in a feedlot. The economically important clinical signs, lesions, and 
death loss in shipping fever can usually be attributed to bacterial pneumonia, but efforts to 
reproduce the disease by challenge-exposure of normal cattle with bacterial agents alone have 
been unsuccessful. A broad spectrum of agents has been isolated and many of these cause 
only asymptomatic infections in the healthy, unstressed host. Experimental infections result in 
mild, transient signs of bovine respiratory disease at best. Most etiologic agents do not 
express their fiill virulence in the healthy calf unless other disease agents are actively involved. 
These observations have led to the concept that bovine respiratory disease has a multifactorial 
etiology involving a complex interaction between stressors and viruses predisposing to 
bacterial infection and fulminant disease . 
5 
Bacteria associated with bovine respiratory disease are frequently found colonizing the 
nasopharyngeal area of normal cattle, but are not found in the lower respiratory tract. 
Bacterial pneumonia in BRD is almost always due to one of only three species of bacteria; 
Mannheimia (Pasteurella) hemolytica, P. multocida^ or Haemophilus somnus. Colonization 
of the lungs by these bacteria can occur when stress or viral infection impair these clearance 
mechanisms suflBciently . 
Role of Haemophilus somnus in Bovine Respiratory Disease 
Haemophilus somnus is a gram-negative, nonmotile, nonsporeforming pleomorphic 
coccobacillus that causes thrombotic meningoencephalitis (TME), bronchopneumonia, 
polyarthritis, myocarditis, and reproductive disorders of cattle . Haemophilus somtms 
causes a septicemia in young calves and feedlot cattle. The resulting manifestations of disease 
have been referred to as '''^Haemophilus sommis complex". In the Mid-Westem United States, 
the pneumonic disease associated with H. somnus is the most frequently encountered 
syndrome. It is most frequent in dairy calves, nursing beef calves and in feedlots. In young 
animals, H. somnus pneumonia is generally manifested as a subacute to chronic 
bronchopneumonia. In feedlot calves it may also produce shipping fever-like pneumonias 
similar to that produced by M. hemolytica and may also produce severe fibrinous pleuritis 
associated with sudden deaths. H. somnus can be isolated from cattle with bronchopneumonia 
and fibrinous pneumonia, but its involvement in typical bovine respiratory disease is unclear 
Ordinarily, H. sommts is difiRcult to isolate from the nasal passages of cattle. Viral infections 
or stress allow colonization of upper respiratory sites by H. sommts. 
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In many calves with cranial ventral pneumonic lesions associated with the isolation of 
H. somnus, there is a concurrent interstitial pneumonia in the remaimng caudal dorsal lung 
lobes. In many instances, this can be demonstrated to be a concurrent BRSV infection. 
However, it is likely that H. somnus can also produce a caudal interstitial pneumonia via the 
release of endotoxin or an unidentified exotoxin ^ . Immune mechanisms have been 
suggested in the pathogenesis of this observed interstitial component of//, sommis 
pneumonias. 
Histologically, H. somnus pneumonia is most fi-equently a purulent bronchiolitis often with 
necrosis of bronchiolar epithelium accompanied by varying degrees of alveolar filling with 
inflammatory cells ^. Because of this airway involvement, a chronic hacking cough is often 
associated with H. somnus pneumonia, particularly in feedlot cattle. In some cases, younger 
calves may not manifest clinical signs until the pneumonia has progressed to a chronic and 
often untreatable (non-responsive) stage. 
Protective Antigens, Virulence Factors, and Evasion of Defense 
Haemophilus sommis is a gram-negative bacterium, so it is not surprising that endotoxin is 
a virulence factor. The endotoxin has been characterized as lipooligosaccharide (LOS) 
without O polysaccharide side chains "•*' ^ . The LOS is though to undergo antigenic variation 
during the course of infectionwhich may partially explain the chronic nature of the 
respiratory infection Adherence to several cell types is a second virulence factor which 
may be mediated by a recently discovered surface fibrillar network ^ . This network and a 
76-kDa surface antigen are also associated with serum resistance and with Fc binding of 
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IgG, to the surface of H. somnus . Other investigators have shown that H. somrms 
suppresses polymorphonuclear (PMN) function which would allow evasion of effector 
cells of the immune response. Iron acquisition via binding of transferrin to the surface of 
H. somrms allows evasion of the host iron sequestration mechanisms and may account for 
species specificity . Lastly, several outer membrane proteins (OMP) have been 
characterized and may serve as virulence factors . In particular, a 40-kDa OMP 
appears to be protective . This could be the same as one of two 40-kDa lipoprotein genes 
cloned and characterized by Theisen et al. . The expressed protein of one of these has some 
protective capacity . 
Allergic Reactions 
Effector mechanisms of specific immunity, such as complement activation, phagocytosis, 
etc. are not specific for foreign antigens. Therefore, immune responses and attendant 
inflammation are often accompanied by local and systemic injury to host self tissues. 
Normally, however, such pathologic side effects are controlled and self-limited, and they abate 
as the foreign antigen is eliminated. Failure to control physiologic immune responses against 
foreign antigens or to maintain self-tolerance leads to diseases in which the primary 
pathogenic mechanisms are immunologic. Disorders resulting from aberrant, excessive, or 
uncontrolled immune reactions are called hypersensitivity diseases. This term is based on the 
observation that an individual who has been exposed to an antigen exhibits a detectable 
reaction to, or is sensitive to, subsequent encounters with the sensitizing antigen. Sensitizing 
antigens may be environmental , chemical , or microbial . Protective immunity and 
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hypersensitivity may coexist because both are manifestations of specific immune responses. 
Hypersensitivity reactions are classified into 4 types: Type I (immediate), n (cytotoxic), HI 
(immune-complex), and IV (delayed type). Immediate (Type 1) hypersensitivity is mediated 
by IgE antibodies, mast cells and basophils and is the main focus of this research. 
Immediate (Type-1) Hypersensitivity 
Immediate hypersensivity reactions can have a variety of clinical manifestations including 
bronchial asthma, urticaria (hives), vasomotor rhinitis (hay fever), and systemic anaphylaxis 
The main characteristic of the immediate hypersensitivity reaction is the short time lag 
(seconds to minutes) between antigen exposure and the onset of clinical signs and symptoms. 
This is because the initial signs of immediate hypersensitivity depend on the release of 
preformed mediators stored in cytoplasmic granules of basophils and mast cells. Release is 
triggered by the reaction of membrane-bound IgE with the corresponding antigen (known as 
an allergen). The classic example of immediate hypersensitivity in humans is the "wheal and 
flare reaction." When a sensitized individual is challenged by intradermal injection of an 
appropriate antigen, the injection site becomes red fi^om locally dilated blood vessels engorged 
with red blood cells. In the second phase, the site rapidly swells as a result of leakage of 
plasma fi^om the venules. This soft swelling is called a wheal and can involve an area of skin 
as large as several centimeters in diameter. In the third phase, blood vessels at the margins of 
the wheal dilate and become engorged with red blood cells, producing the characteristic red 
rim called a flare. 
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Genesis of Immediate Hypersensitivity 
Immediate hypersensitivity reactions involve three main components: 1) the immune 
system which produce reaginic antibodies (IgE antibody in man); 2) cells (basophils and mast 
cells) to which the reaginic antibodies bind and which, when re-exposed to the antigen, 
synthesize and release mediators; and 3) smooth muscle, vascular endothelium, and mucus 
glands which are the main targets for the mediators released by basophils and mast cells. 
Biology of Immunoglobulin E 
Immunoglobulin E (IgE) provides recognition of antigen for immediate hypersensitivity 
reactions. IgE is the isotype of immunoglobulin that contains the epsiion heavy chain. It 
circulates as a bivalent antibody and constitutes only 0.004% of the total immunoglobulin 
content in serum. Total IgE production is very low (< 300 lU/ml) . IgE is normally present 
in human plasma at a concentration of less than 1 ug/ml. In pathologic conditions, such as 
helminth infections and severe atopy, this level can rise to over 1,000 ug/ml. The IgE heavy 
chain variable regions and IgE light chains are products of the same genes as other Ig 
molecules. The heavy chain constant regions are encoded by the epsiion gene located in the 
Ig heavy chain gene cluster. Thus, IgE is produced as a result of heavy chain isotype 
switching. 
A causal association of IgE and mast cells with immediate hypersensitivity has been 
demonstrated. Adoptive transfer studies have shown that IgE is responsible for specific 
recognition of antigen and can be used to adoptively transfer immediate hypersensitivity . 
Immediate hypersensitivity reactions can be mimicked by injecting anti-IgE antibody rather 
than antigen . Anti-IgE elicits a reaction in both atopic individuals who have high levels of 
antigen-specific IgE antibodies and in non-atopic individuals who have low but measurable 
levels of IgE. The anti- IgE antibodies act as an analog of antigen and directly activate mast 
cells and basophils that have bound IgE on their surface. Immediate hypersensitivity reactions 
can also be mimicked by injection of other agents that directly cause mast cell activation, such 
as C5„ or by local trauma, which causes mechanical disruption of mast cells . This 
reaction can be inhibited by agents that prevent mast cell activation. Mast cells can also be 
activated by locally released neurotransmitters, such as substance P. 
Sensitization Phase 
During the sensititization phase, antigen is presented to an antigen presenting cell (APC). 
It is likely that the initiation of a primary immune response occurs in local draining lymph 
nodes when antigen-bearing dendritic cells enter T cell-rich areas of the lymph node and offer 
antigens for scrutiny by T cells . Antigen is ingested and the APC migrates to the lamina 
propria, while the antigen is further processed by the APC and will be finally presented to 
CD4 T-helper cells and the B-cells in a recognizable manner. Interaction within the new 
complex, monitored by cytokines, will lead to the development of memory cells and IgE 
producing plasmocytes. Activated T cells then interact with follicular dendritic cells and B 
cells in the germinal centers of secondary follicles. However, on repeated exposure to 
allergen, the cellular interactions responsible for IgE production could also occur in the 
periphery, such as specialized areas of bronchus-associated lymphoid tissue. The maintenance 
of IgE levels in chronic allergic diseases such as asthma is probably due only in part to the 
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preferential stimulation of Th2 ceils. CD40 iigand and IL-4 signals may be provided by other 
ceils, e.g., mast ceUs ^ . In addition, there are several mechanisms which inhibit IgE 
production, most notably interferon-y, produced by Thl cells and also some CD8+ T cells. 
Thus, atopy may be due in part to failure of T cell inhibitory mechanisms. 
Fc Receptors for IgE 
IgE is bound on the surface of mast cells and basophils by Fc receptors specific for epsilon 
heavy chains, called Fc£R. Two classes of FceR have been identified on different cell types. 
Mast cells and basophils express high-affinity receptors called FceRI " . Each FcsRI molecule 
contains four separate polypeptides, one a, one P, and two identical gamma (y) chains. The 
a-chain mediates binding of IgE. Each FceRJ a-chain has an approximately 20 amino acid 
hydrophobic sequence that is believed to cross the cell membrane once and approximately 20 
carboxy terminal amino acids that form a cytoplasmic domain. The (B-chain of FcsRI is a 243 
amino acid hydrophobic polypeptide whose predicted structure crosses the membrane four 
times. The two identical y-chain polypeptides ai'e only 62 amino acids long and are highly 
homologous to the zeta {Q chains of the T cell antigen receptor complex ^. From its 
predicted structure, only five amino terminal amino acid residues of the gamma chain are 
extracellular. Each y-chain crosses the membrane once, and the remaining residues are 
intracellular. 
A second receptor for IgE, FcsRII, is a 30 kD protein related to C-type mammalian 
lectins, a family which includes the selectins. The affinity of FcfiRII for IgE is much lower 
than that of FceRI and appears to vary considerably among different cell types . In 
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addition, several monoclonal antibodies appear to distinguish FcsRII expressed on eosinophil 
cell lines from those on B cells. Two polypeptides may be generated by alternative 
translational start sites and alternative splicing of messenger RNA (mRNA) from the same 
gene. One product is B cell- specific and is expressed constitutively (FceRIIa); the other 
product, FceRIIb (also called CD23), is induced on B cells, monocytes, and eosinophils by 
IL-4 " . The eosinophil receptor is used in IgE-dependent killing of parasites by eosinophils. 
The exact role of FcsRII on B ceils and monocytes is less well defined. 
Intracellular Signal Transduction Mechanisms 
Mast cells and basophils are stimulated to degranulate by cross-linking of FceRI molecules 
via binding of multivalent antigens to the attached IgE molecules. The antigen-binding 
fragments are noncovalently associated with the transducing subunits FceRJ-P and -y . 
These subunits lack intrinsic enzjmiatic activity and contain one or more copies of a conserved 
sequence called the immunoreceptor tyrosine-based activation motif (IT AM) that is exposed 
to the cytoplasm. To exert their signaling functions, these subunits cooperate with 
nonreceptor tyrosine kinases belonging to the sarcoma (Src) and Syk/Zap-70 families. 
Binding of soluble, multivalent antigens to at least two FcsRI-bound IgE molecules causes 
molecular aggregation of the ITAMS, Src, and Syk/Zap-70 molecules on the cytoplasmic side 
of the membrane. Prior to aggregation, the tyrosine kinase Lyn is already associated with the 
FcfiRI-P subunit by a weak interaction that does not depend on phosphorylation. The increase 
in local molecular concentration that follows FcsRI aggregation allows the bound L)^! 
molecules to transphosphorylate the tyrosine residues on the approximated Fc£RI-P and -7 
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ITAMS . Once phosphorylated, the ITAMs act as high-affinity docking sites for the 
Src-homology-2 domains of Lyn and Syk. Finally, the kinase activity of the recruited Syk 
increases as a result of both phosphorylation by Lyn and trans-autophosphorylation and 
contributes to the successful propagation of intracellular signals. 
The biological potency of an individual FcsR receptor is determined by its lifetime within 
an aggregate which is generally influenced by the dissociation rate constant of IgE. Thus, in 
the case of low-af5nity IgE ligand, only a few^ early intracellular activation events are hkely to 
take place before the receptor dissociates from its ligand and moves out of the aggregate. 
Torigoe et al. ™ demonstrated that FceRI aggregated by low-affinity ligands is ineffective at 
stimulating distal steps of the signaling cascade as compared with FceRI aggregated by 
high-afiBnity ligands. This finding is reminiscent of the partial T cell responses that follow T 
cell receptor stimulation with less-than-optimal ligands . These results suggest that both the 
T cell receptor and FcsRI function according to a kinetic proofreading modes in which the 
cascade of intracellular events that follow interaction with a ligand unfolds as long as the 
initiating reaction is maintained ^ . 
Studies of rat basophilic leukemia cells suggest that the amount of the kinase Lyn available 
to the FcfiRI is limiting. The noncovalent, reversible interactions existing between FceRI and 
such a Umited pool of Lyn results in a flexibility in signaling properties that is not found in 
surface receptors in which a covalent linkage freezes the stochiometry of the ligand-binding 
and catalytic domains. For example, upon aggregation of FceRI, Lyn redistributes rapidly 
from the pool of free Lyn and from low-affinity, nonphosphoiylated FceRI-3 binding sites to 
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the high-afBnity docking sites that constitute the newly phosphorylated FceRI-3 ITAMS . 
An important consequence of this redistribution is tiiat an antigenic ligand capable of inducing 
an extensive aggregation of FceRI can abrogate an ongoing response to a weak, non 
cross-reactive antigen by recruiting Lyn away from the previously formed FceRI aggregates 
Finally, Torigoe et al. demonstrated that aggregates of FcfiRI induced by an excess of 
Iow-afl5nity ligand could sequester Lyn, so that a smaller number of aggregates simultaneously 
induced by a higher aEBnity ligand actually become deprived of Lyn and therefore, unable to 
initiate the signaling cascade. 
Mechcmism of Granule Exocytosis by Mast Cells and Basophils 
The mechanisms of granule exocytosis are only partially understood. Cross-linking of 
FcfiRI results in activation of a phosphatidylinositol-specific phospholipase C (PI-PLC) that 
catalyzes phophatidylinositol biphosphate breakdown into inositol triphosphate (IP3) and 
diacylglycerol (DAG) . The coupling of FcsRI to the activation of PI-PLC may involve 
tyrosine kinases, as is established for other antigen receptors, or a heterotrimeric GTP-binding 
protein, as is established for chemokine receptors, or both. IP3 causes elevation of 
cytoplasmic calcium, and DAG activates protein kinase C. In the basophil, the activated 
protein kinase C phosphorylates myosin light chains, which is thought to lead to disassembly 
of actin-myosin complexes beneath the plasma membrane, allowing granules to come into 
contact with the plasma membrane with release of the granule contents. The role of the 
elevated calcium is less clear, but it is thought that calcium binding to calmodulin leads to 
activation of myosin light chain kinase, which phosphorylates myosin light cham at amino 
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acids distinct from those of protein kinase C. Calcium-cahnodulin complexes may activate 
other proteins involved in the fusion of granules with the plasma membrane. Free calcium 
may also activate phospholipase Aj, the rate limiting enzyme involved in the generation of 
lipid mediators. 
Cross-linking of FceRI also activates adenylyl cyclase through a heterotrimeric GTP-
binding protein . This, in turn, elevates cyclic adenosine monophosphate (cAMP) levels and 
cAMP activates protein kinase A. Protein kinase A inhibits degranulation, suggesting that this 
pathway is a negative feedback loop. 
Mast cells may degranulate by mechanisms other than cross-linking FcsRI. For example, 
mast cells or basophils may respond to mononuclear phagocyte-derived chemokines produced 
as part of natural immunity, to undefined T cell-derived cytokines produced as part of 
cell-mediated immunity, and complement-derived anaphylotoxins, such as C5j, produced 
during humoral responses. Mast cells may also be recruited into inflammatory reactions and 
activated by neutrophil granule contents or by neurotransmitters such as norepinephrine and 
substance P . The nervous system is known to affect the expression of immediate 
hypersensitivity reactions. The flare produced at the edge of the wheal is in part mediated by 
the nervous system, as shown by the observation that the flare is markedly diminished in skin 
sites lacking innervation. 
Regulation of IgE Synthesis. 
There is a critical difference in IgE production between atopic and normal individuals. 
Atopic individuals produce high levels of IgE in response to particular antigens. Normal 
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individuals synthesize other Ig isotypes, such as IgM and IgG, and only small amounts of IgE. 
Four factors contribute to regulation of IgE synthesis: I) heredity, 2) the natural history of 
antigen exposure, 3) the nature of the antigen, and 4) T-helper cells and their cytokines. 
Other, less defined, factors may also influence IgE synthesis. 
Heredity 
Abnormally high levels of IgE synthesis and associated atopy often run in families. 
Although the full inheritance pattern is most likely multigenic, family studies have shown that 
there is a clear autosomal transmission of atopy. However, the target organ of atopic disease 
is variable. Thus, hayfever, asthma, and eczema can be present to various degrees in different 
members of the same family. All these individuals, however, will show higher than average 
plasma IgE levels. In addition to this general predisposition to synthesize IgE, the ability to 
make specific IgE antibodies to certain antigens, e.g., ragweed pollen, is also inherited and 
may be linked to major histocompatability (MHC) class II alleles. In fact, there is substantial 
evidence that the gene for IgE in atopic individuals resides very close to the genes encoding 
certain MHC-II antigens. In the case of ragweed pollen, different class II alleles may serve to 
present different peptides to specific T cells. 
Studies of total IgE levels in normal non-allergic human patients shows a distribution in 
three groups: high, intermediate, and low producers . Family studies further suggested that 
the ability to produce high levels of IgE is a recessive trait, controlled by genes independent of 
the HLA system. On the other hand, the tendency to develop allergic disorders in response to 
specific allergens is HLA-linked . For example, the ability to produce antigen-specific IgE 
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after exposure to the Ra5 antigen of ragweed is observed more often in HLA B7 DR2 
individuals than in the general populatioiL If the same HLA B7 individual is also genetically a 
high IgE producer, he/she will have a more severe allergic disorder than a low responder. 
More recent developments have established that various HLA class n antigens are associated 
to high responses to many different allergens. This correlation assumes that the differentiation 
of plasma cells producing antigen-specific IgE depends on help provided by allergen-specific 
CD4 T-helper cells to allergen-stimulated B cells. 
Natural History of Antigen Exposure 
The natural history of antigen exposure is an important determinant of the level of specific 
IgE antibodies. In general, repeated exposure to a particular antigen is necessary to develop 
an atopic reaction to that antigen. The most dramatic examples of the influence of the natural 
history of exposure to antigen are seen in cases of insect stings. The protein toxins in the 
insect venoms are usually not of concern on the first encounter because the atopic individual 
has no pre-existing specific IgE antibodies. However, an IgE response may occur after a 
single encounter with antigen, and a second sting by an insect of the same species may induce 
fatal anaphylaxis. The response to repeated allergen challenge can show a large variation fi-om 
a strongly enhanced response to complete dimunition of the response. Chronic or repeated 
allergen exposure may result in an enhanced allergen-specific allergic response, involving 
allergen-specific T cell activation 
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Nature of the Antigen 
Antigens that elicit strong immediate hj^ersensitivity reactions are called allergens and are 
proteins or chemicals bound to proteins. Because polysaccharides are T- independent 
antigens, they do not elicit T cell responses. However, polysaccharides have been 
demonstrated to induce the expression of certain costimulatory molecules such as B-7 and 
CD40 . Therefore, the presence of polysaccharides may be involved in the costimulatory 
signals presented to T cells. The property of being allergenic may reside in the antigen itself, 
in epitopes seen by certain T cells. Some drugs such as penicillin characteristically elicit 
strong IgE responses. It is thought that these drugs bind to self proteins, forming hapten-
carrier-conjugates that function as neoantigens. 
Some protein antigens are naturally encountered with adjuvant substances that favor IgE 
synthesis. For example, an antigen and an adjuvant may be present in the same parasite. If 
the adjuvant triggers IL-4 release (from mast cells or basophils), T cells activated in this 
environment are more likely to differentiate into Th, cells that promote isotype switching to 
IgE. Aluminum salts are commonly combined with killed bacteria, usually formalin-killed, to 
induce non-specific stimulation. Even though aluminum hydroxide can compensate for a 90% 
reduction in antigen content and contribute to a reduction in production costs of the vaccine, 
aluminum adjuvants are very efficient inducers of IgE antibody synthesis . 
Helper T Cells and Cytokines 
Activation of Thj or Th, cells in response to protein antigens leads to distinct cytokine 
profiles and resulting immune responses. Evidence from animal and human models suggest 
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that cytokine regulation of IgE synthesis is complex . Eosinophil- and IgE-mediated 
immune reactions are dependent on the activation of CD4' helper T cells of the Th, 
subset . These T cells secrete IL-4, which is required for isotype switching to IgE and 
promotes eosinophil recruitment, and IL-5 which activates eosinophils ^ . Production of 
IL-4 is inhibited by alpha and gamma interferon and by prostaglandin E2 (PGE2). 
Accumulations of Th, cells have been demonstrated at sites of immediate hypersensitivity 
reactions in the skin and bronchial mucosa. Atopic individuals contain larger numbers of 
allergen-specific IL-4-secreting T cells in their circulation than do non-atopic individuals. In 
addition, in atopic patients, the allergen- specific T cells produce more IL-4 per cell than in 
normal patients . All these factors contribute to the increased IgE production associated 
with atopy. Because immediate hypersensitivity reactions are dependent on T cells, T 
cell-independent antigens such as polysaccharides cannot elicit such reactions unless they 
become attached to proteins. 
Different subsets of T cells can exert either activating or suppressive effects on 
inflammatory cells involved in subsequent allergic reactions . CD8+ T cells might exert 
suppressive effects, because they seem to be associated with a subsequent down-regulation of 
the late skin reaction after allergen challenge. 
For B cells to switch isotype and produce IgE, two T cell signals are required. The 
cytokine IL-4 induces somatic recombination which brings the immunoglobulin \DJ gene 
cassette adjacent to the £-heavy chain constant gene region. In man, but not in rodents, 
another Th2 cytokine, IL-13, can also switch B cells to IgE production. Contact signals e.g.. 
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CD40 ligand (CD40-L) on the activated T cell are then required to persuade the B cell to 
proliferate and dififerentiate into an IgE-secreting plasma cell ^ . 
Other Factors 
Whether the APCs play an important role in the regulation of allergy is not yet clear. 
DiflFerent APCs do exist for antigen presentation to T-helper cells, cytotoxic T cells, or B 
cells. Different adjuvants injected in conjunction with the same antigen tend to favor different 
modalities of response . Use of aluminum adjuvants is accompanied by preferential 
stimulation of IL-4 production and stimulation of the Th2 subsets in mice, with enhanced IgGj 
and IgE production . Adjuvants such as cholera toxin and pertussis toxin, which 
preferentially drive Th,-like response, have been shown to enhance IgA and IgE antibody 
production . 
Human antibody production is up regulated and down regulated by T-helper and 
T-suppressor cells, respectively. In cases of hyper IgE syndrome, suppressor cells are 
decreased in number . Cho and Conrad have demonstrated that IgE produced in cell 
culture is highly dependent on B cell level. Once a critical threshold number of B cells is 
present, IgE production is inversely proportional to B cell number. 
The low-afiBnity IgE receptor FceRII has been shown to play a role in IgE regulation. It is 
known that IL-4 up regulates the expression level of both IgE and FcsRIIb . Conrad et 
al. demonstrated a dose-dependent decrease in IgE production at higher proportions of 
double-positive T cells (ICAM-l'/FcfiRUb"). Coactivation of B cells with CD40L and 
multivalent anti-IgD was also shown to suppress IgE production . When membrane 
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FcfiRIIb is present on CD23~ or double-positive (FcsRIIb'/ICAM-F) Chinese Hamster Ovary 
cells, a dose-dependent down-regulation of IgE production occurs. These studies suggest that 
at high FceRIIb" cell levels, a general down-regulation of immunoglobulin production occurs 
and if the number of B cells was increased, B cell proliferation was decreased in concordance 
with FceRIIb* cell number. 
Soluble FceRIIb (s FcsRIIb or CD23) may also be an important diagnostic marker for 
atopy. Senmi levels of sFceRUb and the soluble IL-2 receptor (CD25) are higher at birth than 
later in childhood and the development of skin test reactivity may be associated with 
regulatory mechanisms involving sCD25, whereas sFcsRIIb is not implicated . 
Relationships between sFcsRIIb and IL-4 or IFN-y and allergy have also been investigated. In 
these studies, there was no relationship between serum levels of sFceRIIb and EFN-y and 
allergy . These authors conclude that the IL-4 levels in serum, but not sFcsRIIb and 
IFN-y, were associated with allergic disease in infancy. Elevated levels were detected prior to 
the onset of clinical symptoms, indicating that atopic disease is associated with a primary 
deviation of T cell function. Other investigators propose that sFcsRIIb serum levels are not 
influenced by age, atopy, or IgE levels . 
Mediators of Allergy 
Because mast cells are heterogeneous, not all mast cells will release the same mediators or 
the same combinations of mediators . Mediators released may be classified as 
pre-formed or newly synthesized mediators . Pre-formed mediators include biogenic 
amines and granule macromolecules. Newly synthesized mediators include lipid-derived 
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substances and cytokines. Some cj^okines such as tumor necrosis factor (TNF) in human 
dermal mast cells may also exist in pre-formed storage granules that are released during 
degranulation. 
Histamine 
Histamine is formed by decarboxylation of histidine by L-histidine decarboxylase . 
Most histamine is stored preformed in cytoplasmic granules of mast cells and basophils in 
association with proteoglycans and varies with cell type . Although mast cells and 
basophils are the main source of histamine, rat entero-chromafl5n-like cells called 
histaminocytes also synthesize histamine . In the dog and human mucosa, mast cells are the 
sole source of histamine. In the brain, histamine is synthesized in the neurons of the 
hypothalamus, telencephalon, diencephalon and lower brain stem . Histamine is also found 
within the platelets of some species, but not in humans. 
Histamine acts by binding to target cell receptors, and different cell types express distinct 
classes of receptors (e.g.. Hi, H,, H3) . In vascular endothelial cells, binding of 
histamine leads to endothelial cell contraction and leakage of plasma into the tissues. 
Histamine causes endothelial cells to synthesize vascular smooth muscle relaxants, such as 
prostacyclin and nitric oxide, which cause vasodilation These actions of histamine 
produce the wheal and flare response of immediate hj^jersensitivity. In addition, Hj histamine 
receptor antagonists (commonly referred to as antihistamines) can inhibit the wheal and flare 
response to intradermal allergen or anti-IgE antibody. Histamine also causes constriction of 
intestinal and bronchial smooth muscle and may comribute to the increased peristalsis or 
bronchospasm associated with food allergies or asthma, respectively. However, in these 
instances, especially in asthma, antihistamines are not eflFective at blocking the reaction. 
Bronchoconstriction in asthma is more prolonged than the effects of histamine. 
Histamine also has significant effects on leukocytes. Several studies have demonstrated 
the in vitro effects of histamine on human basophils and mast cells. Histamine (10"^ to 10"^ M) 
inhibits antigen-induced histamine release fi"om human basophils and skin mast cells but 
not from puhnonary mast cells. The inhibitory effect is associated with a rise in cAMP and is 
blocked by Hj antagonists. In contrast to its inhibitory effects on basophils, the in vitro effect 
of histamine on eosinophils is generally stimulatory. Histamine (10'® to 10"* M) is directly 
chemotactic for eosinophils. The chemotactic effect can be abolished only by a combination 
of Hj and Hj antagonists . Although histamine is inhibitory at concentrations greater 
than 10'^ M, at lower levels it augments Cs^-stimulated eosinophil chemotaxis . Histamine 
nonspecificaily enhances neutrophil chemokinesis and inhibits chemotaxis, probably through 
Ht receptors . In other studies, histamine was shown to inhibit N-formyl-methionyl-
leucyl-phenylalanine (FMLP)-induced neutrophil activation and zjmiosan-stimulated 
degranulation . This inhibition was less pronounced in neutrophils from patients with 
asthma or atopic eczema'"*^, suggesting that individuals with these disorders might have 
an impairment in histamine H^-receptor-mediated regulatory processes. In vitro and in vivo 
studies have demonstrated effects of histamine on suppressor T cells . Histamine-stimulated 
T suppressor activity is generally blocked by Hj antagonists, and in some studies 
contrasuppressor activity has been induced, supposedly by activation of Hi receptors. 
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Suppressor activity both in animals and humans is mediated in part by the elaboration of a 
soluble factor(s) termed histamine-induced suppressor factor. 
Most interestingly, certain strains of bacteria readily produce histamine by decarboxylation 
of histidine. Histamine is probably the cause of scombrotoxism (scombroid-fish poisoning) 
The synthesis of histamine by bacteria suggests the possibility that inflammatory reactions 
surrounding areas of infection might in part be due to the production of histamine by invading 
bacteria. In one study of germ-free rats selectively infected with a histamine-producing strain 
of Clostridium perfringens, high histamine levels were found in the cecal contents, but the 
histamine levels of the intestinal mucosa did not change . Histamine is also produced by 
organisms commonly found in the human airways. In a study of pathogenic and 
nonpathogenic respiratory bacterial species, three of the five pathogenic species studied, 
Branhamella catarrhalis, Haemophilus parainfluenzae, H. influenzae, and Pseudomonas 
aeruginosa, produced clinically important amounts of histamine . Members of the 
Enterobacteriaceae family were also shown to produce large quantities of histamine. 
Serotonin 
The other vasoactive amine found in significant amounts in peripheral tissues is serotonin. 
Serotonin is found in blood platelets of all mammalian species, but is also found in other cells 
such as neurons, enterochromaffin cells, and mast cells of some species, especially rodents and 
cattle . Serotonin functions as a neurotransmitter in the central and peripheral nervous 
systems and has a complex effect upon the microcirculation. 
Serotonin is synthesized from L-tryptophan by a two-step process catalyzed first by 
tryptophan hydroxylase to form 5-hydroxytryptophan which is then decarboxylated by a 
nonspecific L-amino acid decarboxylase to form serotonin. There are three major serotonin 
receptors (Si, S2, S3) on various cell types . The Si receptor is actually a group of 
flmctional receptor activities. One subtype of the Si receptor is located on endothelial cells 
where it mediates the release of nitric oxide to cause relaxation of the underlying smooth 
muscle. A second Si receptor subtype is located on the vascular smooth muscle, where it 
mediates relaxation by stimulating adenyly cyclase activity in response to serotonin 
stimulation. A third Si receptor subtype is located on the vascular smooth muscle where it 
induces strong vasoconstriction in certain vessels, including the dog saphenous vein, carotid 
and coronary arteries, and human basilar and coronary arteries. Sj receptors are located 
primarily on vascular smooth muscle, where they mediate contraction. S3 receptors are 
located on sensory and autonomic nerve endings in skin, gut, and the right chamber of the 
heart 
Granule Proteins and Proteoglycans 
Mast cell granules contain several enzymes, such as serine proteases and aryl sulfatase, as 
well as proteoglycans such as heparin or chondroitin sulfate. Tryptase is a serine protease that 
has been isolated and purified from human intestinal and lung mast cells rat 
canine and cattle and appears to be involved in the late phase reaction. It has been 
demonstrated that measurement of tryptase levels during and after an anaphylactic episode is a 
better indicator of immediate hypersensitivity as compared to measurement of histamine and 
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IgE levels . Depending on the anatomical location, mast cells can be classified as either 
chymase- or tiyptase-positive based on binding of the respective monoclonal antibody . 
Mast cells also contain chymotrypsin within their granules. These various enzymes may cause 
tissue injury when released upon mast cell degranulation. One function of the negatively 
charged proteoglycan may be to bind and store the positively charged biogenic amines. 
Lipid Mediators 
Two general classes of lipid mediators are synthesized by activated mast cells: eicosanoids 
(prostaglandins and thromboxanes, leukotrienes), and platelet-activating factor. The 
precurosrs of eicosanoids are lipid components of cellular membranes. Activation of the 
phospholipase A, (PLAj) family induces the mobilization of fatty acids, particularly 
arachidonic acid (AA), fi-om the membrane lipid pool for synthesis of lipid intermediates. This 
process occurs at the site of cellular damage or inflammation. Large quanitites of AA are 
stored in membrane glycerolipids of human mast cells and basophils Upon cell stimulation 
by inflammatory stimuli such as complement fragments, IgE receptor activation, immune 
complexes, opsonized particulate matter, and microorganisms AA is mobilized from the 
storage pools by different phospholipases and is converted to prostanoids by cyclooxygenases 
(COX) and to leukotrienes by 5-lipoxygenase (5- LOX) . 
Prostaglandins and thromboxanes are derived from arachidonic acid via the action of 
cyclooxgenases . All prostaglandins have the same general structure of prostanoic acid. 
Prostaglandin D, was the first mast cell-specific lipid mediator of immediate hypersensitivity 
to be described. PGDj binds to receptors on smooth muscles and acts as a vasodilator and as 
a bronchoconstrictor . PGD2 levels in bronchoalveolar lavage fluid rose an average of 
150- fold during asthmatic bronchoconstriction . Prostadlandins PGE2 and PGI, (measured 
as 6-keto PGFjcJ cause smooth muscle relaxation; PGFjo and TxA, (measured as TXBt) cause 
smooth muscle contraction. The TxAj-induced vasoconstriction and bronchospasm 
predominates over the relaxing effects of simultaneouly generated 6-keto-PGFi^ and PGE^ on 
smooth muscle ceils of vessels and bronchioli. Whereas TxA, is a potent bronchoconstrictor, 
puhnonary vasoconstrictor, and platelet aggregator, 6-k;etoPGio, is a bronchodilator, 
vasodilator, and inhibitor of platelet aggregation . 
Prostaglandins also affect airways by altering the amount and composition of the fluid 
layers. PGFt;,, increases secretion of mucus by human airway explants by guinea pig 
tracheal epithelial cells and by explants of human bronchi . PGEo and PGD, stimulate 
secretion by cultured bovine tracheal epithelial cells . In contrast, no effect on mucus 
secretion by prostaglandins is seen in hamster tracheal epithelial cells in primary culture or 
in ferret trachea . Despite its prostimulatory effect on human bronchial explants, PGE, 
decreases mucus glycoconjugate release from human lung explants . In addition to altering 
mucus solids, prostaglandins can alter the water content of the mucous fluid layers by altering 
ion transport across tracheal epithelium. Prostaglandins, especially PGE2, PGF^o, and POD,, 
stimulate chloride ion secretion across human, canine and bovine tracheal epithelium . 
Other actions of prostaglandins may also influence airways during inflammation. For example, 
some PGs can decrease histamine release by basophils . By lowering histamine 
concentations in the airways, PGs could secondarily decrease airway inflammation. 
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Lipooxygenase products of AA metabolism are the hydroxyeicosatetraenoic acids 
(HETEs) and leukotrienes (LTs), including the compounds formerly called the slow-reacting 
substance of anaphylaxis (SRS, now known to be LTC4, LTD4, and LTE4), as well as the 
potent chemotaxin LTB4. LTs cause airway smooth muscle contraction . LTB4 has many 
important effects on leukocyte functions relevant to the mediation of airway 
inflammation . LTB4 stimulates leukocyte chemotaxis, chemokinesis, aggregation, 
degranulation, and adherence to vascular endothelium. Instillation of LTB4 into the airways of 
human volunteers promotes the influx of functionally active neutrophils into the lungs . 
LTB4 has modest bronchial smooth muscle constricting activity, which may be secondary to 
the release of other lipid mediators (e.g., TXA2), which are more potent broncho-
constrictors . Elevated urinary levels of LTE4 and TxA, have been found in human patients 
following allergen challenge . In the presence of vasodilators such as PGEo, LTB4 can 
increase vascular permeability of peripheral vascular beds. The sulfidopeptide leukotrienes 
LTC4 and LTD4 are potent bronchoconstrictors. Asthmatic patients are hyperresponsive to 
bronchial inhalation of LTC4 or LTD4 compared with histamine. LTD4 infusion in animal 
lungs induces pulmonary edema . Intracutaneous injection of sulfidopeptide leukotrienes in 
humans causes a wheal and flare response; LTC4- and LTD4- induction of increased systemic 
vascular permeability is mediated by terminal arteriolar consctriction and venular dilation. On 
a molar basis, LTC4 and LTD4 have much greater activity than do prostaglandins (PGD,, 
PGE2, PGF2O„ and 6-ketoPGj J or histamine in the induction of airway glycoprotein mucus 
secretion . LTC4, LTD4, and LTE4 stimulate glycoconjugate, mucin, and lyso^mie 
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secretion by human bronchial explants . Peptidyl LTs also stimulate secretion of mucin 
by guinea pig feline and canine trachea . Exogenous LTs stimulate chloride 
secretion across tracheal epithelium and 15-HETE stimulates fluid secretion by canine 
trachea in vivo . 
Like PGs, LTs can affect tracheal epithelium in ways other than altering mucus 
composition. The overall effect of LTs is to decrease tracheal mucus velocity . High 
concentrations of LTs are found in sputum from cystic fibrosis patients . Leukotrienes 
C4, D^, and are mitogenic to human airway epithelial cells in a concentration-dependent 
manner The proinflammatory leukotriene LTB^ is a potent chemoattractant for 
neutrophils and eosinophils, and also increases microvascular permeability . 
Generation of this product could then potentiate an inflammatory response in the airways. 
The third lipid mediator produced by mast cells is platelet activating factor (PAF) and was 
named for it's ability to induce rabbit platelet aggregation . PAF is synthesized by acylation 
of lysoglyceryl ether phosphorylcholine, which is derived from a membrane phospholipid by 
PLA, release of a fatty acid. Depending on the fatty acid, precursors of all three lipid 
mediators may be generated in one reaction. PAF has direct bronchoconstricting actions. It 
also causes retraction of endothelial cells and can relax vascular smooth muscle. However, 
PAF is very hydrophobic and is rapidly destroyed by enzymes in plasma. Even though there is 
evidence that PAF can be measured and correlated to certain immunologic diseases, it is 
uncertain whether mast cell-released PAF can reach it's target cells. Pharmacologic PAF 
receptor antagonists ameliorate some aspects of immediate hypersensitivity in rabbit lung. 
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PAF may be of particular importance in the late phase reactions where it can activate 
inflammatory leukocytes. In this situation, the major source of PAF may be the surface of 
vascular endothelial cells stimulated by histamine or leukotrienes rather than mast cells. 
Mast Cell Cytokines 
Cultured mast cells are significant sources of cytokines, including tumor necrosis factor 
(TNF), interleukin (IL)-l, IL-4, IL-5, IL-6, and various colony-stimulating factors such as 
granulocyte macrophage colony stimulating factor (GM-CSF) and IL-3 . Many of these 
cytokines, especially IL-3 and IL-4 were once thought to be exclusively produced by T cells. 
The relative contributions of mast cells versus T cells to the production of these molecules in 
vivo are not clear. Cytokines are released upon IgE- mediated mast cell activation and after 
Th, cell recruitment; these processes are predominantly responsible for the late phase reaction. 
TNF may account for sequential polymorphonuclear and mononuclear infiltrates by the same 
mechanisms for DTH reactions. The main differences between the inflammatory infiltrates of 
the late phase reaction and those of DTH are the large numbers of eosinophils and Th, cells in 
the late phase reaction as compared with activated macrophages and Thi cells in DTH. 
Interleukin-4 selectively induced endothelial expression of vascular cellular adhesion 
molecule-1 (VCAM-1) and eosinophil chemotactic factor and, consequently, is responsible for 
selective recruitment of eosinophils. It is not known how Th, cells may be selectively 
recruited in the late phase reaction. 
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Cellular Infiltration 
Eosinophilia has long been associated with allergic diseases. Eosinophils can affect the 
allergic response by releasing cytotoxic proteins (e.g., major basic protein), lipid mediators 
(e.g., LTC^), oxygen radicals, and cytokines (e.g., lL-3) . Investigators have studied the 
movement of eosinophils and other cells to the site of antigen provocation. 
Hours after challenge, the number of eosinophils and basophils increase in nasal 
secretions . The recruited cells release mediators that affect the local environment. In the 
submucosa, eosinophils also increase in number, but the greater increase is in the number of 
lymphocytes, particularly T-helper cells. These cells provide a source of cytokines, proteins 
released and secreted by stimulated cells that amplify and regulate local immune responses 
The pattern of cytokine secretion of T-helper cells allows their further subdivision into Th, 
and Th2 cells. Thj cells elaborate cytokines involved in effector functions of cell-mediated 
immunity (i.e., IL-1, interferon), whereas Th, cells elaborate cytokines that control and 
regulate antibody responses (e.g., IL-4, GM-CSF, EL-13) . 
Tho cells, the predominant lymphocytes in allergic mucosal inflammation, help to 
perpetuate the allergic response. For example, IL-4, released mainly by Th, lymphocytes, 
supports B cell growth and differentiation, increases expression of VCAMs on endothelial 
cells, induces uncommitted T cells toward the Th2 phenotype, and promotes switching to IgE 
antibody formation. Other cytokines support eosinophil growth and prevent apoptosis. The 
importance of individual cytokines is speculative at this time because cytokines have 
overlapping functions and multiple activities. 
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Chemokines, or chemotactic cytokines, attract and activate lymphocytes, granulocytes, 
and monocytes . They are 7-16 kDa proteins with four conserved cysteine residues. Based 
on the position of the first two conserved cysteines, they are divided into two subfamilies, 
which differ in the cells they primarily attract and in the chromosome location for their 
encoding genes. The C-C subfamily of chemokines selectively attract eosinophils . These 
include RANTES, monocyte chemotactic protein (MCP)-l, MCP-3, and eotaxin. Although 
they are classified as chemokines, some have other activities, such as affecting 
immunoglobulin production. Despite the fact that the number of chemokines is great, many 
activate eosinophils through a shared receptor, CKR-3. Thus, a strategy to lessen their effect 
on eosinophil migration may be the use of receptor blockade rather than inhibition of their 
synthesis. 
Accumulating evidence supports the importance of leukocyte and vascular endothelial cell 
adhesion molecules in the migration of inflammatory cells, including eosinophils, into tissue 
sites during allergic reactions. This involves a sequence of events that includes margination of 
leukocytes along the walls of the microvasculature, adhesion to the endothelium, 
transmigration through the vessel walls, and migration along a chemotactic gradient within the 
extravascular compartment that contains extracellular matrix proteins such as fibronectin. 
These events are mediated by adhesion molecules such as integrins, selectins, and members of 
the Ig gene superfamily . 
Intercellular adhesion molecule (ICAM)-l, VCAM-1, and E-selectin are three 
representative endothelial adhesion molecules. They can be upregulated on endothelial cells 
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by IL-1, TNF-a, and lipopolysaccharide. ICAM-1, a ligand for the Bj-integrin molecules 
lymphocyte ftinction-associated (LFA)-1 and the type 3 complement receptor Mac-1, which 
are present on the surface of leukocytes, mediates the attachment of all classes of leukocytes 
to endothelial cells. ICAM-1 is known to be constituitively expressed on vascular endothelial 
cells and can be induced by inflammatory mediators on other extravascular cells. E- selectin 
binds to sialyl Lex, which is expressed on the surface of leukocytes . 
VCAM-1, like ICAM-I, is a member of the Ig gene superfamily and supports the adhesion 
of leukocytes to endothelial cells through interactions with the integrin molecule VLA-4 
(a4Pi), which is present on the surface of lymphocytes, monocytes, eosinophils, and basophils, 
but not neutrophils. VCAM-1 expression can be selectively induced on the endothelium by 
treatment with IL-4 . 
Montefort et al.observed increased expression of ICAM-1 and VCAM-1 in nasal 
mucosal biopsy specimens from subjects with perennial allergic rhinitis compared with that in 
normal control subjects. Georas et al."'~ reported increased levels of a soluble form of E-
selectin 19 hours after bronchoscopic allergen provocation in subjects with allergies. 
Subsequently, Lee et al."^^ confirmed the previously reported constituitive expression of 
ICAM- 1 on the vascular endothelium in nasal biopsy specimens. They also showed that the 
percentage of vessels expressing VCAM-I is upregulated 24 hours after allergen challenge 
and that E-selectin is modestly upregulated by ICAM-1 is not. This is consistent with a role 
for IL-4 in the induction of these changes and suggests that these events are mediated by an 
IgE-dependent mechanism, as they were observed by subjects with allergies, but not in 
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subjects without allergies after antigen challenge. Because the counterligand for VCAM-1, 
VLA-4, is present on eosinophils but not on neutrophils, it is speculated that the upregulated 
recruitment of eosinophils into the nasal mucosa after antigen provocation and may play an 
important role in the pathogenesis of allergic inflammation. 
Clinical Manifestations of Immediate Hypersensitivity 
Immediate Hypersensitivity Reactions in the Skin 
When an allergen is introduced into the skin of a sensitized, atopic individual, the reaction 
that ensues is mediated largely by histamine . Histamine binds to venular endothelial cells, 
which express numerous histamine receptors. Almost immediately, the endothelial cells 
synthesize and release prostacyclin, nitric oxide, and platelet activating factor (PAF). These 
mediators cause vascular smooth muscle cell relaxation, and the injection site becomes red 
from local accumulation of red blood cells. The endothelial cells also retract, allowing plasma 
to extravasate. The initial redness (erythema) is then replaced by soft swelling, the 
characteristic "wheal." Finally, the blood vessels on the edge of the wheal dilate in a reaction 
augmented by the nervous system, producing the "flare". Antihistamines (HI receptor 
antagonists) can block this response almost completely. Skin mast cells appear to produce 
little in the way of long-acting mediators, such as leukotrienes, and the wheal and flare 
response typically subsides after about 15 to 20 minutes. Clinically, this reaction can occur 
after contact of the skin with an allergen,, or after an allergen enters the circulation via the 
intestinal tract or by injection. The cutaneous reaction to systemic allergens, called urticaria, 
may persist for several hours, probably because antigen persists in the plasma. 
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In many atopic patients, a late phase reaction begins after about 2 to 4 hours. Tumor 
necrosis factor, IL-4, and other cytokines, probably derived from mast cells, act on the venular 
endothelial cells to promote inflammation involving the production of vasodilators, adhesion 
molecules, and chemokines that facilitate leukocyte diapedesis. As may be expected for a 
cytokine-mediated response, the late phase inflammatory reaction is not inhibited by 
antihistamines. It can be blocked by pretreatment with corticosteroids, which inhibit cytokine 
synthesis. Chronic eczema is probably a clinical manifestation of the late phase reaction in the 
skin. Eczema is often treated with corticosteroids. 
Immediate Hypersensitivity Reactions in the Lung 
Immediate hypersensitivity (asthmatic) reactions in the lung resemble skin reactions in 
some ways, but differ in others. In the lung, mast cell mediators act not only on the blood 
vessels but also on bronchial smooth muscle. Bronchial asthma is characterized by paroxysms 
of bronchial constriction and increased production of thick mucus, which leads to bronchial 
obstruction and exacerbates respiratory difficulties. The smooth muscle cells in the airways of 
asthmatics are often hypertrophied and are hyper-reactive to constricting stimuli. Bronchitis 
and infections are frequent complications. Most cases of asthma are due to immediate 
hypersensitivity, and the bronchial mucosa contains increased numbers of eosinophils and 
CD4+ T cells of the Th, subset. However, less frequently asthma may not be associated with 
atopy. 
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Systemic Immediate Hypersensitivity 
In systemic immediate hypersensitivity, such as anaphylactic shock, vasodilation and 
vascular exudation of plasma occur in vascular beds throughout the body. This usually 
implies the systemic presence of antigen, either by injection, insect sting, or absorption across 
an epithelial surface, such as the skin. The decrease in vascular tone and leakage of plasma 
lead to a fall in blood pressure, or shock, that may be fatal. The cardiovascular effects are 
complicated by constriction of the upper and lower airways, hypersensitivity of the gut, 
outpouring of mucus in the gut and respiratory tree, and urticarial lesions (hives) in the skin. 
The most important mast cell mediators of anaphylactic shock are not fully known. The 
mainstay of treatment is systemic epinephrine, which can be lifesaving, reversing the 
bronchoconstrictive and vasodilatory efiFects of the various mast cell mediators. Epinephrine 
also improves cardiac output, further aiding survival from threatened circulatory collapse. 
Antihistamines may also be beneficial in anaphylaxis, suggesting a role for histamine in this 
reaction. In some animal models, PAF receptor antagonists ofifer partial protection. It is also 
possible that TNF is an important mediator of anaphylactic shock, much as it is in septic 
shock. 
Hypersensitivity Reactions in Cattle 
One of the earliest hypersensitivity reactions described in cattle was milk allergy 
This syndrome is characterized by respiratory distress and coughing and pathologically by 
pulmonary edema and hemorrhage. The syndrome was associated with milk retention by the 
cow. Campbell demonstrated that the udder-derived protein, a-casein, was responsible for 
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this allergic reaction in cattle. This view was supported by the earlier observation that casein 
was iso-antigenic in the goat ^ . Systemic anaphylactic-type reactions have been reported in 
c a t t l e  e x p e r i m e n t a l l y  s e n s i t i z e d  t o  e q u i n e  s e r u m ,  e g g  a l b u m i n ,  a n d  p u r i f i e d  o v a l b u m i n  — .  
Induction of respiratory allergy in cattle has not been extensively studied. Limited 
attempts have been made to reproduce hypersensitivity in the respiratory tract of cattle. 
Allergic response to aerosolized ovalbumin was induced in calves by previous parenteral 
sensitization by repeated intramuscular injection of antigen in adjuvant ^ . Most calves 
developed precipitating and skin-sensitizing IgE antibody. The response to aerosol challenge 
was proportional to the magnitude of detectable serum antibody responses. Unsensitized 
animals did not respond. When high concentrations of aerosolized antigen were used, 
responses occurred within 90 minutes or not at all. Lower concentrations induced responses 
within 3-4 hr. Elevated respiratory rate, dyspnea, moist cough, and rales were usually 
observed. However, in animals which had the highest level of IgE antibody, clinical response 
was of the asthmatic type and included labored, open-mouthed breathing, wheezing, and death 
within a few minutes of exposure. Repeated exposure usually resulted in a reduction in 
severity of signs. Peripheral blood neutrophilia, lymphopenia, and eosinopenia occurred 
within 3-4 h of exposure. The findings of Dungworth, using ovalbumin as antigen, have been 
confirmed and extended by a series of studies employing particulate and soluble antigens of 
Micropolyspora faeni Mannheimia (Pasteurella) hemolytica BRSV BHV-1 
, Bluetongue virus and border disease virus . In most cases, hypersensitivity was 
evaluated using viable or killed microorganisms. 
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In BRS V and human RS V infections, there is evidence that immunoglobulin responses are 
not always protective and, in some instances, such as post vaccination reactions, the resultant 
disease is more severe than in nonvaccinates . Observational evidence suggests that there 
appears to be more severe clinical respiratory disease in vaccinated than nonvaccinated calves. 
Immune hypersensitivity has been considered as a possible factor in the pathogenesis of bovine 
respiratory disease due to BRSV . One would, therefore, expect that limited sequential 
viral exposures would induce increasingly severe or prolonged disease expression. For this 
process to have a role, initial viral exposure must occur to induce a sensitized state. 
Vaccinations could participate in the pathogenesis of bovine respiratory disease by 
aggravating the disease process during subsequent infections. This hypothesis is supported by 
a large field study where a positive correlation existed between increased mortality in cattie 
and the use of various types of respiratory vaccines . However, these were not exclusively 
inactivated vaccines nor were they all administered parenterally. 
The basic objectives of this research were to determine if type-1 hypersensitivity to 
H. somrtus could be induced in calves. Clinical signs (e.g., tachypnea, excessive lacrimation 
and salivation, abdominal bloating, unsteady gait, and collapse) were monitored as physical 
measures of type-1 hypersensitivity reactions. Urinary, plasma, or serum concentrations of 
biochemical mediators of allergic hypersensitivity (e.g., IgE, eicosanoids, histamine, and 
serotonin) were also determined. Diflferential white blood cell counts were determined as 
well. 
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CHAPTER 2. BOVINE TYPE-1 HYPERSENSITIVITY I: 
HAEMOPHILUS SOMNUS 
A paper submitted to Comparative Immunology, Microbiolog>', and Infectious Disease 
K. W_ Ruby, R. W. Griffith, L. J. Gershwin . and M.L. Kaeberle 
Abstract A small number of calves w^ere experimentally sensitized to live Haemophilus 
sommis organisms and Micropolyspora faeni. Calves 452 and 454 were H. ic/m/m.v-sensitized 
and challenged; Calves 451 and 455 were M 7^7tr///-sensitized and challenge; Calves 453 and 
456 served as controls and were challenged with H. sommis Skin testing was performed with 
H. sommis. M. faem. and bovine respirator^' syncytial virus (BRSV) one week prior to 
challenge- Antigen-specific lg£ & IgG, and plasma histamine were measured by ELISA. 
Differential white blood cell counts were also performed. Ail animals were monitored for 
clinical signs of anaphylaxis throughout the study. .Anti-M faeni and ami-//, somnus IgE and 
IgG antibodies rose steadily throughout the sensitization period. Sensitization did not alter 
serum histamine concentrations. Most calves reacted to M faeni and BRSV antigen by skin 
testing; only Group 2 calves reacted to H. somnus antigen. Except for one calf all calves had 
detectable levels of anti-M faeni and anti-//. sommis IgE and IgG prior to challenge. 
Basophilia and increased percentages of eosinophils were noted in all calves prior to 
challenge. Serum histamine concentrations were increased by 0.5 h post-challenge. 
Tachypnea was present in all calves 0.5 h post-challenge. Results of this pilot study suggest 
that H. somjHis may be able to induce a hypersensitized state in calves. This study also 
suggests that many Iowa calves may have IgE and IgG levels against M. faeni 
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Introduction. 
Respiratory disease continues to be a major disease problem in ail types of cattle 
operations. Etiological agents include Pasteurella haemolytica, Pasteurella multoctda, 
Haemophilus somtms, as well as several viruses. Vaccines have been developed for most of 
the recognized infectious agents and are utilized extensively. These are efficacious in many 
situations but have not always provided adequate control of the disease and, in some 
instances, may be contributory to a disease process. 
Various bacterial components are associated with the development of hypersensitivity in 
humans with production of arachidonic acid metabolites. Induction of respiratory allergy has 
not been extensively studied in cattle. Reports are basically restricted to the reactions 
associated with Micropolyspora faeni ^ ^ and bovine respiratory syncytial virus (BRS V) 
®. Micropolyspora faeni, a thermophilic actinomycete present in moldy hay, has been 
associated with induction of type-1 hypersensitivity reactions in bovine lungs . 
Observational evidence suggests that there is more severe clinical disease in vaccinated cattle 
than in nonvaccinated cattle. The purpose of the study reported here was to experimentally 
induce a hypersensitive state to H. sommis organisms using a small number of calves. 
Materials and Methods 
Animals. 
Seven 6-week: old (150-200 pounds), Holstein calves seronegative ^ov Haemophilus 
somtms antibody were obtained from a local supplier. Calves were maintained on a 
commercially prepared diet containing tetracycline (400 g/ton). Ail calves were vaccinated 
with a four-way viral vaccine prior to arrival. All animals were housed at the Iowa State 
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University College of Veterinary Medicine. 
Experimental Design. 
Description of treatments are shown in Table 1. Calves 451 & 455 served as positive 
controls and were sensitized to Micropolyspora faeni sonicated antigen by intratracheal 
injection or intranasal aerosol (5 ml or 1 ml per sensitization, respectively). Calves 452 & 454 
were sensitized to washed, live H. somnus organisms by intratracheal injection (5 ml per calf 
per sensitization). Calves 453 & 456 served as non-sensitized controls. After a resting period 
of 4 weeks, all calves were challenge-exposed to either M faeni or H. somnus. 
Antigen Preparation. 
A stock culture ofM faeni was obtained from the American Type Culture Collection and 
was grown on V-8 agar^ for 4 days at 48 °C. The growth was harvested, washed, and 
resuspended in sterile phosphate buffered saline (PBS; 0.05 M phosphate, pH 7.2) and 
sonicated for 5 minutes at fiill output. The V-8 agar growth provided spores as well as 
mycelial growth. The sensitizing material was prepared by suspending a wet-cell mass (0.3 g) 
in 5-ml sterile PBSS for each calf. Sensitizing material for the last two sensitizations was 
prepared in a similar manner using a 0.6 g wet-cell mass suspended in 5-ml sterile PBSS. 
Sensitizing material was kept on ice until time of sensitization. 
A stock culture of H. somnus was used to inoculate brain-heart-infiision broth 
supplemented with 10% bovine serum and 0.05% yeast extract (BHISY). The broth was 
incubated for 2 days at 37°C in 10% CO2 in air and 0.1 ml spread on BHISY plates. After 
incubating for 48 h at 37°C, growth was harvested in sterile phosphate buffered saline (PBS, 
pH 7.2; 3 ml/plate) and centrifuged at 13,000 x g and the cell pellet was resuspended in PBS 
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followed by centrifugation. This procedure was repeated twice more. The cell pellet from the 
last centrifugation was resuspended in 20 ml PBS and the cell density adjusted so that each 
calf received approximately 2.4 x 10" organisms/ml Sensitizing material was kept on ice until 
use Challenge material was prepared in a similar manner except each calf received 1 x 10" 
organisms/ml. 
A Triton X-100 extract of H. sommis was utilized as one antigen in intradermal skin 
testing and was prepared according to estabUshed protocol Approximately 150 ml of//. 
sommis broth culture was centrifliged at 13.000 x g for 30 minutes at 4 C. The pellet was 
washed as described above. After the final wash, the cell pellet was resuspended in 11 ml of a 
Tris-tricine solution containing 5 mM EDTA and 0.01% (v/v) of Triton X-lOO (Sigma 
Chemical Co., St. Louis. MO). The mixture was incubated for 24 h on a platform rocker at 
room temperature (26°C±2°C) followed by centrifugation at 12.000 x g for 30 minutes at 
4°C. The supernatant containing the outer membrane antigens was removed and stored at 
4°C. The protein concentration of the extract was determined using the Biuret method. 
Sensitization Procedurti (Table 1) 
Micropolyspora faeni-stnsxtizQd calves received ten sensitizations at 3-4-day intervals for 
three weeks followed by daily sensitizations for 6 days. Each M faeni sensitization consisted 
of an intratracheal injection (10 ml) and an intranasal spray (1 ml/nostril) of a sonicated M 
faeni antigen. Haemophilus sommis-sQx\s\tixed calves received a total of 7 sensitizations at 
3-4-day intervals. Each of the first 6 H. sommis sensitizations consisted of an intratracheal 
injection of 20 ml PBS containing approximately 4.8 x 10' washed, live H. sommis 
organisms/ml. The last sensitization consisted of an intravenous injection of 1 ml of washed. 
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live H. somnus organisms (2 x lO'* org/ml). 
Ifitradermal Skin Test. 
Calves were tested for immediate and delayed-type hypersensitivity by intradermal 
injection ofM faeni, H. sommis, and BRSV antigens 1 week prior to challenge. Testing was 
done on the inner aspect of the hind quarters. The M factu antigen was prepared in a similar 
manner used to prepare sensitizing antigen. There were two H. sommis preparations, a Triton 
X-100 extract (13.4 mg/ml) and one prepared using a French press provided by Dr M. L 
Kaeberle. The BRSV was a sonicated whole virus preparation provided by Dr. M. L. 
Kaeberle. Two-hundred microliters of each antigen was injected intradermally Histamine 
(0.2 ml of a 1.10.000 dilution) and sterile saline solution (0.85%) served as positive and 
negative controls, respectively. Injection sites were measured for characteristic wheals of type 
I immediate hypersensitivity 0.5-. 1-. and 24-h later. Wheal diameter was measured by 
palpation and were considered to be positive (^) if the diameter was 10-20 mm. firm, and 
diffuse. 
(ha/lan^e Procedure (Table 2) 
Micropolyspora faeni-sensitized calves were challenged with 20 ml of an M. faeui 
sonicate by aerosol exposure. The duration of exposure was approximately 15 minutes. 
Haemophilus iomw/i-sensitized calves were challenged intravenously with 10 ml of washed, 
live H. somnifs organisms (1 x 10®* org/ml). 
Sample C \)lleciion. 
Blood samples were obtained from the jugular vein in EDTA. oxalate, and serum tubes. 
Samples were collected weekly during the sensitization period as well as at time 0, 0.5 h. Ih, 
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and 24 h relative to challenge. Serum or plasma was harvested by centrifligation at 700 x g 
for 15 minutes and frozen at -20°C 
Enzyme-linked immmiosorbem assay (ELISA) for M. faeni-specific IgE and IgG. 
Anti-M faeni IgE was determined by a modification of the method of Gershwin et al. 
Briefly, 100 p.! of sonicated M. faeni antigen (diluted in 0.05 M carbonate buffer (pH 9.6)) 
was added to wells of a 96-well Immulon I microtitration plate (Dynatech Laboratories. Inc., 
Alexandria. V.A.) at a concentration of 4 ug/well. The plate was incubated for 3 hours at j7°C 
and washed once with PBS containing 0.05% Tween 20 (0.05% PBST). Serum samples 
(undiluted and I;2 in PBST) were added (100 jil/well) to duplicate wells and the plate 
incubated for 30 minutes at 37°C on an orbital shaker. After washing 7 times with PBST. a 
1: l.OOO dilution of anti-bovine IgE monoclonal antibody (L. J. Gershwin. UC Davis, C.A) was 
added to each well (100 iil/well) and the plate incubated for 30 minutes at 37°C on an orbital 
shaker. After washing the plate 5 times, a 1:2.000 dilution of goat anti-mouse IgG (H^L) 
horseradish peroxidase-labeled antibody conjugate (Kirkegaard-Perry Laboratories, Inc., 
Gaithersburg. MD) was added to each well (100 y.l/well). Following a 30 minute incubation 
at 37°C without agitation, the plate was washed 4 times. The color substrate ABTS 
(Kirkegaard-Perry Laboratories. Inc., Gaithersburg. MD) was added to each well 
(100 |il/well). The plate was incubated 30 minutes at 37°C and the color reaction was 
stopped by adding 100 jil/well of a 10% SDS solution. The plate was read at a dual 
absorbance of 405/490 nm (Vmax Microtiter Reader, Molecular Devices, Inc., Menlo Park, 
C.A.). Blank absorbance values were subtracted from all wells. Negative controls consisted of 
PBSS. sterile fetal bovine serum (Intergen. Inc.), and normal calf serum negative for 
H. somniis antibody. Pooled sera obtained from calves exhibiting clinical signs of H. somnus 
pneumonia was used as a positive control. Absorbance values of the normal calf serum wells 
were subtracted from all test sample absorbance values. Anti-M faeni IgG levels were 
determined in a similar manner with the following modifications Bovine sera were used at a 
1:400 dilution. A I ;2500 dilution of rabbit anti-bovine IgG horseradish peroxidase antibody-
conjugate was used. All other steps in the ELISA protocol were the same. 
Enzyme-linked immiinosorhenl assay (ELISA) for H. sommis-specific IgE and IgG. 
One hundred microliters of a 1:100 dilution (in carbonate-bicarbonate buffer. pH 9.6) of 
heat-inactivated whole cells of H. somnus was added to each well (5.6 [ig/well) of a 96-well 
lmmulon-2 microtitration plate (Dynatech Laboratories. Inc., Alexandria. VA) and incubated 
overnight (16-20 h) at room temperature (25-27°C) with agitation. .After washmg the plate 
once, wells were blocked with 200 |j.l of a 1% solution (w/v) of polyvinyl alcohol (PVA: 88° b 
hydrolyzed, Aldrich Chemical Co. Inc.. Milwaukee, WI) dissolved in sterile PBSS. After a 30 
minute incubation at room temperature (25-27C°), the plate was washed twice with distilled 
water, and serial two-fold dilutions (beginning with 1:5) of sera in 1% PV.A were added to 
duplicate wells (lOOfil/well). After a 30 minute incubation at 37°C on an orbital shaker, the 
plate was washed 9 times with distilled water followed by addition of a 1:1,000 dilution (in 
1% PV.A) of anti-bovine IgE monoclonal antibody (100 |a.l/well). The plate was incubated for 
I.5 h at room temperature (25-27°C) on an orbital shaker. After washing the plate 6 times 
with distilled water. 100 pi of a 1 ;2,000 dilution (in 1% PVA) of goat anti-mouse IgG (H+L) 
horseradish peroxidase-labeled antibody conjugate (Kirkegaard-Perry Laboratories. Inc.. 
Gaithersburg, MD) was added to each well. The plate was incubated for 30 min at room 
temperature (25-27°C) on an orbital shaker followed by washing 6 times with distilled water 
The color substrate ABTS was added (100 |il/well) and allowed to react at 37°C for 30 
minutes. The color reaction was stopped by adding 100 jil/well of a 10% SDS solution and 
the plates read on an ELISA reader (Molecular Devices, Inc., Menio Park, CA) at a dual 
wavelength of 405/490 nm. Blank absorbance values were subtracted from all wells. 
Negative and positive controls were the same as those indicated above. After the average 
optical density (OD) of blank wells was subtracted from the OD values of control and test 
sera, the average OD value of the normal calf sera was subtracted from all test sample 
absorbance values. Anti-//. sommis IgG levels were determined in a similar manner with the 
following modifications. Bovine sera were used at a 1:400 dilution and a 1:2500 dilution of 
rabbit anti-bovine IgG horseradish peroxidase antibody conjugate was used. 
Histamine A nalysis. 
Samples were assayed for histamine content by a modified fluorometric technique'' . 
Positive controls consisted of various concentrations (5,000, 1,000, 500, 250, 100, 50. 25. 10. 
5. 0.5, 0.05, and 0.005 |J.g/ml) of histamine (Sigma Chemical Co., St. Louis, MO) and were 
prepared m 0 12 N HCl. Negative controls consisted of normal calf sera as described above 
and were prepared in 0.12 N HCl. Briefly, 4.5 ml sterile, distilled water was added to 5.0 ml 
of oxalated blood followed by 0.5-ml perchloric acid. After mixing for 30 minutes at room 
temperature, samples were centriftiged at 500 x g for 15 minutes at 4°C and the supernatant 
was stored at -20°C until organic extraction was performed. One-milliliter of acidified sample 
was added to a glass tube containing 300 mg NaCl and 1.25 ml n-butanol. Next. 100 ^1 of 3 
N NaOH was added and the tubes agitated for approximately 5 minutes followed by 
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centrifugation at 600 x g for 10 minutes at 4°C. After centrifligation. 1 ml of the butanol 
phase (top layer) was removed and transferred to a glass tube containing 600 |il of 0.12 N 
HCl and 1.9 ml of «-heptane. After mixing for 5 minutes, the samples were allowed to stand 
upright for approximately 10-15 minutes. After separation of the two phases, 0.5 mi of the 
0.12 N HCl phase (the histamine-containing bottom layer) was removed and placed into a 
cuvette. 
To each control and test sample. 100 iil of 1 N NaOH was added and the mixture 
agitated for 2 minutes followed by addition of 25 |j.l of o-phthaldialdehyde (OPT) solution in 
methanol. After mixing for 20-30 minutes. 50 |il of 2 M HjPO^ was added to stop the 
reaction and the samples were read in a fluorometer with an excitation wavelength of 360 nm 
and a fluorescent emission of 450 nm. After subtracting the blank emission value from all test 
samples and controls, a standard curve was generated by plotting histamine concentration vs 
fluorescence emission at 450 nm. The histamine concentration of test samples was determined 
by finding the emission value on the standard curve and drawing a perpendicular line to the 
x-axis 
Results 
Sensitization Period. 
All calves had detectable levels of anti-M faeni IgE after the 4th and 5th week of 
sensitization (Tables 4 & 5). .All calves had detectable anti-M faeni IgG antibody at the start 
of sensitization. Although detectable anti-//. somnus IgE antibody was present in all calves by 
the 4th week, higher levels were seen in Group 2 calves. Group 2 calves had higher levels of 
anti-/^. sommis IgG by the 4th week 
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Intradermal Skin Testing. 
All calves reacted to sonicated M. faeni 30 minutes after injection; only Group 2 calves 
failed to react at I and 24 h after injection (Table 3). Only Group 2 calves reacted to H. 
somrnis antigen. Except for calf 451, all calves reacted to BRSV antigen. 
Challenge. 
Prior to challenge, basophilia and increased percentages of eosinophils were present in all 
calves (data not shown). Regardless of challenge, all calves had detectable levels of anti-
M. faeni and anti-//. sommis IgE prior to challenge (Tables 4 & 5). Similar results were noted 
for anti-M faeni and anti-//. sommis IgG levels except that Group 1 calves had no detectable 
anti-//. sommis IgG levels. Histamine levels increased significantly in all calves by 0.5 h 
post-challenge (data not shown). All animals exhibited dyspnea and tachypnea by 0.5 h 
post-challenge. The increase in respiratory rates were generally accompanied by an 2-3°F 
increase in temperature. Dyspnea continued for 2 days after challenge in Group 3 calves but 
did not require intervention. 
Discussion 
Induction of respiratory allergy has not been extensively studied in cattle. Reports have 
been basically restricted to the reactions associated with M faeni and BRSV Allergic 
responses to environmental antigens are the most difficult to monitor. Micropolyspora faeni. 
which is commonly found in moldy hay produces such antigens. Immediate hypersensitivity is 
a result of an allergic state mediated by cross-linking of IgE bound to receptors on mast cells 
and basophils in response to the appropriate antigen exposure, Degranulation results in the 
clinical signs/symptoms associated with allergic phenomena: tachypnea, fever, itchy eyes. 
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salivation, edema, depression, anorexia, etc. The purpose of this pilot study was to determine 
the ability of H. sommis to induce an immediate hypersensitive state in calves and to measure 
that response. Sensitization with M. faeni was used as a positive control. 
In this small study, the occurence of M. faeni-s^QC&c IgE and IgG in all calves was not 
surprising since this organism is commonly found in hay in Iowa. However, H. sommis-
specific IgE was observed inM yorew-sensitized calves. H. somnus is a part of the normal 
flora in the nasopharynx of apparently healthy calves. These calves may have developed 
anti-H. somnus IgE antibody due to maternal transfer of anti-^. somnus IgE into colostrum or 
to the continued presence of this organism in low numbers ove an extended period of time. In 
humans, prenatal allergic sensitization to microoranisms may occur , suggesting that the 
fetus can mount a humoral response against these antigens. A similar mechanism may occur 
in the bovine fetus. Weil et al.^° suggested that cord blood IgE against helminth parasites was 
derived from the fetus in most cases and not from transplacental antibody transfer in humans. 
The influence of maternal heredity factors may also explain the low levels of anti-//. somnus 
IgE. Martin Esteban et al. " demonstrated that food hypersensitivity in infants without prior 
antigen intake may be due to breast milk and/or transplacental antigen passage of antigen in 
utero. ff transplacental transfer of H. somnus antigen does occur in cattle, minute quantities 
of antigen may sensitize the fetus, provided the possible genetic (maternal- or 
patemal-derived) high responsiveness for IgE synthesis. Associated with sensitization in utero 
is the influence of paternal and maternal heredity. In human studies, a general finding weis 
that paternal heredity had no significant influence on infant IgE and atopic disease, whereas 
there was a strong influence of maternal heredity . 
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Because the commercially prepared feed contained tetracycline, growth of H. sonnnis may 
have been restricted but may not have completely contained the organism on mucosal 
surfaces. As a result, calves may have become sensitized to H. summis. Finally, the low 
levels of znli-H. sommis IgE antibody detected in these calves may be a result of 
cross-reactive epitopes with other Gram negative bacteria that are more resistant to 
tetracycline. It is likely that Pasieiirella spp. share antigens and that these calves most likely 
had a subclinical infection with P. mnltocida or P. hemolytica. 
Gershwin et al." demonstrated high M,g to low-mg quantities of histamine in M. faetii-
sensitized and challenged calves. Higher levels of histamine have been reported by other 
workers in calves sensitized and challenged with M. faetii or BRSV. In the present study, 
mg-quantities of histamine were detected in H. .so/7?//?/5-sensitized and control calves following 
a challenge with H. sommis. We have previously demonstrated histamine production by 
H. samnus The high histamine levels may reflect the H. somnus challenge. 
All calves exhibited tachypnea and fever (data not shown) follov»ang challenge with either 
M faeni or H. sommis. The greatest increase in respiratory rate was observed in H. sommis-
sensitized calves in which respiratory rates rose to 140 per minute accompanied by a 2-3 °C 
rise in temperature. It is of interest that non-sensitized control calves exhibited similar clinical 
anaphylactic responses and of longer duration after H. sommis challenge. This could suggest 
that calves may have a low, but sufficient, level of IgE antibody against H. sommis organisms. 
However, it is more likely that these responses were due to histamine production by the 
H. sommis challenge. Histamine has been shown to enhance anaphylactic histamine release 
from bovine lung and leukocytes via the histamine H, receptor . Thus, the responses 
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observed in non-sensitized calves following challenge may be due to the effects of the 
challenge organism. 
Based on clinical responses to challenge with live organisms, skin testing results, and 
profiles of mediators of anaphylaxis, this small study suggests that young calves can become 
sensitized to H. sommis. In addition, this study suggests that many calves in Iowa may have 
IgE and IgG antibody against M. faeni Further study into the sensitizing capabihty of H. 
somnus is indicated. 
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Table 1 Description of sensitization treatments. 
Calves 451 & 455 Calves 452 & 454 Calves 453 & 456 " 
T reatment 
.A.ntigen Sonicated XL faeni 
(0.2 g m 5 ml PBS) 
Washed. live H. somnus 
(2.4 .\ 10° orgs/ml in PBS) 
None 
Route IT/IN aerosol'' IT 
Volume 5 ml/ 1 ml 5 ml 
Total No. Sensitizations 10 7 
Interval 3-4 Days 3-4 Days 
Resting Period 4 weeks 4 weeks 
'* = Non-sensitizcd control calves. 
' = Each calf was administered an intratracheal injection with 5 ml of sonicated M. faeni antigen and an 
aerosol spray iniranasall\ (I ml/nare). 
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Table 2. Description of challenge procedures. 
Calves -451 & -155 Calves 452 & 45-4 Calves 453 tfe 456 " 
Treatment 
Antigen Sonicated XI. faeni 
(0.6 g in 20 ml PBS^ 
Washed, live H. somnus 
(1 \ lO' orgs/ml in PBS) 
Washed, live H. 
somnus 
(I X lO** orgs/ml m 
PES'") 
Route Aerosol (15-imnute 
duration) IV IV 
Volume 60 ml 10 ml 10 ml 
Table 3. Intradermal Skin Testing Each calf was injected (id) with 0.2 ml of each antigen on 
the inner aspect of the thigh one week prior to challenge. Results were recorded 30 minutes 
later 
M. faeni-
Sensitized Calves 
H. somnus-
Sensitized Calves Control Calves 
451 455 452 454 453 456 
Antigen ^ 
H. sontnus 
Tx-WU E.xtract _ b _ 
M.f aeni Sonicate - - -
H. sontnus (French Press) - - -
BRSV 
- - - -
Normal Saline 
- - - - -
Hi.stamine - - • 
•* = 0.2 ml of each antigen was injected intradermally. Histamine (1:10.000 dilution in normal saline solution) 
and nonnal saline solution ser\ed as positive and negative controls. respectiveK. 
'• = Results e.\pressed 30 iiunutes after intradermal injection of antigen. A positi\ e (-^) reaction was denned as 
wheal dimensions of I(i-20 cm. diffuse, and finn. 
Tabic 'I. Anii-A/ facni Igl- and IgCJ lc\ cIs of individual cah cs during llic .scnsilizalion and challcngi;. Results arc expressed as a 
percentage of a reference serum. 
IgE IgG 
Calf No; 451 452 453 454 455 456 451 452 453 454 455 456 
Week ofSensitizadon 
0 0 0 0 0,5 0 0 5,2 5,9 4.9 6,4 12,1 7.3 
1 1 0 0 0 6,9 9,4 47,2 21,3 9.8 22,4 37,7 7,8 
2 0 0 11.8 0 27 18,1 41,4 25,8 7.6 25 53.1 8,9 
3 8.7 0 19.8 0 37,1 34,2 65,2 29,3 15.6 29,5 66.8 16,2 
4 51.1 0 9.4 7,4 45,5 54,2 82,8 33,9 19.5 36,1 73,5 25,6 
5 63.9 0 38,8 12.3 54,9 66,7 98.2 39,3 24.9 43,5 78,3 23,6 
Challdigc (hours)' 
0 46.7 0 4.8 17,1 32,5 43,1 126,5 90,8 31,8 78,5 96,1 33,2 
0.5 43.1 0 0 0 0 35,2 118,7 71,6 28.8 57,4 71,2 27,4 
24 80.5 0 0 0 0 37,4 126.3 67.5 30,4 64.1 67 24,2 
'  = Cahes 451 and 455 were challenged with M. f(ieni\ remaining calves were challenged with washed, live II. somnus organisms. 
Tabic 5, Ami-//. .v(»(»;}i(.v Igl: ami IgG levels ol'uuiividnal calves during llie sensitization and challenge, Results arc expressed as a 
percentage of a refcrcnce scrum. 
IRE IgG 
451 452 453 454 455 456 451 452 453 454 455 456 
1 f'ee/c ofSensilizalion 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 7.5 0 0 0 0 0 0 3,9 0 7,3 0 0 
2 33,3 0 13.7 5.1 0 0 0 2.3 0 14,6 0 0 
3 1 1 8  0 0 4.1 0 0 0 8,0 0 17,9 0 0 
4 4.2 33 9 23.1 39.8 2.7 2.3 0 14,6 2,3 24,2 0 0 
Challenge (lioiirs) " 
0 4.1 42,2 159,3 101.4 92.5 19«.l 0 53,8 6,6 63,1 0 9,9 
0.5 20.5 5.3 24.6 4.8 54,4 126,0 0 52,3 4,4 72,5 0 6,6 
24 58.3 66.9 96,8 131.3 90.1 67,2 10,8 74,8 0,4 84,5 0 0,9 
" = Cal\cs 451 and 455 were cliallcngcci willi M. faem\ remaining caKcs were cliallengcd willi washed, live //. xoiiinus organisms, 
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CHAPTER 3. A PRELIMINARY STUDY II: ENHANCED BOVINE 
TYPE-1 HYPERSENSITIVITY WITH ALUMINUM HYDROXIDE 
ADJUVANT 
A paper submitted to Comparative Immimology, Microbiology, and Infectious Disease 
Kevin W. Ruby, Ronald W. Griffith, Laurel J. Gershwin, and Merlin L. Kaeberle 
Abstract. To evaluate various antigen preparations for their ability to sensitize calves for an 
allergic response, calves were sensitized to either ovalbumin (OA) or equine sera (with or 
without aluminum hydroxide (Al(OH)3) adjuvant) or to Haemophilus somrms bacterins. 
Seven days after the last sensitization, calves were challenged by intravenous injection. Blood 
samples were collected prior to experimentation and weekly during sensitization as well as 
prior to challenge and 0.25-, 1-, 6-, 24-, 48-, & 72-hours after challenge exposure. 
Antigen-specific IgE levels and differential white blood cell counts were determined. Prior to 
challenge, all calves had detectable levels of IgE antibody against the sensitizing antigen with 
basophilia and eosinophilia. Sensitization with antigen in A1(0H)3 produced more dramatic 
clinical signs than did calves sensitized with antigen alone. The most dramatic clinical signs of 
anaphylaxis were noted in the calf sensitized with OA in A1(0H)3 and control calves. Within 
30 seconds after challenge, these calves collapsed and exhibited tachypnea, abdominal 
bloating, excessive lacrimation and salivation, and were recumbent. Calves sensitized with OA 
in A1(0H)3 and the conmiercial H. sommis bacterin required two doses each of epinephrine 
and diphenhydramine were required to reverse clinical signs. Intravenous sensitization with 
OA or equine sera alone produced few, if any, clinical signs after challenge. This study 
suggests that calves can become sensitized to antigen after a single exposure and that the 
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presence of Al(0Ei)3 may enhance this process Results of this study suggest that veterinarv' 
bacterins, at least H. somtms bacterins. may be involved in allergic responses in calves 
Introduction 
The induction of respiratory allergy has not been extensively studied in cattle. It has 
received considerable attention in children and laboratory animals. There have been few-
reports of attempts to study anaphylactic reactions in cattle by direct challenge of 
experimentally sensitized animals . Bovine respiratory disease continues to be a major 
disease problem in all types of cattle operations. Vaccines have been developed for most of 
the recognized infectious agents and are utilized extensively. These are efficacious in many 
situations but have not always provided adequate control of the disease and, in some 
instances, may be contributory to a disease process. 
There is anecdotal (unpublished) evidence that more severe respiratory disease can 
occasionally be seen in vaccinated cattle compared to nonvaccinated cattle. A role for Type 1 
(immediate) hypersensitivity as a component of bovine respiratory disease has not received 
extensive study. Reports are basically restricted to the reactions associated with 
Xficropolyspora facta '*• , a thermophilic fungus commonly found in moldy hay, and bovine 
respirator},' syncytial virus It is believed that the peracute form of BRSV infection 
probably involves a type-1 hypersensitivity response. 
Preliminar\' studies performed in our laboratory indicate that H. sommis organisms can 
induce an immediate (Type-1) hypersensitive state in young calves. Using a small number of 
calves, we have shown that M faeni is not an adequate positive control in Iowa because most 
calves likely develop IgE and increasing IgG levels against this thermophilic flingus ~ . The 
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puqjose of this study was to evaluate various antigen preparations for their ability to sensitize 
calves for an allergic response. 
Materials and Methods 
Animals. 
Seven 2-month old seronegative calves (150-200#) were utilized in this study. Prior to 
arrival, calves were vaccinated against bovine viruses (i-e., BRSV, BVD, IBR, PI3), but not 
against bacterial pathogens. Upon arrival calves were administered antibiotics until 3 days 
prior to the start of the study. Calves 1 & 3 were sensitized to ovalbumin (OA); Calves 2 & 4 
were sensitized to equine sera; and, calves 5 & 6 were vaccinated with either a commercial or 
an experimental H. somrtus bacterin. Calf 7 served as a non-sensitized control. 
Experimental Design. 
Calves 1 and 3 were each sensitized by two subcutaneous (s.c.) injections of either 
ovalbumin (OA; 15 mg/kg) or equine sera (0.15 ml/kg), respectively, suspended in 20% (v/v) 
aluminum hydroxide gel as adjuvant. Injections were administered at 5-day intervals. Calves 2 
& 4 were sensitized by a single intravenous (i.v.) injection of either OA (15 mg/kg) or equine 
serum (15 ml/kg) without adjuvant. These four calves were challenged with the sensitizing 
antigen 7 days after the last sensitizing dose by i.v. injection. Ovalbumin-sensitized calves 
(1 & 2) were challenged with a concentration of 25 mg of OA per Kg of body weight. Equine 
serum-sensitized calves (3 & 4) were challenged with a concentration of 0.20 ml of equine 
serum per Kg of body weight. 
Calves 5 & 6 were sensitized by two subcutaneous injections of either a commercial 
H. somnus bacterin (2 ml) or an experimental Triton X-100 extract (5 ml) of H. somnus 
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suspended in aluminum hydroxide adjuvant. Both bacterins contained an equal protein 
content and had aluminum hydroxide adjuvant at 20% (v/v). Injections were administered at 
two week intervals. Calves 5, 6, & 7 were challenged with washed, live H. sortmus organisms 
by i.v injection ten days after the last sensitizing dose. 
Sampling and Observation. 
Sera and plasma samples were collected from these animals weekly for 2 weeks prior to 
the start of the study as well as on the first day of immunization/sensitization. Samples were 
collected approximately every 2-3 days thereafter. Samples were collected at the time of 
challenge and 15 minutes, 1-. 6-, 24-, 48-. and 72-hours after challenge and serum was 
harvested, filter sterilized (0.45 u, Millipore Corp., ) and stored at 4°C until used. Blood 
smears were prepared and stained with HemaQuick Differential Stain. 
Differential White Blood Cell Counts. 
White blood cell differential counts were determined manually by counting the number of 
white blood cells in 100 cells seen. 
Haemophilus somnus Challenge Preparation 
Stock cultures of H. somnus were used to inoculate Brain Heart Infusion Agar 
supplemented with 10% bovine serum and 0.5% yeast extract (BHIA-SY) plates. Plates were 
incubated at 37°C at 15% CO, in air for 2 days. Growth was harvested with 3 ml phosphate 
buffered saline (PBS, pH 7.2) Thiny-five BHIA-SY agar plates were inoculated with the 
harvested culture and the plates were incubated as above. Growth was harvested as described 
above and the organisms were centrifliged at 13,000 x g for 30 minutes at 4°C. The 
supernatant was discarded. The cell pellet was resuspended in 50 ml of PBS, centrifliged and 
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the supernatant discarded. The cell pellet was washed twice more for a total of three washes 
After the final centrifligation. the cell pellet was suspended in PBS and adjusted to an optical 
density (OD) of 0.650 at 595 nm 
H. sommis Baciehns. 
A commercial monovalent H. sommis bacterin containing 20% (v/v) aluminum hydroxide 
was purchased from a veterinary vaccine distributor and administered according to label 
recommendations. The experimental bacterin consisted of a Triton X-100 extract of H. 
sommis suspended in 20% (v/v) aluminum hydroxide. Both H. sommis bacterins contained 
equivalent protein concentration per dose. 
The Triton X-100 extract was prepared by growing and harvesting H. sommis as 
described above. After washing the organisms three times in PBS. the final cell pellet was 
resuspended in 50 ml Tris-bufFered saline (TBS) containing 5 mM EDTA and 0.01% Triton 
X-lOO (Sigma Chemical Co.. St. Louis. MO) The mixture was allowed to incubate on a 
rocker platform at 37° C. .After an 18 hour incubation, the mixture was centrifiiged at 
13,000 x g for 30 minutes at 4°C and the supernatant containing outer membrane components 
was saved. Protein concentration of the supernatant was determined by the Biuret method. 
Supernatant was suspended in aluminum hydroxide gel (Resorbtor, 2% AlO,) to a final 
concentration of 20% (v.'v). 
Anti-H. sommis IgE ELISA. 
The procedure for performing the anti-//. sommis IgE ELISA is described elsewhere^'. 
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Results 
Senim IgE Levels. 
Regardless of sensitizing antigen, all calves had measurable levels of antigen-specific IgE 
type antibody prior to challenge (Table I). In Groups I & 2, higher IgE levels were induced 
when antigen was suspended in aluminum hydroxide than without the adjuvant Haemophilus 
.vo/77/«/i-sensitized calves had the highest antigen-specific IgE levels. In most cases. IgE levels 
decreased within 0.25 h of challenge followed by a rebound effect. 
Heterologous Challenge. 
Equine serum sensitization produced verv' mild clinical signs following an H. sommis 
challenge; clinical signs disappeared within 0.25 h The non-sensitized control calf 
experienced mild tachypnea following H. somnus challenge. When H. somnus-sensitized 
calves were challenged with Equine sera, no clinical signs of anaphylaxis were noted. 
Homologous (^hallenge. 
Calves sensitized to equine sera had the fewest and most mild clinical signs. Calves 
sensitized by H. sommis bacterin vaccination and the calf sensitized with 0.\ in .AJ(0H)3 
exhibited dramatic clinical signs. These calves collapsed within 20 seconds of challenge. 
Within 3 minutes, frequent coughing and increased respiratory rate (from 48 to 136 in the O.A. 
in .AJ(OH)j-sensitized calf and from 36 to 148 in H. io/nm/.v-vaccinated calves ) were evident. 
By 9 minutes post-challenge, these calves were recumbant with severe abdominal bloating, 
excessive lacrimation and salivation. At 30 minutes post-challenge, respiratory rate decreased 
to 28 (OA in the Al(0H)3-sensitized calf) and 22 (//. iowm/i-sensitized calves), and 
respirator^' stridor was evident. The OA in Al(0H)3-sensitized calf and the calf sensitized with 
84 
the commercial H. somnus bacterin required two injections of epinephrine (1:10,000): clmical 
signs were reversed only after tv^'^o injections of diphenhydramine. Plasma histamine and 
serotonin concentrations increased 0.25 h post-challenge; serotonin levels were 10-20-foId 
higher than histamine concentrations (data not shown). Occasional coughing was observed in 
the non-sensitized control calf after challenge with washed, live H. somnus organisms. 
Discussion 
Preliminary results in our laboratory indicated that young calves can become sensitized to 
H. somnus organisms and that many calves in Iowa may have detectable levels of IgE and IgG 
antibody against Micropolyspora faeni ^ . Using a small number of calves, we evaluated the 
clinical response of three groups of experimentally sensitized Holstein calves to intravenous 
challenge with the same antigen used for sensitization (homologous). 
In the present study, experimental sensitization induced measureable levels of Ig£ type 
antibody with basophilia and eosinophilia (data not shown) prior to challenge. Calves 
sensitized to equine sera with or without aluminum hydroxide had mild clinical signs of 
anaphylaxis following a homologous challenge. Sensitization with OA-i-AJ(OH)T and H. 
somnus bacterins produced dramatic clinical signs It is possible that the sudden collapse was 
a consequence of cerebral anoxia due to an abrupt fall in systemic blood pressure. 
Sensitizing antigen suspended in aluminum hydroxide induced a greater anaphylactic 
response than did the same antigen without aluminum hydroxide. Aluminum salts are 
commonly combined with killed bacteria, usually formalin-killed. Even though aluminum 
hydroxide can compensate for a 90% reduction in antigen content and contribute to a 
reduction in production costs associated with vaccme production, aluminum adjuvants are 
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very efficient inducers of IgE antibody synthesis 
Commercial H. somnus bacterins may contain residual quantities of equine sera from 
growth medium. Obi et al." demonstrated anaphylaxis in Ayrshire and Hereford bull calves 
experimentally sensitized to equine sera. In the present study, H. somnus-sensitiZQd calves 
and the non-sensitized control calf failed to react to a challenge with equine sera. This 
suggests that allergic reactions are not likely due to the presence of significant quantities of 
equine sera, at least with the H. somnus bacterins utilized in this study. However, if a calf is 
sensitized to equine sera as a result of previous vaccinations with biologicals containing 
residual equine sera, the likelyhood of an anaphylactic response is increased. 
This preliminary study support the hypothesis that aluminum hydroxide adjuvants can 
enhance the IgE response to non-viable antigens, resulting in severe anaphylaxis following 
challenge with the sentizing antigen. Results also suggest that the presence of residual equine 
sera and H. sommis organisms present in at least one commercial H. somnus bacterin may be 
associated with some of the adverse events associated with vaccination. Similar studies 
utilizing additional commercial H. somnus bacterins are needed. 
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Table 1. Antigen-specific IgE antibody levels prior to challenge with the 
homologous antigen. Values are given prior to experimentation and prior 
to challenge (0), and 0.25-, 1-, 6-, 24-, 48-, and 72-h post-challenge. Pre-experiment 
and post-challenge values are 27 days apart. Results are expressed as absorbance 
values X 1000. 
OA 
Sensitized 
Calves 
Equine 
Sera-
Sensitized 
Calves 
H. sonutus-
Sensitized 
Calves 
Control 
Calf 
CalfNo.: 1 2 3 4 5 6 7 
Pre-Experiment 
25 0 92 76 66 75 14 
Post-Challenge' 
0 339 289 203 174 351 394 45 
0.25 h 233 111 169 185 336 396 43 
1 h 170 244 107 193 283 396 49 
6h 157 243 140 219 358 416 44 
24 h 269 374 190 197 355 394 51 
48 h 294 294 173 170 398 405 55 
11 h 354 404 205 135 449 438 73 
' = Calves 1 & 2 challenged with OA; Calves 3 & 4 challenged with equine sera; Calves 5.6. & 7 
challenged with washed, live H. somnus organisms. Challenge antigen was administered intravenously 
without aluminum hydroxide. 
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CHAPTER 4. HAEMOPHILUS SOMNUS-lND\JCET> IgE IN CALVES 
VACCINATED WITH COMMERCIAL MONOVALENT 
HAEMOPHILUS SOMNUS BACTERINS 
A paper submitted to Veterinary Microbiology 
Kevin W. Ruby, Ronald W. Griffith, Laurel J. Gershwin, Merlin L. Kaeberle 
Abstract. The ability of commercially available Haemophilus somnus bacterins to elicit an 
IgE response was examined in healthy calves usmg enzyme-linked immunosorbent assay 
(ELISA) and Western blotting techniques. Thirty five calves were utilized in this study 
Calves in Group I (n = 7) did not receive any H. somnus vaccination and served as negative 
controls. Calves in each of Groups 2-5 (n = 7 each) were vaccinated on days 0 (primary) and 
14 (booster) with one of four commercially available H. somnus bacterins. Sera were 
harvested on Days 0 and 14 and at weekly intervals for a total of 45 days. Sera were tested 
for the presence of IgE antibodies using a bovine IgE-specific ELISA. 
Low levels of H. .y6»/w«M5-specific IgE were detected by ELISA in all animals prior to the 
initiation of the study. All bacterins induced IgE levels that were significantly higher than 
control levels. Two bacterins elicited higher IgE levels at all time points. Sera were adsorbed 
agamst washed whole cells of either Salmonella typhimunum. P. multocida. or H. somnus or 
extracts of H. somnus ELISA absorbance values were significantly decreased by adsorption 
with washed whole cells or extracts of H. somnus. whereas adsorption with other 
gram-negative bacteria only minimally decreased ELISA absorbance values. 
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Western blot analysis was used to partially characterize protein antigens reacting with 
bovine IgE. Several antigens were recognized by sera from vaccinated calves. Each bacterin 
induced IgE antibody that recognized a different subset of antigens recognized by reference 
sera containing high levels of IgE. Antigens most frequently recognized by all four of the 
bacterins studied were approximately 90-, 65-, 40 5-, 36-. 29-, 25-, and 6.9- kDa. These 
results indicate that commercially available H. somm/s bacterins can induce IgE antibody. 
This IgE can be detected 45 days after the primary vaccination. Results also indicate that 
H. somnus-specific IgE antibodies can be found in serum of some cattle, possibly induced by 
existing or previous sensitization. 
Introduction 
Bovine respiratory disease continues to be a major disease problem in all types of cattle 
operations." The etiologic complex includes viruses, bacteria, mycoplasma, and stresses often 
associated with weaning, shipping, and other management factors '' Vaccines and/or 
bacterins have been developed for most of the recognized infectious agents and are utilized 
extensively. These are efficacious in many situations but have not always provided adequate 
control of the pneumonic form of disease. Although Haemophilus sommts bacterins are 
effective against the systemic forms of disease due to H. sommis infections, observational 
evidence suggests that they may not provide a desirable level of protection against pneumonic 
disease. .Anecdotal evidence indicates some bacterins/vaccines may contribute to the disease 
process. More severe respiratory disease has occasionally been seen in vaccinated cattle 
compared to non-vaccinated cattle. There is observational evidence that commercial vaccines 
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containing H. somnus and Bovine Respiratory Syncytial Virus (BRSV) antigens may have a 
higher rate of adverse reactions than desirable. 
A role for Type 1 (immediate) hypersensitivity as a component of BRDC and the adverse 
reactions observed with H. somnus and BRSV vaccines has not received extensive study. 
Reports are restricted to the reactions associated with Micropolyspora faeni, a thermophilic 
fungus commonly found in moldy hay, and BRS V.^' It is widely believed that the 
peracute form of BRSV infection probably involves a Type 1 hypersensitivity response. 
Preliminary work in our laboratory has also demonstrated a possible role for Type 1 
hypersensitivity in disease caused by H. somnus. Cattle "sensitized" by exposure to virulent 
H. somnus., treated to clear the organism, and subsequently re-challenged, developed severe 
clinical signs consistent with hypersensitivity (unpublished data). 
There is gradually accumulating evidence that bacterial infection can lead to specific 
immunoglobulin E (IgE) responses that may contribute to immediate hypersensitivity 
reactions. Agents such as Bordetella pertussis, Pasteurella hemolytica, Escherichia coli. 
Salmonella enteritidis. Staphylococcus aureus. Streptococcus spp.. Brucella abortus, 
Borrelia burgdorferi, and Neiserria flavescens have been shown to induce IgE responses. 
1- Bordetella pertussis and Neisseria flavescens have been associated with 
respiratory allergy. The presence of IgE antibody specific for bacterial antigens has 
been,, reported in sera of human patients with various respiratory tract diseases, especially 
those in which a chronic host-bacterium association exists. Significant concentrations 
of IgE specific for H. influenzae were found in sera of human patients with chronic bronchitis. 
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High serum concentrations of bacteria-specific IgE were found in 97% of human paitents with 
nasal polyps. Ubiquitous organisms, such as Proteus mirabilis, were the most frequently 
involved bacteria. Children with cystic fibrosis were found to have serum IgE specific for 
Pseudomonas aeruginosa. 
The character and chronicity of disease caused by H. somnus led us to skin test calves 
with extracts of H. somnus. Intradermal administration of these antigens induced wheal and 
flare reactions typical of immediate hypersensitivity (unpublished data). There is also 
anecdotal evidence that administration of H. somnus bacterins contributes to clinical 
respiratory disease. Many commercial bacterins/vaccines contain aluminum hydroxide as an 
adjuvant. Use of aluminum adjuvants is accompanied by preferential stimulation of IL-4 
production and stimulation of the Th, subsets in mice, with enhanced IgGj and IgE 
production. ~ ^  Therefore, the objective of this study was to determine whether routine 
vaccination with different commercially available H. somnus bacterins would elicit an IgE 
response in calves. 
Materials and methods 
Animals arid Randomization 
A total of thirty-five, 1-2-month old seronegative calves (150-200#) were utilized in this 
study. Upon arrival calves were placed on pasture and administered Naxcel (Upjohn, 
Kalamazoo, MI) for the first three days. Calves were maintained on a commercially prepared 
diet containing tetracycline (400 g/ton). All animals were housed together at the Iowa State 
University College of Veterinary Medicine. Calves were randomly divided into 5 treatment 
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groups of 7 calves each. Treatments consisted of no vaccination (Group I) or vaccination 
with one of four commercial monovalent H. somttus bacterins (Groups 2-5). Booster 
injections were administered fourteen days later 
Bacterins and Vaccination 
Four monovalent H. somrnis bacterins were purchased from a local veterinary distributor 
and used in the study. General characteristics of these bacterins are shown in Table 1. All 
bacterins were administered according to label recommendations. 
Sampling and Observation 
Blood was collected from all animals on Days 0 (primary injection). 14 (booster injection). 
21. 25. 29, and 45. Blood samples were collected by venipuncture from the jugular vein into 
serum separation tubes. Sera were harvested by centrifugation (2400 rpm). filter-sterilized 
(0.45«) and stored at -70°C. Animals were closely monitored for clinical signs of respiratory 
disease and any potential adverse reactions throughout the study. 
Antigen Preparation 
Inactivated whole cells of a respiratory isolate of H. somnus obtained from Dr. Dagmar 
Frank (College of Veterinary Medicine. Iowa State University) were used to coat wells of 
Immulon- 2 plates for ELIS.A. Organisms were grown on brain-heart-infiision (BHI. Difco. 
Detroit. MI) agar supplemented with 10% newborn bovine serum for 2 days at 37°C in a 15% 
CO^ atmosphere. Selected colonies were used to inoculate one tube containing 5 ml 
H. somnus liquid medium followed by incubation overnight (16 h) 37°C in a 15% CO^ 
atmosphere. The culture was used to inoculate 100 ml of liquid medium and incubated 
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overnight as described above. Cells were harvested by centrifiigation (13.000 x g for 30 
minutes), and the pellet was resuspended in 50 ml sterile phosphate buffered saline solution 
(PBSS, 0.05M. pH 7.2) and washed two more times for a total of three washes. After the 
final wash, cells were resuspended in 100 ml of PBSS. 
Triton X-100 and EDTA extracts of H. sommis were also used in adsorption studies. 
The Triton X-lOO extract was prepared by centrifiigation of 10 ml of the final wash 
suspension and resuspension of the cell pellet in 6 mi of Tris-tricine-EDTA (5mM) solution 
containing 0.01% Triton X-IOO. The suspension was incubated overnight on a rocker 
platform at 37°C followed by centrifiigation. The supernatant was used as the adsorbant. The 
EDTA extract was prepared in a similar manner using 10 ml of the final wash suspension. 
.Afl:er centrifiigation, the cell pellet was resuspended in Tris-tricine EDTA (5mM) solution, 
centrifijged. and the supernatant used as adsorbant. Extracts were standardized to contam 
-25 mg protein per ml by the Biurette method 
ELISA and Western Blot Antibody Controls and Reagents 
Sera was obtained fi-om feedlot cattle exhibiting clinical signs of respiratory disease due to 
H. sommis. Calves fi-om which the individual sera were obtained were skin test positive for 
H. sommis Normal calf sera (negative for//, sommis antibody by CF testing) and fetal calf 
sera served as negative controls. The anti-bovine IgE monoclonal antibody (Mab) was 
provided by Dr. Laurel Gershwin. University of California, Davis, C A. The anti-species 
immunoglobulin antibody-conjugates were purchased fi"om Jackson Laboratories. 
Anii-H. somnus IgE E2JSA 
Immulon-2 microtitration plates (96-well) were coated with 100 «1 of a 1:100 dilution of 
washed H. sommis whole cells (approximately 60 Kg/well) in carbonate-bicarbonate coating 
buffer (pH 9.6). Plates were sealed and incubated overnight (18-22 h) at room temperature 
(22-25°C) on a rotary" shaker (120 rpm). After washing the plate twice with distilled 
deionized water, wells were blocked with 300 /zl of 1% polyvinyl alcohol in PBS (PV.A/PBS) 
for 30 min at 37°C. After washing wells twice with 300 wl of distilled deionized water, 
duplicate serial 2-foid dilutions (beginning with 1:5 dilution) of control and test sera were 
added to preassigned wells (100 ul/well). The antibody (sera) diluent was 1% PVA/PBS. 
Plates were sealed and incubated for 30 minutes at 37°C on a rotary shaker (120 rpm). Plates 
were washed 9 times with deionized water and 100 ,«l of a 1:1.700 dilution (in PVA/PBS) of 
anti-bovine IgE Mab was added to all wells except those designated as antibody-conjugate 
control wells. Plates were sealed and incubated for 1.5 hour at room temperature on a rotary-
shaker (80 rpm). Wells were washed 6 times with distilled deionized water and 100//I of a 
1:4.000 dilution of goat anti-mouse IgG (H-t-L) horseradish peroxidase labelled antibody-
conjugate (Jackson Labs) was added to all wells. Plates were sealed and incubated for 30 
minutes at room temperature on a rotary shaker (80 rpm). After washing 5 times with 
distilled deionized water. 100 /zl of ABTS color substrate was added to all wells. Plates were 
sealed and incubated for 20-30 minutes at 37° C. The enzymatic reaction was stopped with 
an equal volume (100 .«1) of 10% sodium dodecylsulfate (SDS) and the plates were read in an 
ELIS.A. reader (Dynatech). The average optical density (OD) absorbance of background wells 
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was subtracted from all other wells. For each dilution tested, the average OD value of the 
normal calf sera was subtracted from the corresponding dilution of the reference and test sera 
Results were expressed as either mean OD absorbance values or percent of the reference 
standard. 
Adsorption of Sera Samples With Bacterial Antigens 
In some e.xperiments. selected sera were adsorbed with inactivated whole cells of 
Fasteurella nmltocida {sivzm 1062), or Salmonella typhimurmm, or various//. somniis 
preparations Approximately 0.5 ml of packed cells (cultures adjusted to similar cell density 
by comparison with appropriate McFarland nephalometer tubes) or extract was added to I ml 
of serum and mixed for 2 h at room temperature, .\fter centrifiigation (13.000 x g) for 30 
min. the sera was removed by pipette and centrifiiged as described above. The adsorbed 
serum was stored at 4°C until used in the ELISA 
SDS-PAGE and Western Blotting 
Proteins were separated by discontinuous sodium dodecyl sulfate-polyacrylamide gel 
electrophoreses (SDS-PAGE) as follows Inactivated washed whole cells of H. somniis 
(5 X IC organisms/ml) were mixed with an equal volume of 2X sample buffer and the 
mixture boiled for 3-5 minutes. One hundred forty-five microliters were loaded onto a 
preparative well of a 8-20% gradient polyacrylamide gel with a 5% stacking gel (Novex. Inc. ). 
Fifteen microliters of Kaleidoscope markers (BioRad. Inc., Melville. NY) were loaded onto a 
single well adjacent to the preparative well. Antigens were electrophoresed at 30 mA for 1.5 
to 2 hours or until the dye front reached the bottom of the gel. After electrophoresis, antigens 
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were electro-transferred to nitrocellulose membranes (Millipore. Bedford, MD) overnight at 
25 mA. The membrane was cut into strips and each strip was placed into a different glass 
screw cap tube containing phosphate buffered saline (PBS, pH 7.2) supplemented with 0.5% 
Tween 20 (PBST). Strips were washed 4 times (15 minutes each) in PBST and placed into 
tubes containing 3 ml of a 1:2 dilution (in PBST) of reference sera, normal calf sera or test 
sera and allowed to incubate for 30 minues to 1 hour at room temperature on a rocker 
platform. After washing the strips 6 times (15 minutes each) in PBST, each strip was 
incubated with a 1:80 dilution of anti-bovine IgE Mab in PBST overnight (18 to 22H) at room 
temperature on a rocker platform. Strips vvere washed 4 times (10 minutes each) in PBST 
and incubated with a 1:2,500 dilution (in PBST) of goat anti-mouse IgG (H-rL) horseradish 
peroxidase labelled antibody conjugate for 1 hour at room temperature on a rotar>' shaker. 
The substrate consisted of two solutions. Solution A was prepared by dissolving 75 mg of 
4-chloro-naphthol in 25 ml of cold methanol. Solution B was prepared by adding 80//I of 
hvdrogen peroxide (30%) to 125 ml of TBS. Immediately prior to use. Solutions A and B 
were miced together After washing 5 times (10 minutes each), bands were developed for 
approximately 15 minutes. 
Data Presentation and Statistical Analysis of Data 
Data obtained from ELIS A are presented as either optical density or a percentage of the 
reference standard sera, corrected for background. Percentage of reduction of absorbance 
values by adsorption with different bacteria was calculated by dividing the absorbance value 
(mean of duplicates) of the treated serum by the absorbance value of the nontreated serum and 
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multiplying the quotient by 100. Differences between group means were compared using 
Least Significant Differences. 
Results 
ELISA Serum H. sommis -Specific IgE Values 
The reference standard sera was obtained from a calf exhibiting clinical signs of respirator\-
disease which was positive to H. sommis antigens by skin testing. Other sera obtained from 
the same herd yielded OD values 50% and 25% of the reference standard sera and was 
designated as medium and low IgE containing sera, respectively 
Serial 2-fold dilutions of the reference standard, normal calf, and fetal calf sera are shown 
in Figure 1 to demonstrate the range over which serum dilution has a linear relation to 
absorbance and for comparative purposes. There was no significant difference between 
controls and vaccinated groups prior to vaccination (Table 2). On Day 14 (day of H. sommis 
booster), there was a significant difference between all treatment groups and the controls 
(P < 0.05), On days 21. 25. and 29 IgE levels elicited by Bacterins C & D were significantly 
greater than Bacterins A & B. On Day 45, all bacterins ehcited significantly higher (P< 0.05) 
LgE levels compared to controls; there was no significant difference between bacterins. 
Adsorption of Senim Samples With Bacterial Antigens 
Sera adsorbed with inactivated whole cells of Pastevrella miiltocida. 
Salmonella typhimiirnim or Haemophilus sommis or EDTA and Triton X-100 extracts of 
H. somnus were assayed by ELISA to determine specificity of IgE antibodies. Hesults of this 
study are shown in Table 3. When inactivated whole cells were used as adsorbants, ELISA 
98 
absorbance values decreased most when H. sommis whole cells were used as adsorbant. 
Similar decreases were seen with the H. sommis extracts. Adsorption with Pasieurella 
miiliocida (strain 1062) whole cells produced the next greatest decrease in absorbance value, 
followed by Salmonella typhimiihim whole cells. 
Western Blot Analysis 
Sera from calves vaccinated vvith 4 different commercial H. sommis bacterins were tested 
for the presence of serum IgE antibodies reactive with antigens of H. sommis whole ceils. 
Antibody controls included the ELISA reference sera containing high levels of IgE by ELISA, 
sera containing moderate and low levels of IgE by ELISA, normal and fetal calf sera. Strips 
were also incubated with only TBST or anti-bovine IgG antibody-conjugate. Figure 2 shows 
the results of a blot in which inactivated whole cells of H. sommis were probed with the 
reference sera containing high, moderate, or low IgE levels by ELISA and normal calf sera. 
Sera containing high levels of IgE by ELISA contained IgE antibody that reacted with 8 
bands, but the most dominant bands had a molecular weight (mass) of approximately 90-. 65-. 
40.5-, 29-. and 6.9- kDa (Lane 1). Sera with moderate IgE levels reacted with two antigens 
of 90- and 40.5 kDa. Sera with low IgE levels reacted with a single antigen of approximately 
40.5- kJDa. A 6.9-kJDa antigen was recognized by normal calf sera (CF-test negative). 
Control strips incubated with only TBST or anti-bovine IgG recognized no antigens. 
Sera from non-H. iomm/5-vaccmated control calves failed to reacted with any H. sommis 
antigen (Figure 3). Each bacterin induced IgE that reacted with a different subset of antigens 
that reacted with the ELISA reference sera. Seven H. somnus antigens of approximately 90-. 
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65", 40.5", 36", 29", 25-, and 6.9- kDa reacted with IgE induced by each of the 4 bacterins 
Figure 4 shows the results of a blot probed with sera from calves vaccinated with Bacterin A 
Sera from 3 calves contained IgE that recognized 4 antigens of approximately 120-. 40.5-, 
29-. and 25- kDa (lanes 5-7). Bacterin B induced IgE that reacted with eleven antigens 
(approximately 90-. 76-. 71-, 65-. 50-. 45-. 40 5-. 36-. 29-. 25-, and 6.9-kDa) with varying 
intensities (Figure 5). Four calves (lanes 3. 4. 6. and 7) strongly reacted to H. somrnis 
antigens while 3 calves (lanes 1, 2. and 5) had a minimal reactivity. Although ail calves 
vaccinated with Bacterin C had serum IgE that reacted with various antigens of approximately 
90-. 75-. 50-. 36-. 30.6-. and 6.9-kDa. all sera reacted with the 30.6- and 6.9-kDa antigens 
Three calves vaccinated with Bacterin D contamed serum IgE that reacted to antigens of 90-. 
75-. 40.5". 36-. 30.6-. and 6.9-kDa (lanes 4. 6, and 7). One calf weakly reacted with a 
36-kDa antigen (lane 5). .Antigens of 120-kDa and > 202 kDa were weakly detected by 3 
calves (lanes 1-3). 
Discussion 
There has been increasing evidence that bacterial infection can lead to specific IgE 
responses. Gershwin and Friebertshauser ' demonstrated Pasteiirella-sp&cific IgE in 
calves with bronchopneumonia, feedlot steers with a history of bronchopneumonia and with 
acute signs of interstital pneumonia, and nonaifected dairy cows. Other investigators 
showed that IgE antibodies specific for antigens of E. cali and others for Pseudomonas 
aeurginosa were easily induced by parenteral vaccination of mice with whole heat-killed 
bacteria or an aqueous extract. The antibodies were not reactive with homologous 
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lipopolysaccharide, and the antigens were determined to be surface-associated proteins. 
Although the use of lipopolysaccharide as adjuvant increased the passive cutaneous 
anaphylaxis titer, adjuvant was not required to induce an IgE response to an aqueous extract 
of P. aeruginosa These observations would provide support for the hypothesis that 
vaccinating calves with killed H. som/tus with aluminum hydroxide adjuvant could induce an 
lg£ response. 
In the present study, calves were vaccinated with four different commercially available 
H. somnus bacterins. All four bacterins induced detectable levels of IgE reactive to 
H. somnus organisms by ELISA. This antibody was detectable by ELISA as soon as 14 days 
after the primary injection and could be demonstrated by Western blot analysis up to 45 days 
after the primary' injection. We observed a low level of H. 5o/wm/-v-reactive IgE in 
nonvaccinated. normal calves. This is consistent with results of Gershwin. " Thus, many 
normal calves may have some level of IgE specific for H. somnus. There was slight increase 
in IgE levels in control calves on Day 45. It is possible that these calves became subclinically 
infected with H. somnus or a cross- reactive organism despite the presence of tetracycline in 
the feed throughout the study. 
This study demonstrates that H. somnus bacterins can elicit IgE antibodies that recognize 
H. somnus antigens by ELISA and confirmed by Western blot analysis. This is in contrast to 
Gershwin, who failed to see an induction of IgE in response to parenteral vaccination with P. 
haemolytica. This induction does not appear to be related to adjuvant; Bacterin B 
(oil-adjuvanted) induced IgE levels similar to Bacterins A. C, & D which contained aluminum 
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hydroxide as an adjuvant. 
The specificity of the IgE antibodies for H. sommis was demonstrated by the great 
reduction in ELISA absorbance values after adsorption was done with inactivated whole cells 
of H. sommis. Adsorption of sera with EDTA and Triton X-lOO extracts of//, sonnnis 
reduced the absorbance values to a similar degree as inactivated whole cells. This suggests 
that the IgE antibodies are directed against the outer membrane proteins (OMPs) and/or 
integral membrane proteins. There was less reduction by adsorption with potentially 
cross-reactive P muliocida (strain 1062) or S. typhimxirhim. suggesting that some of the IgE 
induced by the H. sommis bacterins can cross-react with these bacteria. 
Western blot analysis was performed to confirm ELISA results. Whereas all bacterins 
induced IgE that reacted with H. sommis antigens by ELISA, at least 3/7 calves vaccinated 
with Bacterin .A. produced IgE and all calves vaccinated with Bacterins B. C. and D {in. bib. 
7/7, respectively)produced IgE in response to vaccmation. Antigens that appear to be most 
involved in the induction of IgE by the bacterins tested are approximately 90-. 65-. 40.5-. 36-. 
29-. 25-. and 6.9- IcDa in size. Bactenn A was the only bacterin administered subcutaneously. 
It induced IgE agamst the fewest antigens. Bacterins B. C, and D were administered 
intramuscularly and induced IgE against a greater number of antigens. Like Bacterins C and 
D. Bacterin A was adjuvanted with aluminum hydroxide which suggests differences due to 
adjuvant are unlikely. The most likely explanation may be due to differences in the antigen 
processing and presentation of antigen by antigen presenting cells found in these two sites. 
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Although bacterins used to vaccinate against diseases caused by H. somnus are generally 
thought to be safe and effective, observational evidence suggest that they may not provide 
adequate protection against the pneumonic form of H. somnus infections. In some cases, 
vaccinated cattle develop more severe clinical disease as compared to nonvaccinated cattle. 
The results of this study suggest that more severe clinical disease in vaccinated cattle may be 
partially explained by vaccine-induced IgE. Ahematively, the vaccine may stimulate a 
secondary IgE response to previous sensitization with live H. somnus. This study also 
suggests that the route of administration may have a significant impact on the magnitude of 
the IgE response. 
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Table 1 Characteristics oi Haemophilus sommis 
jacterins utilized in this study. 
BACTERm ADJUVANT ROUTE 
A -AJCOH), sc 
B Oil IM 
C MOH), IM 
D -AJfOH), IM 
Bacterins were purchased from a local veterinary' 
supply warehouse. .'Vll bacterins were administered 
according to label recommendations (2 ml dose). 
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Fig 1. Absorbance values (405/490 nm) are shown for serial 2-fold dilutions of reference sera 
used for calculation of IgE levels. Normal calf sera (NCS), negative for sommis antibodies 
as determined by the complement fixation test, and fetal calf sera (FCS) are also shown. 
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Table 2. Mean IgE levels of vaccinated and nonvaccinated calves from Day 0 through 
Day 45. Results are expressed as a percentage of a reference sera (± SEM) containing 
high IgE antibody. 
DAY 
0 14 21 25 29 35 45 
Control 23.1 
(4.7) 
18.7' 
(6.3) 
21.8' 
(5.7) 
24.1 ' 
(6.8) 
23.7' 
(4.1) 
24.8' 
(5.6) 
49.7' 
(8.3) 
Bacteria A 20.8 (3.8) 61.6" (5.6) 
78.8 
(7.9) 
72.2" 
(6.4) 
76.2" 
(5.6) 
90.1 
(6.5) 
107.3 
(7.8) 
Bacterin B 24.7 
(2.9) 
77 
(4.9) 
86.3 
(7.6) 
73.9 
(5.3) 
89.4 
(7.6) 
95 
(5.5) 
103.2 
(7.7) 
Bacterin C 28.4 
(3.2) 
121.7" 
(4.7) 
135.5 
(5.8) 
145.2 
(7.3) 
151.8" 
(6.3) 
139.2 
(4.8) 
116.1 
(4.8) 
Bacterin D 39.4 
(3.6) 
94.9 
(5.7) 
110.7 
(6.1) 
153.1" 
(6.7) 
153.1" 
(7.9) 
129.4 
(4.9) 
112.4 
(3.1) 
' Significant difference (P<0.05) between all vaccinates and controls. 
'' Significant difference (P<0.05) between bacterins. 
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Table 3. Reduction of enzyme-linked immunosorbent assay values by serum adsorption. 
Data are presented as mean percentage decrease (-) or increase (+) of absorbance values of 
the reference sera (± SEM). 
ADSORBANT 
P. muUocida S, typhinmrium HsWC^ HsEDTA"^ HsTXlOO^ 
Serum: 
Control -1 +8 -34 -44 -34 
(0.6) (l-l) (2.3) (1.3) (2.1) 
Bacterin A -5 -4 -65 -63 -57 
(0.9) (1.4) (2.8) (3.1) (2.2) 
Bacterin B -19 -13 -46 -48 -49 
(2.1) (3.6) (1.3) (2.9) ( l . l )  
Bacteria C -20 -13 -51 -59 -51 
(3.3) (3.1) (2.3) (3.6) (0.8) 
Bacterin D -14 -7 -55 -59 -58 
(3.5) (2.8) (4.1) (3.3) (1.2) 
Reference Sera -5 1 -54 -54 -45 
(2.8) (0.8) (3.7) (2.8) (2-1) 
^ H. somnus adsorbants yielded significantly lower (P < 0.01) OD values as compared to nonadsorbed sera or sera 
adsorbed with Pasteurella and Salmonella whole cells. 
There were no diEferences (P<0.05) between H. somnus preparations. Hs WC = H. somnus whole cells; Hs 
EDTA = EDTA extract ofH. somnus-, Hs Tx-lOO = Triton X-100 extract of ff. somnus. 
Fig 2. Tmmunoblot of H. somnus whole cells probed with the ELIS A reference and negative 
control. Lanes 1-3: reference sera containing high, moderate, and low amounts of IgE; Lane 
4: normal calf sera; Lane 5: TEST only, and Lane 6: bovine IgG followed by anti-bovine IgG 
antibody conjugate. Molecular mass markers are shown at the left. 
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Fig 3. Immunoblot of H. somnus whole cells probed with sera from nonvaccinated control 
calves. Lanes 1-7 represent strips incubated with individual calf sera. Molecular mass 
markers are shown at the left. 
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Fig 4. Immunoblot of H. sommts whole cells probed with sera from calvesimmunized with 
Bacterin A. Lanes 1-7 represent strips incubated with individual calf sera. Molecular mass 
markers are shown at the left. 
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Fig 5. Immunoblot of H. somrms whole cells probed with sera from calves immunized with 
Bacterin B. Lanes 1-7 represent strips incubated with individual calf sera. Molecular mass 
markers are shown at the left. 
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Fig 6. Immunoblot of H. somnus whole cells probed with sera from calves immunized with 
Bacterin C. Lanes 1-6 represent strips incubated with individual calf sera. Molecular mass 
markers are shown at the left. 
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Fig 7, Immunoblot of H. sontnus whole cells probed with sera from calves immunized with 
Bacterin D. Lanes 1-7 represent strips incubated with individual calf sera. Molecular mass 
markers are shown at the left. 
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CHAPTER 5. VIRAL VACCINATION ALTERS PLASMA 
EICOSANOIDS IN CALVES PREVIOUSLY VACCINATED WITH 
HAEMOPHILUS SOMNUS BACTERINS 
A paper to be submitted to Biologicais 
Kevin W. Ruby, Ronald W. Griffith, Merlin L. Kaeberle 
Abstract. The effect of modified live viral vaccination on plasma levels of leukotrienes, 
prostaglandins, thromboxanes and differential white blood cell counts was examined in calves 
previously vaccinated with four commerical Haemophilus somrms bacterins. Holstein calves 
were randomly divided into 4 experimental groups (A3,C,D) consisting of 7 calves per 
group. Each experimental group received a different H. somnus bacterin injection according 
to label recommendations. Primary and secondary (booster) injections were given on Days 0 
and 14, respectively. On Day 14, all calves received a single intranasal instillation of a 
IBR-PI3 modified live virus (MLV) vaccine. On Day 25, all calves were vaccinated with a 
BRSY (MLV) vaccine. Seven calves served as non-H. somrms vaccinated but virus-
vaccinated controls. Plasma concentrations of leukotriene (LT), prostaglandin (PG), and 
thromboxane (Tx) were detennined by enzyme-linked immunoassay fi^om blood samples 
collected on Days 0, 14, 21, 29, and 45. The effect of H. somrms vaccination were increased 
plasma POFj^, 6-ketoPGFi(^, TxBj, and LTB4 concentrations on Day 14. All groups had an 
increase in plasma PGE, concentrations. IBR-PI3 (MLV) vaccination induced higher plasma 
PGE2, 6-ketoPGFijj, and TxB, concentrations in controls on Day 21 as compared to Day 14. 
The effect of a combination IBR-PI3 (MLV) vaccination in H. 50OT«M5-vaccinated calves was 
to lower plasma PGEj, PGEj^, 6-ketoPGFi„, TxBj, and LTB4 concentrations on Day 21 as 
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compared to Day 14. No change in LTC4 concentrations were noted. The effect of BRSV 
(MLV) vaccination was more variable and dramatic. All groups had higher plasma POFt^ 
Three of four treatment groups had higher plasma 6-ketoPGFi^ concentrations on Day 29 as 
compared to Day 21. Controls had higher plasma 6-ketoPGFijj and LTB4, and lower FGE^ 
and TxB, concentrations on Day 29. The effects of BRSV (MLV) vaccination in H. somtrus 
vaccinated calves were higher plasma PGEj and TxB,. Two of four treatment groups had 
higher plasma LTC4 concentrations. Basophilia was observed on Days 21, 25, and 29 (all 
groups) and Day 45 (only in group D). This study demonstrates that H. somfius bacterins can 
increase the production of eicosanoids associated with broncho-constriction and pulmonary 
edema. These increases can be detected as early as two weeks after the primary injection. 
Results also indicate that modified live virus vaccination (especially BRSV) can alter the 
eicosanoid levels and white blood cell populations of calves vaccinated with H. somtius 
bacterins. These data may partially explain the observation of more severe clinical disease 
occasionally observed in vaccinated compared to nonvaccinated calves. 
Introduction 
Respiratory disease continues to be a disease problem in all types of cattle operations. 
Etiologic agents include infectious bovine rhinotracheitis virus (IBR), parainfluenza 3 (PI3), 
bovine respiratory syncytial virus (BRSV), and Haemophilus somnus among other 
microorganisms. Hypersensitivity reactions to BRSV have been implicated in pathogenesis of 
some of the more severe forms of respiratory disease^' ^ Observational evidence suggests 
that on occasion there appears to be more severe clinical respiratory disease in vaccinated than 
in nonvaccinated calves. One would, therefore, expect that limited sequential viral exposures 
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would induce increasingly severe or prolonged disease expression. For this process to have a 
role, initial viral exposure must occur to induce a sensitized state. Vaccinations could 
participate in the pathogenesis of bovine respiratory disease by aggravating the disease 
process during subsequent infections. Results of the present study provide some support for 
the role of vaccination in the exascerbation of bovine respiratory disease. 
The potential contribution of immimologic reactions and arachidonic acid metabolites 
released during the course of BRSV infection in pathogenesis of the ensuing disease process 
has been examined in an experimental infection study". Arachidonic acid metabolites, 
leukotrienes (LT), prostaglandins (PG), and thromboxanes (TXB^) have been implicated as 
regulators of airway responsiveness in the lung. Thromboxanes, LTC4, PGFjc, and PGD, 
have bronchoconstrictor activity, and PGE, has bronchodilator activity ~ 
Changes in various plasma eicosanoid concentrations have been reported in calves 
infected with Pasteurella hemolytica ^  and BRSV - . We have demonstrated H. somnus-
specific IgE induced in calves vaccinated with four commercial H. somnus bacterins. The 
study reported here focused on quantitation of the concentrations of the arachidonic acid 
metabolites, PGEo, PGEj^, PGI2 (measured as 6-keto-PGF,o), Tx A, (measured as TxB,,), 
LTB4, and LTC4 due to their physiologic effects as bronchoconstrictors and bronchodilators. 
In BRSV and human RSV infections, there is evidence that immunoglobulin responses 
are not always protective and, in some instances, such as post-vaccination reactions, the 
resultant disease is more severe than in nonvaccinatesBecause arachidonic acid metabolites 
have been implicated as regulators of bonchoconstriction and bronchodilation *' the 
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effect of viral vaccination in the face of an existing hjrpersensitivity was measured. In the 
present study, hypersensitivity was induced by vaccination with four different commercial H. 
somnus bacterins. This is the first report of changes in plasma eicosanoid levels in calves in 
response to vaccination with a commercial bacterin and modified live virus (MLV) vaccines. 
The purpose of the study reported here was to evaluate changes in PG, Tx, LT, and 
differential white blood cell counts in response to a combination IBR-PI3 and a monovalent 
BRS V (both modified live virus) vaccination in H. 5om««5-vaccinated calves. 
Materials and Methods 
Animals. 
Thirty five Holstein calves, obtained after weaning, were utilized in this study. Calves 
were randomly divided into 5 groups of 7 calves each. Treatments consisted of non-//. 
somnus vaccinated controls and calves vaccinated with one of four commercial H. somnus 
bacterins followed by viral vaccination with two different modified live virus (MLV) vaccines. 
Experimental Design. 
Monovalent H. somnus bacterins representing different manufacturers and MLV 
vaccines were obtained fi"om a local veterinary distributor (Table 1). Immunizations were 
administered according to label recommendations. Table 2 shows the schedule of procedures 
and treatments. The four treatment groups received primary (Day 0) and secondary (Day 14) 
H. somnus vaccinations according to label recommendations. On day 14, all calves, including 
controls, received a single intranasal vaccination with a Qpnmercial combination IBR-PI3 
(MLV) vaccine. On Day 25, all calves received a single intramuscular injection with a 
commercial BRSV (MLV) vaccine. Calves were monitored for adverse reactions through 
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Day 45. Concentrations of LTB4, LTC4, PGE,, PGFja, 6-k:eto PGFj^, and tTxB, were 
measured in plasma on days 0, 14 (prior to vaccination), 21, 29, and 45. 
Scanple Collection and Processing. 
Blood samples were obtained by venipuncture from the jugular vein into EDTA tubes 
with and without 10 mg of indomethacin and placed on ice until transport back to the 
laboratory. Blood smears were prepared using noncoagulated whole blood. Smears were 
stained with QuickDiff (St. Louis, MO) stain and differential white blood cell counts were 
determined manually. For eicosanoid determination, plasma was harvested by centrifligation 
(2400 rpm), aliquoted into 0.5-ml aliquots, and stored at -70° C until assayed. Animals were 
observed for clinical signs of respiratory disease and any potential adverse reactions 
throughout the study. 
Eicosanoid Determination Assay. 
Samples were processed and tests performed according to the manufacturer's 
instructions. All eicosanoid levels were determined using ELISA-based detection assays 
obtained from. Cayman Chemical Co. Inc., Ann Arbor, MI. Sep-Pak C-18 reverse phase 
cartridges were obtained from Waters, Inc.,. 
Statistical Analysis. 
Eicosanoid concentrations were evaluated for significance by Least Significant 
Differences to compare group mean values. Differences were considered to be significant at 
P<0.05. 
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Results 
Eicosanoids Associated With Bronchoconstriction (Table 3) 
Plasma PGF-^  ^ concentratiom. 
On Day 14, plasma PGFjo concentrations were significantly (P<0.05) higher in 
treatment groups A, B, C, and D on Day 14 as compared to the control group. No 
differences were noted among treatment groups on Day 14. Significantly higher (P<0.05) 
PGFj^ concentrations were noted in all treatment groups on Day 29 as compared to the 
controls group. No differences were noted among treatment groups on Day 29. 
Plasma TxB  ^concentrations. 
Plasma TxB, concentrations of treatment groups B, C, and D were significantly higher 
(P<0.05) than the control group on Days 14 and 29. The plasma TxB, concentration of group 
D was significantly different (P<0.05) fi'om that of group A on Day 29. Plasma 
concentrations of TxB, had decreased by Day 45 but group C had a significantly lower 
(P<0.05) TXB22 concentration than groups A, B, and D. 
Plasma LTC  ^Concentrations. 
Plasma LTC4 concentrations did not change significantly (P<0.05) throughout the 
study. On Day 14, treatment group A had a significantly higher (P<0.05) LTC4 concentration 
than did the control group or groups B and C. On Day 14, group A had a significantly higher 
(P<0.05) plasma LTC4 concentration than did groups B, C, and D. On Day 29 significantly 
higher (P<0.05) concentrations were noted in groups A and D as compared to the control 
group; group D was significantiy higher than groups B and C. Except for group D, increased 
LTC4 concentrations were noted in all treatment groups on Day 45. Group A had a plasma 
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concentration that was significantly higher (P<0.05) than that of the control group. 
Eicosanoids Associated With Bronchodi lotion. Edema Formation, or Chemotaxis (Table 4) 
Plasma PGE  ^concentrations. 
There were no significant differences in plasma PGE^ concentrations between control 
or treatment groups. Plasma PGE2 concentrations of the control group increased steadily 
fi'om Day 0 to a peak concentration on Day 29. Group A had a significantly higher (P<0.05) 
PGE2 concentration on Day 14 than on Day 0. On Day 45, plasma PGE2 concentrations were 
significantly lower (P<0.05) in groups A, B, and C than on Day 29. Plasma PGE2 
concentrations in group D calves was significantly higher (P<0.05) than groups A and C. 
Plasma 6-keto PGF^  ^concentrations. 
Control calves had increasing plasma 6-ketoPGF,„ concentrations after viral 
vaccination (Days 21 and 29). On Day 14, although all treatment groups had higher 
concentrations of 6-ketoPGFu. than controls. Groups B, C, and D were significantly higher 
(P<0.05) than Controls. On Day 29, Group A had significantly lower (P<0.05) 6-keto PGFi^, 
concentrations than Group C. On Day 45, Groups A and B had significantly higher (P<0.05) 
concentrations than did other groups. 
Plasma L TB3, concentrations. 
Significantly higher (P<0.05) plasma LTB4 concentrations were noted between the 
control group and treatment groups A, B, C, and D on Days 14, 21, and 29. On Day 45, 
groups A, B, and C had significantly lower (P<0.05) LTB4 concentrations as compared to Day 
29. 
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Differential White Blood Cell Counts. 
Percentages of circulating monocytes, lymphocytes, neutrophils, and eosinophils were 
within the normal limits for 4-8 month old calves throughout the study (Table 5). However, a 
mild lymphopenia was noted on Day 29 in controls and treatment groups A, B, and C. 
Although basophilia was noted on Days 21, 25, and 29 in all treatment groups and controls, 
there were no significant differences noted. 
Discussion 
In the present study, calves previously vaccinated with H. sommis bacterins were 
administered a combination IBR-PI3 and monovalent BRSV (MLV) vaccines on Days 14 and 
25, respectively. Control calves received only the viral vaccines. Haemophilus somtTus 
vaccinated calves had higher plasma PGFj^, 6-ketoPGFj^, Txfi,, and LTB4 concentrations on 
Day 14. All groups had increased plasma PGEi concentrations. A combination IBR-PI3 
(MLV) vaccination induced higher plasma PGEj, 6-ketoPGFij„ and TxB, concentrations in 
the control group on Day 21 as compared to Day 14. The effect of a combination IBR-PI3 
(MLV) vaccination in H. somnus-vdLCcmsted calves was to lower plasma PGE2, PGEj^, 6-
ketoPGFijj, TxB,, and LTB4 concentrations on Day 21 as compared to Day 14. No changes 
in LTC4 concentrations were noted. The effect of a monovalent BRSV (MLV) vaccination 
was more variable and more dramatic. All calves had higher plasma PGFj^. Three of four 
treatment groups had higher plasma 6-ketoPGFi<j concentrations on Day 29 as compared to 
Day 21. The control group had higher plasma e-ketoPOF^ and LTB4, and lower PGE, and 
TxBt concentrations on Day 29. The effect of BRSV (MLV) vaccination in H. somtrus 
vaccinated calves were higher plasma PGE, and TxBj. Two of four treatment groups had 
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higher plasma LTC4 concentrations. Basophilia was observed on Days 21, 25, and 29 (all 
groups) and Day 45 (only in group D). 
Eicosanoids Associated With Bronchoconstriction 
PGFjo has potent bronchoconstrictor activity. A selective stimulation of PGFjc 
production appeared to be induced by H. somnus bacterins. Plasma concentrations of PGFjj, 
of control calves remained considerably lower than those of the H. somnus vaccinates. 
Haemophilus somnus vaccinates had significantly higher PGFTO concentrations on Day 14 than 
did the control group. Decreased concentrations in all groups on Day 21 indicate that 
EBR-PD (MLV) vaccination had little effect on PGFj^ production. However, had we 
measured plasma fi^om these calves 3 days after vaccination, these concentrations may have 
been increased. Gershwin et al. ~ demonstrated a decreased PGFja production in lung lavage 
fluids fi-om BRSV vaccinated calves but plasma concentrations remained at baseline. These 
authors hypothesized that decreased PGFjo in lung lavage fluids may be an advantage induced 
by immunization. Although this study measured plasma eicosanoid changes in response to 
bacterial and viral vaccination without infection, concentrations of PGFj^ of both studies were 
very similar. Peak plasma PGFto concentrations in this study were noted 4 days after a BRSV 
vaccination whereas peak concentrations in Gershwin's study occurred 10 days after BRSV 
infection. Although higher plasma PGFj^ concentrations may have occured 10 days after 
BRSV vaccination, samples were not collected at that time point. The route of administration 
and adjuvant did not appear to significantly affect PGFj^ concentrations. Results of the 
present study suggest that vaccination with H. somnus bacterins may adversely affect calves 
by stimulating PGFj^ production. This stimulation may be enhanced if a modified live viral 
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vaccine is administered subsequent to a H. somnus bacterin. 
TxB, is the metabolite of TxA, and has potent bronchoconstrictor activity, activates 
PMNs, causes platelet activation/aggregation and has vasoconstrictor activities. The increase 
in plasma TxBj concentrations in H. 50/nA7M5-vaccinated calves on Day 14 suggests stimulation 
of TxB, production by H. somnus bacterins. The decrease in plasma TxBj concentrations in 
H. somnus vaccinates on Day 21 suggest that either IBR-PI3 (MLV) vaccination had a mild 
inhibitory effect on TxB, production in H. 507w/n/5-vaccinated calves or samples were not 
collected at the time of peak concentrations. A signficant increase in plasma TxB, 
concentration was noted among H. 50/w/m5-vaccinated groups B, C, and D four days after the 
BRS V (MLV) vaccination. It is unlikely that increased concentrations of plasma TXB2 would 
be caused by physical trauma associated with sampling. If this assumption were true, one 
would expect all groups, including controls, to have shown an increase which was not the 
case. It is noteworthy that calves vaccinated with H. somnus bacterin A did not show a 
significant rise in TxB, concentration on Day 29. It is interesting that bacterin A was 
administered subcutaneously and induced lower TxB, concentrations. This is in contrast to 
bacterins B, C, and D which were administered intramuscularly. This may suggest that 
subcutaneous vaccination benefits the animal by causing less TxB, production. Results of this 
assay indicate that BRSV (MLV) vaccination enhances the TxB, production induced by 
H. somnus bacterins and this enhancement may be diminished by subcutaneous administration 
of the bacterin. 
LTC4 is a potent bronchoconstrictor and vasoconstrictor and mediates increases in 
capillary permeability. Except for calves vaccinated with H. somnus bacterin A, there were no 
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significant effects on plasma LTC4 concentrations as a result of H. somrms bacterins through 
Day 21. Bacterin A, (administered subcutaneously), induced higher, but not significantly 
higher, LTC4 concentrations on Day 14. Plasma LTC4 concentrations of the control group 
dropped dramatically on Day 21 which indicates that either a combination IBR-PI3 (MLV) 
vaccination had no effect on LTC^ production or the samples were not collected when peak 
concentrations could be detected. We noticed that calves previously vaccinated with H. 
somrms bacterins A (administered subcutaneously) and D (administered intramuscularly) had 
significantly higher plasma LTC4 concentrations than did the control group or calves 
vaccinated with H. somrms bacterins B and C. These results could be explained by differences 
in the strains, antigenic mass of H. somrms organisms, or the inactivation process utilized in 
the formulation of these two bacterins. Plasma concentrations of group A calves continued to 
increase at Day 45. 
Eicosanoids Associated With Bronchodilation, Edema Formation, or Chemotaxis 
PGEo has potent bronchodilator and vasodilator effects as well as being an activator of 
polymorphonuclear lymphocytes (PMNs). PGE, has been shown to play a significant role in 
the modulation of T cell responses in septic rats^~ and, along with LTB4, is involved in the 
control of mitogen-induced proliferation" . In the present study, it is unlikely that the increase 
in plasma PGE, concentrations was due to the four H. somrms bacterins since the control 
group, which did not receive the H. somrms vaccination, had a similar increase on Day 14. 
However, on Day 21 plasma concentrations of the control group continued to increase; those 
of groups A, B, C, and D decreased. In contrast, four days after a single administration of a 
MLV BRSV vaccine groups A, B, and C had increased concentrations of PGE,, whereas 
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PGE2 concentrations were decreased in the control group. These differences in control and 
H. somnus-vaccinsted. groups suggests a possible enhancement of BRSV-induced PGE^ 
production by H. somrms bacterins. Gershwin et al. ~ demonstrated a significant increase in 
plasma PGE2 concentrations in nonvaccinated calves 3 days after a primary infection with 
BRSV and 7 days after a secondary infection. The high FGE^ concentrations in H. somnus 
vaccinates on Day 29 may provide an explanation of the severity of disease due to BRS V. 
Vaccination route or adjuvant differences did not appear to have an effect on PGE, 
production. 
6-keto PGFi^ is a stable metaboUte of PGI, (prostacyclin) and induces slight 
bronchodilation, increased edema formation, and leukocyte infiltration to areas of 
inflammation. Plasma 6-ketoPGFi(^ concentrations obtained in this study were approximately 
6-fold higher than those obtained by Gershwin et al. ~. This difference may be due to a depot 
effect of vaccination or differences in environment. On Day 14, plasma 6-ketoPGFic 
concentrations were significantly increased in H. somnus vaccinated calves and decreased in 
the control group, indicating that H. somnus bacterins preferentially stimulate 6-ketoPGFi„ 
production. The increase in plasma 6-ketoPGFi5, observed in H. 5om/n/5-vaccinated calves on 
Day 14 may reflect the endotoxin content present in the bacterins. Markedly elevated 
concentrations of 6-keto PGFj^^ have been described in calves challenged with Pasteurella 
hemolytica and in sheep after infusion of P. hemolytica endotoxin^^. 
Plasma 6-ketoPGFj^ concentrations in control calves increased after each viral 
vaccination. On Day 21, plasma 6-ketoPGFi£, concentrations in the control group increased 
while concentrations in H. 50/wm/5-vaccinated calves were decreased. This suggests that 
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either a combination IBR-PI3 (MLV) vaccination had minimal effect on 6-ketoPGFio 
production or samples were not collected from H. 5om7n/5-vaccinated calves at a time when 
high 6-ketoPGF,^ concentrations could be detected. Four days after vaccination with BRSV 
vaccine (MLV), calves previously vaccinated subcutaneously with H. somrrus bacterin A had 
dramatically lower 6-k;etoPGFia concentrations than controls or other H. somnus vaccinates. 
This suggests that the route of administration may be advantageous to the animal by lowering 
the production of 6-ketoPGFi^. There did not appear to be differences due to adjuvant. 
These results indicate that although bronchoconstriction was not a predominant effect, 
increased interstital fluid may have been enhanced by 6-ketoPGF,t^ production. 
LTB4 is a potent activator of PMNs, increases capillary permeability, and is 
chemotactic. On Days 14, 21, and 29 we noticed significantly higher plasma LTB4 
concentrations in H. vaccinated calves as compared to the control group. Highest 
plasma concentrations were seen on Day 29, four days after BRSV (MLV) vaccination. The 
higher plasma LTB4 concentrations observed in H. 5omm/5-vaccinated and control groups 
after BRSV (MLV) vaccination may be due to a synergistic effect between the modified live 
BRSV virus and the H. sommis bacterins. There did not appear to be a significant difference 
in route of administration or adjuvant. The high plasma LTB4 concentrations may have 
contributed to the alterations in white blood cell populations observed on Days 21, 25, and 
29. 
Plasma prostaglandin concentrations have been measured in calves in response to 
other stimuli. Emau et al." studied the effects of P. hemolytica endotoxin on PGEj, PGFtc, 
6-ketoPGFj„, and TxB, concentrations. The concentrations of PGE^ measured in that study 
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were in the range of 60 to 130 pg/ml. Those reported by Gershwin et al. ~ in response to 
BRSV infection were in the range of 180 to 250 pg/ml as baseline values with peak 
concentrations of greater than 1,000 pg/ml. The concentrations we measured were in the 
range of 18 to 40 pg/ml (Day 0) with a peak concentration of over 70 pg/ml and are more 
similar to those of Emau et al.". 
In Gershvra's work nonvaccinated BRSV-infected calves had peak PGF,^ 
concentrations after virus exposure well over 1,000 pg/ml; the highest value in Emau's 
endotoxin-stimulated calves was approximately 600 pg/ml. In our study, plasma PGET^J 
concentrations were more similar to those of Emau " after//, somms vaccination. However, 
after viral vaccination with modified live virus vaccines, plasma PGF,^ concentrations were 
more similar to those reported by Gershwin in nonvaccinated BRSV-infected calves. Peak 
plasma concentrations of 6-ketoPGFij, in BRSV-exposed calves remained below 150 pg/ml, 
whereas peak concentrations in Emau's work for endotoxin-inflised calves were tenfold 
higher. The concentrations we measured were higher than those of BRSV-exposed calves but 
lower than endotoxin-infused calves. Thromboxane concentrations in Gershwin's 
BRSV-exposed calves ranged from about 2-23 pg/ml after a primary BRSV exposure to 
around 40-82 pg/ml after a second BRSV exposure. These values were lower than Emau's 
endotoxin-infused calves. In our study, TxB, concentrations were more similar to those of 
Emau, reaching a peak concentration of482 pg/ml four days after BRSV vaccination. 
Results of this study demonstrate that the effects of vaccination can become systemic 
and affect other organ systems such as the lung. Haemophilus somnus bacterins can alter the 
eicosanoid levels of calves in favor of PGET^, TXB, (bronchoconstrictors), and 6-ketoPGF,„. 
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Vaccination with modified live vimses (especially BRSV) may have a synergistic effect in 
H. vaccinated calves resulting in enhanced production of bronchoconstrictors and 
mediators of edema formation. Although bronchoconstriction was not a predominant effect, 
increased interstitial edema and mucus secretion may be enhanced by 6-ketoPGFio and LTB^ 
production, respectively. Alteration in plasma eicosanoid concentrations may be influenced by 
H. somrtus antigens, suppressive effects of the modified live viruses in the vaccines, the 
presence of adjuvants, or bacterial inactivation procedures. Results of this study raise safety 
issues of veterinary biologicals. 
References 
I. Gershwin LJ and Giri SN. 1992. Effects of allergen challenge on plama concentrations of 
prostaglandins, thomboxane B2, and histamine in calves infected with bovine respiratory 
syncytial virus. 1992. Am J Vet Res 53:1670-1674. 
2. Gershwin LJ, Giri SN, Sterwart RS, and Chen J. 1989. Prostaglandin and thromboxane 
concentrations in plasma and lung fluids during sequential infection of vaccinated and 
nonvaccinated calves with bovine respiratory syncytial virus. Am J vet Res 50:1254-1262. 
3. Stewart RS and Gershwin LJ. 1989. Role of IgE in the pathogenesis of BRSV in 
sequential infections in vaccinated and nonvaccinated calves. Am J Vet Res 50:349-355. 
4. Hanley SP. 1986. Prostaglandins and the lung. Lt(ng 164:65-11 
5. Gershwin LJ and Friebertshauser K. 1987. Demonstration of Pti^^ej/reZ/a-specific 
immunoglobulin E in bovine serum. Am J Vet Res 38(2): 169175. 
6. Stewart RS and Gershwin LJ. 1989. Detection of IgE antibodies to bovine respiratory 
syncytial virus. Vet Immimol Immunopathol 20:313-323. 
7. Gershwin LJ, Dungworth DL, and Himes SR. 1990. Immunoglobulin E responses and 
lung pathology resulting fi-om aerosol exposures of calves to respiratory syncytial virus and 
Micropolysporafaeni. Int Arch Allergy ApplImmunol 92:293-300. 
8. Gershwin LJ and Giri SN. 1992. Eflfects of allergen challenge on plasma concentrations 
of prostaglandins, thromboxane B2, and histamine in calves infected with bovine respiratory 
syncytial virus. Am J Vet Res S3:1670-1674. 
136 
9. Fulginiti VS, Eller JJ, and Sieber OF. 1969. Respiratory virus immunization. I. A field 
trial of two inactivated respriatory virus vaccines, and aqueous trivalent parainfluenza virus 
vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 
89:435-448. 
10. Hyman AL et al. 1978. Prostaglandins and the lung. Am Rev Respir Dis 117:111-136. 
11. Kunkel SI. Editorial 1988. The importance of arachidonate metabolism by immune and 
nonimmune cells. Lab Investig 58:119-121. 
12. Choudhry MA, Ahmad S, and Sayeed MM. 1995. Role of Ca~~ in prostaglandin 
Eo-induced T lymphocyte proliferative suppression in sepsis. Infect Immun 63:3101 -3105. 
13. Shapiro AC, Wu D, and Meydani SN. 1993. Eicosanoids derived firom arachidonic acid 
and eicosapenaenoic acids inhibit T cell proliferative response. Prostaglandins 45:229-240. 
14. Emau P, Giri SN, and Bruss ML. 1987. Viral-bacterial pneumonia in calves: effects on 
plasma eicosanoids and long chain fatty acids. Int J Tissue React 9:199-214. 
15. Emau P, Giri SN, Bruss ML, and Zia S. 1985. Ibuprofen prevents Pasteurella 
hemolytica endotoxin-induced changes in plasma prostanoids and serotonin, and fever in 
sheep. J Vet Pharmacol Ther 8:352-361. 
137 
Table 1. Characteristics of the Haemophilus somnus bacterins and 
modified live virus (MLV) vaccines utilized in this study 
BIOLOGICAL ADJUVANT ROUTE DOSE 
H. somnus Bacterins 
' 1 / A. A1(0H)3 sc 2ML 
OIL IM 2ML 
^ . s A1(0H)3 IM 2ML 
D AI(0H)3 IM 2ML 
a 
ML V Virus Vaccines 
roR-pij None IN 1 ML/NARE 
BRSV None IM 2ML 
Bacterins were purchased from a local veterinary supply warehouse. 
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Table 2. Definition of groups and vaccination schedule. All animals were bled on Days 0, 14, 
21, 25, 29, and 45. Plasma concentrations of eicosanoids and differential white blood cell 
counts were determined on Days 0, 14, 21, 29, and 45. Differential white blood cell counts 
were also determined on Day 25. 
Group 
Designation 
H. Somnus 
Bacterin 
IBR-PI3 
Vaccination 
BRSV 
Vaccination 
Control None Day 14 Day 25 
A Bacterin A 
Day 0 = Primary 
Day 14 = Booster 
Day 14 Day 25 
B Bacterin B 
Day 0 = Primary 
Day 14 = Booster 
Day 14 Day 25 
C Bacterin C 
Day 0 = Primary 
Day 14 = Booster 
Day 14 Day 25 
D Bacterin D 
Day 0 = Primary 
Day 14 = Booster 
Day 14 Day 25 
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Table 3. Mean plasma concentrations of eicosanoids associated with bronchoconstriction of 
control and experimental calves previously vaccinated with H. somrms bacterins. Results are 
expressed as group mean concentrations (pg/ml) ± standard error of the mean. Calves 
vaccinated with H. somrtus bacterins received the primary and secondary injections on Days 0 
and 14. All calves, including controls, were vaccinated with IBR-PI3 vaccine on Day 14 and 
with BRSV vaccine on Day 25. (See Table 2 legend for definition of groups). 
Day 0 Day 14 Day 21 Day 29 Day 45 
PGF,, 
Controls 282.9 = 32.1 292.7 ± 58.8 371.2 ±38.4 566.2 ± 64.5 123.8 ±33.1 
Group A 460.3 ±28.1 928.4 ±28.8' 471.1 ± 14.1 1.182.6 ±58.0' 166.2 ± 26.8 
Group B 281.0 ±33.6 839.8 ± 70.3 • 552.9 ±28.5 1.139.1 ±47.2* 759.5 ± 105.6* 
Group C 490.0 ±67.0 648.8 ±54.7' 512.5 ±42.9 1.089.7 ± 197.6* 1.000± 122.3 • 
Group D 525.0 ±63.7 714.8 ±46.4* 476.6 ±55.4 1.634.7 ±214.1 * 349.7±35.1• 
TxBj 
Controls 53.3 ± 5.7 48.1 ± 12.1 99.4 ± 16.7 82.6 ±7.0 38.3 ±8.7 
Group A 59.4 ± 10.2 98.7 ± 15.1 • 76.5 ± 5.5 164.7 ± 18.8 56.8 ± 12.8 
Group B 79.3 ±4.8 128.4 ± 17.8* 109.6 ± 11.5 294.5 ±22.9* 53.1 ±8.3 
Group C 48.7 ±7.8 118.7 ±28.5" 86.2 ± 16.8 285.7 ±44.1 * 21.2 ±6.3 
Group D 59.1 ±3.9 150.2 ± 19.5* 85.9 ± 14.5 482.0 ±65.5* 68.3 ±21.8 
LTQ 
Controls 62.6 ± 1.2 21.6 ±3.0 10.6 ±0.9 12.6±3.1 18.3 ±2.7 
Group A 23.6 ±2.1 38.0 ± 2.6 12.1 ±1.1 33.5 ± 1.5* 49.2 ± 1.1 
Group B 12.7 ± 1.4 14.6 ± 2.9 24.7 ± 5.3 18.0 ±4.5 25.1 ±6.3' 
Group C 15.8 ±3.5 13.2 ± 1.5 15.6 ±2.6 18.5 ±2.1 28.3 ±2.3* 
Group D 12.9 ± 2.4 17.0 ± 9.9 16.9 ±2.1 45.6 ±4.4* 31.1±3.1 
' = Statistical^ different from Controls at P<0.05. 
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Table 4. Mean plasma concentrations of eicosnaoids associated with bronchodilation, edema 
formation, and chemotaxis in control and calves previously vaccinated with H. somnus 
bacterins. Results are expressed as group mean concentrations (pg/ml) ± standard error of the 
mean. Calves vaccinated with H. somnus bacterins received the primary and secondary 
injections on Days 0 and 14. All calves, including controls, were vaccinated with IBR-PI3 
vaccine on Day 14 and with BRSV vaccine on Day 25. (See Table 2 legend for definition of 
groups). 
Day 0 Day 14 Day 21 Day 29 Day 45 
PGE, 
Controls 23.7 ± 1.9 37.5 ±3.6 51.3 ±5.7 41.4 ± 10.1 17.4 ±3.7 
Group A 20.0 ± 1.9 45.4 ±4.2 44.5 ±5.1 60.9 ± 10.2 14.0 ±4.3 
Group B 36.0 ±5.4 47.8 ±3.2 35.0 ±8.7 71.5 ± 9.0 18.2 ±2.4 
Group C 24.2 ±3.4 47.5 ±4.9 47.0 ±7.1 55.8 ±8.7 14.6 ±3.4 
Group D 41.4 ±4.2 60.4 ±3.3 42.9 ±3.1 42.8 ±8.1 32.9 ±7.0 
6-ketoPGFi^ 
Controls 296.4 ±43.8 207.0 ±37.5 347.8 ±23.5 429.2 ± 98.7 36.2 ± 9.0 
Group A 196.4 ± 29.7 449.8 ±68.9* 370.1 ±9.2 232.2 ±47.4 251.3 ± 12.8' 
Group B 197.7 ±27.2 530.8 ±45.9 "• 326.3 ± 20.8 448.7 ±103.6 239.4 ± 58.6' 
Group C 242.5 ± 20.5 544.1 ±25.9 • 377.0 ±21.8 526.5 ± 55.4 30.3 ± 8.6 
Group D 255.7 ± 15.9 602.1±23.8• 292.1 ±21.6 489.5 ±64.2" 48.9 ± 9.7 
LTB^ 
Controls 62.6 ±6.8 44.4 ± 4.4 38.1 ±2.4 12.6 ±3.1 63.6 ±7.1 
Group A 69.0 ±4.9 141.4 ±7.8* 88.0 ±6.6" 236.4 ±39.4 • 102.9 ±7.0 
Group B 47.6 ±2.4 124.0± 12.8• 129.7 ±44.8 • 248.7 ±72.2 • 73.7 ±6.4 
Group C 66.8 ± 4.6 l31.8±15.1• 97.8 ±20.8" 250.2 ±27.8* 106-2 ± 22.0 
Group D 67.9 ±7.3 170.1 ±9.9" 145.7 ± 25.3 • 191.4 ±10.6* 105.3 ±21.6 
^ = Statistically different from Controls at P<0.05. 
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Table 5. Differential white blood cell counts of control and calves previously vaccinated with 
H. somrms bacterins. Results are shown for lymphocytes, eosinophils, and basophils. All 
other white blood cell populations were within normal ranges. Data are expressed as 
percentage of total white blood cells. Calves vaccinated with H. somnus bacterins received the 
primary and secondary injections on Days 0 and 14. All calves, including controls, were 
vaccinated with IBR-PI3 on Day 14 and with BRSV on Day 25. (See Table 2 legend for 
definition of groups). 
Day 0 Day 14 Day 21 Day 25 Day 29 Day 45 
Lymphocytes (normal: 39-77%) 
Controls 53.9 ±3.5 52.9 ±1.4 57.6 ±3.7 65.0 ±2.5 31.2 ±2.9 61.9 ±2.5 
Group A 53.5 ±3.0 55.9 ±4.1 54.0 ±3.5 54.3 ± 1.5 33.0 ±2.8 56.7 ± 2.5 
Group B 46.4 ±3.8 57.7 ±3.0 42.6 ±3.5 41.5 ±4.5 35.4 ±3.5 51.6 ±3.3 
Group C 46.6 ± 2.2 54.0 ± 1.8 53.3 ±4.4 53.2 ±3.9 35.6 ±3.5 57.3 ±3.0 
Group D 51.2 ±1.9 60.1 ±3.3 55.6 ±3.4 6I.6±2.5 44.3 ±4.9 56.7 ±1.74 
Eosinophils (nonnal: 0-14%) 
Controls 2.1 ±0.7 0.52 ±0.31 0.38 ±0.17 0.67 ±0.22 1.33 ±0.46 1.5 ±0.52 
Group A 1.7 ±0.3 0.24 ±0.14 0.62 ±0.19 0.48 ±0.20 0.38 ±0.66 0.86 ±0.25 
Group B 1.5 ±1.0 1.0 ±0.25 0.91 ±0.17 0.43 ±0.23 0.67 ±0.21 0.62 ±0.32 
Group C 3.7 ±0.8 0.17±0.11 0.56 ±0.22 0.72 ±0.43 1.61 ±0.92 1.17 ±0.78 
Group D 1.8 ±0.6 1.0 ±0.61 0.57 ±0.32 0.62 ±0.22 0.48 ±0.24 1.10 ±0.46 
Basophils (nonnal: 0%) 
Controls 0.57 ±0.21 0.38 ±0.17 1.57 ±0.56 3.0 ±0.74 5.10 ±1.0 0.10 ±.010 
Group A 0.71 ±0.25 0.43 ±0.14 2.72 ±1.1 4.1 ±0.89 4.57 ±1.16 0.I0±0.I0 
Group B 0.62 ±0.29 0.95 ±0.29 2.10 ±0.50 2.4 ±0.60 1.95 ±0.64 0.05 ±0.05 
Group C 1.06 ±0.34 0.17 ±0.07 2.29 ±0.60 3.1 ±1.4 4.67 ±1.47 0.56 ±0.27 
Group D 0.86 ±0.19 0.81 ±0.44 2.95 ±0.79 3.2 ±0.80 3.43 ±0.56 1.33 ±0.39 
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CHAPTER 6. HAEMOPHILUS SOMNUS BACTERINS AND BRSV 
VACCINE SYNERGIZE TO INCREASE PLASMA EICOSANOIDS 
ASSOCIATED WITH LATE-PHASE ALLERGIC REACTIONS 
Kevin W. Ruby, Ronald W, Griffith, Merlin L. Kaeberle 
A paper to be submitted to Vaccine 
Abstract. To examine the interaction of modified live virus (MLV) BRSV vaccines and 
Haemophilus sommis bacterins on the development of immediate hypersensitvity. four 
experimental groups (A,B,C,D) of Holstein calves received a different commercial H. somnus 
bacterin injection according to label recommendations. Primary and secondary (booster) 
injections were given on Days 0 and 14, respectively On Day 25 ail calves received a single 
intramuscular injection of a commercial BRSV (MLV) vaccine. Seven calves served as 
non-H. somnus vaccinated but virus-vaccinated controls (group E). On Day 45, calves v/ere 
challenged at random with live, washed whole cells of H. sommis alone (subgroups Al-El) or 
with (MLV) BRSV (subgroups A2-E2) by intratracheal injection. Blood samples were 
collected immediately prior to and 15 and 60 minutes after challenge. Plasma concentrations 
of prostaglandins (PG), leukotrienes (LT), and thromboxanes (Tx), histamine, and serotonin 
were determined by enzyme-linked immunoassay. Regardless of challenge, plasma 
concentrations of LTB^, LTC4. PGE,, and 6-ketoPGF,„ were significantly increased 15 
minutes after challenge in most calves. Significantly higher plasma TxB, concentrations were 
noted 15 minutes post-challenge with H. somnus+BKSW as compared with calves challenged 
with H. sommis alone. Plasma histamine concentrations were significantly increased in two 
of four and three of four H. ^omwz/^-vaccmated groups 15 minutes after a H. sommis and 
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H. sommis+EKSV challenge. Control calves also had significantly higher histamine levels 
regardless of challenge. Plasma serotonin levels did not change significantly after either 
challenge. There were more calves that had dyspnea and tachypnea after challenge with 
H. sommis+EKSW challenge than after H. somnns challenge. No differences were noted 
within or between challenge groups in temperatures This study demonstrates that vaccination 
with H. sommis bacterins and BRSV (MLV) vaccines may adversely affect the animal by 
enhancing higher concentrations of eicosanoids associated with development of a 
hypersensitized state (PGE,) and a late phase asthmatic-like bronchoconstriction (LTB4 , 
LTC4. and TxB^)- These data may partially explain the more severe clinical disease 
occasionally observed in vaccinated than nonvaccinated calves. These results have important 
implications for the veterinary industry and regulatory officials regarding adverse events 
attributable to biologicals. 
Introduction 
Respiratory disease continues to be a disease problem in all types of cattle operations. 
Etiologic agents include infectious bovine rhinotracheitis virus (IBR), parainfluenza, (PI,), 
bovine respiratory syncytial virus (BRSV), and Haemophilus somnus among others. 
Hypersensitivity reactions to BRSV have been implicated in pathogenesis of severe disease 
outbreaks ~ Induction of IgE responses have been described for BRSV-*, Micropolyspora 
faani *. Pasteiirella hacmolyticaand H. somnus °. Arachidonic acid metabolites have been 
implicated as regulators of bronchoconstriction and bronchodilation; thromboxanes (TxB,), 
leukotrienes (LTC^). and prostaglandins ( PGF,„, and PGDT) have bronchoconstrictor activity, 
and PGE, causes bronchodilation - " 
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Observational evidence suggests that there occasionally appears to be more severe 
clinical respiratory disease in vaccinated than nonvaccinated calves. One would, therefore, 
expect that limited sequential viral exposures would induce increasingly severe or prolonged 
disease expression. For this process to have a role, initial viral exposure must occur to induce 
a sensitized state. Vaccinations could contribute to the pathogenesis of bovine respirator>' 
disease by aggravating the disease process during subsequent infections. 
Changes m various plasma eicosanoid concentrations have been reported in calves 
infected with P. haemolytica and BRSV - "•. M. faerii and bovine herpesvirus-1 ' 
We have recently reported on the effect of modified live virus (MLV) vaccmation on plasma 
eicosanoid concentrations in calves previously vaccinated with commercial H. somtms 
bacterins The purpose of this study was to examine the influence of a preexisting allergy on 
the pathogenesis of bovine respiratory disease in calves. Because atopic calves are not readily 
identifiable, we induced IgE production by vaccination with four different commercial H. 
sonmus bacterins followed by sequential vaccination with a modified live virus BRSV vaccine. 
Serum concentrations of H. iOA77/7z/5'-specific IgE induced by these H. sommis bacterins are 
reported elsewhere ^ 
Materials and Methods 
Animals a} id Vaccination 
Twenty-eight 40-day-old Holstein calves were randomly divided into 4 treatment 
groups (n=7 each) and each vaccinated with a different H. somnus bacterin (designated as A. 
B, C, and D) followed by a single BRSV (MLV) vaccine. Seven calves (Group E) served as 
non-H. io/77?///.v-vaccinated but BRS V-vaccinated controls. Haemophilus sommis bacterins 
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and the BRSV (MLV) vaccines were obtained from a local veterinary distributor. 
Imnnunizations were administered according to label recommendations. 
Experimental Design (Table I). 
Groups A, B, C, and D received primary (Day 0) and secondary (Day 14) H. sommis 
vaccinations according to label recommendations. On Day 25, all calves including controls 
received a single vaccination with a commercial BRSV (MLV) vaccine. Calves were 
monitored for adverse events through Day 45. On Day 45, all calves were challenged with 
washed, live H. sommis organisms; four randomly selected calves from each group were 
subsequently challenged with BRSV (MLV) by intratracheal injection. The calves not 
receiving the BRSV challenge were designated Groups AL B1, etc.. and the calves that 
received the BRSV challenge were designated groups A2, B2. etc. 
Preparation of Challenge Material. 
The BRSV (MLV) challenge material was the same lot of BRSV (MLV) vaccine that 
was used for vaccination and was prepared according to manufacturer's instructions. Strain 
155A was used in the H. sommis challenge. Brain-heart-inflision agar plates supplemented 
with 10% bovine serum and 0.5% yeast extract (BHISY) were inoculated with a stock culture 
of strain 156 A and the cultures were incubated 2 days at 37°C in 5% CO, in air. Colonies 
showing typical growth of H. sommis were used to inoculate 10-ml of BHI plus serum and 
yeast (BfflSY) broth and incubated 2 days at 37°C in 5% CO, in air. Thirty-five plates of 
BHISY agar were individually inoculated with 0. l-ml of the broth culture and the plates were 
incubated at 37°C for 2 days in 5% CO, in air. Growth was harvested with 3-ml of sterile 
phosphate buffered saline (0.05 M phosphate, PBS, pH 7.2) per plate. The harvested growth 
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was pooled and centrifuged at 13,000 x g for 20 minutes at 4°C. The cell pellet was 
resuspended in 50-ml sterile PBS and washed two more times. The suspension was adjusted 
to an optical density of 1.0 at 595 nm and kept on ice until challenge. 
Challenge. 
Intratracheal injections were performed in the upper half of the trachea. All calves 
received an intratracheal injection of live, washed N. somnus organisms suspended in 60-nil of 
PBS Each calf received approximately 7.5 x 10'" organisms suspended in 60-ml of PBS. 
Four randomly selected calves per group were administered an intratracheal injection of 2-ml 
of BRSV (MLV) vaccine at random. Table 1 shows the schedule of procedures and 
treatments. 
Sample C 'oUection and Processing. 
Blood was collected prior to challenge as well as 15 and 60 minutes after challenge 
exposure with either//, somnus alone or H. sommis-r^KSiW (MLV). Blood samples were 
obtained by jugular venipuncture into EDTA tubes with and without 10 mg of indomethacin 
and placed on ice until transported to the laboratory. For determination of eicosanoid. 
histamine, and serotonin concentrations, plasma was harvested by centrifligation (2400 rpm), 
aliquoted into 0.5-ml aliquots. and stored at -70° C until assayed. Animals were observed for 
clinical signs of respiratory disease and any potential adverse events throughout the study. 
Respiratory rates and temperatures were recorded prior to challenge as well as 15 and 60 
minutes after challenge. 
Eicosanoid. Histamine, and Serotonin Assay. 
Concentrations of eicosanoids. histamine, and serotonin were measured in plasma on 
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days 0, 14 (prior to vaccination). 21. 29. and 45 All eicosanoid levels were determined using 
ELISA-based detection assays (Cayman Chemical Co. Inc., Ann Arbor. MI). Sep-Pak C-IS 
reverse phase cartridges v/ere obtained from Waters. Inc. Histamine and serotonin levels were 
determined using ELISA-based detection assays (Immunotech, Inc.. Marseille, France). 
Samples were processed and assays performed according to the manufacturer's instructions 
Statistical Analysis. 
Eicosanoid concentrations were evaluated for significance by least significant 
differences (LSD) to compare group mean values Differences were considered to be 
significant at P<0.05 
Results 
Eicosanoids Associated With Bronchoconstriction (Table 2) 
Plasma PC/F^a concetwations. 
The combination challenge (A2, B2. etc.) of H. somtnis-rEKSV had a greater effect on 
plasma PGF^^ concentrations 15 minutes post-challenge than did a challenge with H. somniis 
organisms alone (Al, B1. etc.). The only change after an H. sonimis challenge was a 
significant increase in the control group 15 minutes post-challenge. Groups A1 and D1 had 
maximal increases of 1.8-fold whereas plasma PGFia concentrations of groups B1 and C1 
decreased by 2.2- and 1.2-fold, respectively. Except for Group CI, plasma PGFi^ 
concentrations decreased 60 minutes post-challenge. In contrast, the effect of a combination 
challenge with H. sommis-^^KS>W was an increase in plasma PGF,^ concentrations 15 minutes 
post-challenge. These ranged from a 2.2-fold increase (group B2) to a 5.2-fold increase 
(group A2). Significant increases were noted in the controls and two of the four H. somnus-
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vaccinated groups (A2 and D2). 
Plasma 7x5, concentrations. 
The combination challenge of H. sommis-rQKS'V had a greater effect on plasma TxB, 
concentrations 15 minutes post-challenge than did a challenge with H. sommis organisms 
alone. Whereas no significant increases in plasma TxB; were noted following a H. somnus 
challenge, a combination challenge with H. caused significant (P<0 05) 
increases. These ranged from a 2.5-fold increase in group D2 calves to a 16.6-fold increase in 
group A2 calves. Plasma TxB, concentrations increased 9.2-fold 15 minutes after a 
combination challenge as opposed to a 1.3-fold increase after an H. somnus challenge 
Plasma LTi\. 
Plasma LTC4 concentrations were significantly CP<0.05) increased in control and all 
treatment groups 15 minutes post-challenge, regardless of challenge material. There was no 
significant difference (P<0.05) between the increases in plasma LTC4 concentrations due to 
either challenge. Control calves had similar increases in plasma LTC^ concentrations 
regardless of challenge material. 
Eicosanoids Associated With Bronchodilatiun. Edema, and Chemotaxis. (Tahle3) 
Plasma P( TE^ concentrations. 
Challenge with H. sommis organisms had a greater effect on plasma PGE, 
concentrations than did a combination challenge with H. sommisr-B^SV. Fifteen minutes 
after a H. somnus challenge plasma PGE^ concentrations significantly (P<0.05) increased in 
control and H. somnus-vaccinated calves (groups Al-Dl) 15 minutes post-challenge. 
Challenge with H. somnus+BKSW significantly increased plasma PGE, concentrations in three 
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of four H. iro/w/m5-vaccinated groups 
Plasma 6-ketoPGF^a^ concentrations. 
Changes in plasma 6-k:e£oPGFijj concentrations were similar regardless of the 
challenge material. Groups B1 and CI had a 2.6- and 2.9-fold increase in plasma 6-
ketoPGF,tt concentrations 15 minutes after a H. somniis challenge. Groups A2 and C2 had a 
6.2- and 5.8-fold increase 15 minutes after the combination H. somtms-^BKS\' challenge 
Groups A and B had high plasma levels of 6-ketoPGFi£j prior to challenge with H. sommis or 
the combination challenge, respectively In both cases, these concentrations decreased 73 9-
and 4.4-fold 15 minutes after the respective challenges. Plasma concentrations of 6-
ketoPGF,£, in control calves did not change significantly after either challenge Only one 
group, (group A2). had an increased plasma 6-ketoPGF,„ concentration 60 minutes after 
challenge v/ith the combined H. somnns^QRSV 
Plasma L TBi concamrations. 
Plasma LTB4 concentrations were significantly (P<0.05) increased in control and all 
treatment groups 15 minutes post-challenge, regardless of challenge material. There was no 
significant difference (P<0.05) between the increases in plasma LTB^ concentrations 
associated with either challenge. Control calves (group E2) had a 9.2-fold increase 15 
minutes after a combination H. somnus-r^KS,\' challenge. Control calves (group El) had a 
6.1-fold increase 15 minutes after an H. sommis challenge. 
Plasma Histamine and Serotonin concentrations (Table 4). 
Plasma histamine concentrations increased in all groups within 15 minutes regardless 
of challenge. Within 15 minutes of H. sommis challenge, significant (P<0.05) increases were 
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noted in controls and groups AI and Di Values continued to rise at 60 minutes post-
challenge and were all significantly (P<0.05) higher than pre-challenge. The most significant 
increases in plasma histamine 15 minutes after a combination H. somnus+BKS'V challenge 
were noted in controls and groups A2. C2, and D2. 
Changes in plasma serotonin concentrations were variable. Serotonin concentrations 
in control calves decreased 1.8-fold 15 minutes after a H. sommis challenge but increased 1.3-
fold 15 minutes after a combination H. sommis^BKSV challenge. Only group C calves had a 
decrease in plasma serotonin concentrations 15 minutes after each challenge. Addition of 
BRSV to the H. somnus challenge had the opposite effect on plasma serotonin concentrations 
in groups A2, B2. and D2 15 minutes post-challenge Sixty minutes after challenge with H. 
samnits-+QKSW, control calves (group E2) had a significantly (P<0.05) higher serotonin 
concentration. 
Respiraioiy Rates and Temperatures. 
One calf in the control group and two calves in each of groups A C. and D had mild 
dyspnea and tachypnea following H. somnus challenge (data not shown). In contrast, three 
controls and three calves ft'om each of groups A and B had mild dyspnea and tachypnea 
following an H. somnus -^BRS V challenge. Regardless of challenge, all calves recovered 
within 1 hour post-challenge. There were no differences in temperatures (data not shown). 
When group means are compared, there were no differences between experimental groups in 
respiratory rates or temperatures among or between challenge groups throughout the study. 
Discussion 
Increased production of prostaglandins (PGs) from arachidonic acid has been 
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associated with chronic viral infections in humans respiratory syncytial virus " and 
bluetongue virus infections in cattle, and with border disease virus infection in sheep '' In 
other studies increased production of prostaglandins have been demonstrated in allergic 
states such as anaphylaxis. Serum POF^a concentrations in human beings with asthma have 
been found to be greater than those in clinically normal controls. However, treatment with 
indomethacin does not prevent or alleviate bronchoconstriction. The arachidonic acid 
metabolites responsible for asthmatic-type bronchoconstriction are the leukotrienes (LTs). 
Therefore, it has been suggested that prostaglandins may play a secondary or modulating role 
in asthmatic-type bronchoconstriction 
We recently demonstrated that modified live virus vaccines administered to calves 
previously vaccinated against commercial H. sommis bacterins cause changes in plasma 
concentrations of eicosanoids and differential white blood ceil counts . In that study. 
H. somnus vaccination induced significant increases in plasma concentrations of PGFj^. TxB, 
(bronchoconstrictors). LTB^. and 6-ketoPGFm as compared to controls. 
In the present study, calves were vaccinated with four different commercial H. somnus 
bacterins and a commercial BRSV modified live virus (MLV) vaccine. Various mediators of 
allergic responses were examined after challenge exposure to these agents. Data reported 
here e.Ktends our previous study which demonstrated that vaccination can induce significant 
increases in eicosanoids associated with edema, chemotaxis. and late phase allergic reactions. 
This study suggest that vaccinated calves are sensitized or ''primed" for an allergic 
reaction upon exposure to these agents subsequent to vaccination. Observational evidence 
suggests that more severe clinical disease occasionally occur in vaccinated calves compared 
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with nonvaccinated calves. This study provides some evidence for these observations. 
Although vaccinated calves may apparently be protected from some of the disease 
manifestations due to these agents, they may also be sensitizing these animals for allergic 
responses upon subsequent exposure to these agents. Other studies have demonstrated similar 
responses to BRSV P. haemolytica ^ M faeni ^ and bovine herpesvirus-1 ^ 
infections. Therefore, it is not surprizing that when vaccinated animals are exposed to these 
agents in the field, more severe clinical disease is a possible outcome. 
Products of arachidonic acid metabolism, histamine, and serotonin have potent 
immunoregulatory properties, as well as potent physiological effects on target organs 
containing smooth muscle. Results of the present study extended our previous observations 
that BRSV (MLV) vaccines when administered to calves previously vaccinated with H. 
somnus bacterins can have adverse results. The data reported here demonstrate that 
vaccination with H. somnus bacterins and BRSV (MLV) vaccines may adversely affect the 
animal by enhancing higher concentrations of eicosanoids associated with development of a 
hypersensitized state (PGE^) and a late phase asthmatic-like bronchoconstriction (LTB4, 
LTC4, and TXBT). PGE, and LTB^ play mediator roles in edema formation. Leukotriene C4 
and TxBj are potent bronchoconstrictors. These eicosanoids may be important in some 
reported adverse events associated with the use of these biologicals. 
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Table 1. Schedule of procedures and treatments. 
Group Procedure/Treatment ® Adjuvant Dose/Route'' 
Day of 
Experiment 
.A H. soninus Bacterin A Ai{OH), 2ml/SC 0. 14 
Al 
A2 
Challenge 
3 calves; H. soninus 
4 calves H. .To/7;nw.v^BRSV 
60 ml/IT 
60 ml 2mI/IT 
45 
45 
B H. soninus Bactenn B Oil 2 ml/IM 0. 14 
CO 
CD 
Challenge 
3 calves; H soninus 
4 calves; H. soninus+'BRS\' 
60 ml/IT 
60 ml 2ml/IT 
45 
45 
c H. soninus Bacterin C -AKOH), 2 ml/IM 0. 14 
CI 
C2 
Challenge 
3 calves; H. soninus 
4 calves; H. soinnus~BRS\' 
60 ml/IT 
60 ml - 2ml/IT 
45 
45 
D H. soninus Bactenn D A1(0H)3 2 ml/IM 0. 14 
D1 
D1 
Challenge 
3 calves: H soninus 
4 calves; H. sownwiH-BRSV 
60 ml/IT 
60 mi 2ml/IT 
45 
45 
E (Controls) 
El 
E2 
Challenge 
3 calves: H. soninus 
4 calves; H. iow«£/.s-^BRSV 
60 ml/IT 
60 ml - 2 ml/IT 
45 
45 
•* = Treatment groups A-D were \ accuiaied with a different H. sommis bacterin on Day 0 (,primar\- injection) 
and Day 14 (booster injection). All calves received a single vaccination witli a commercial BRSV (MLV) 
vaccine on Da> 25. Ail animals were challenged on Da\ 45 with live, washed H. soninus organisms with (.A2. 
B2. etc.) or without (Al. Bl. etc.) BRSV (MLV). 
•• = 80 = subcutaneous; IM = intramuscular 
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Table 2. Mean plasma concentrations of eicosanoids associated with bronchoconstriction in vaccinated calves (A-
E) after challenge with live, washed H. somnus alone (1) or with (MLV) BRSV (2). Results are expressed as the 
mean concentration ± standard error of the mean prior to chaUenge (0) and 15- and 60 minutes post-challenge. 
Significant increases are shown in bold ^pe. 
Time Relative to H. somnus Challenge 
Time Relative to H. somnus + BRSV 
Challenge 
0 15 60 0 15 60 
PGF_ (pg/ml) 
A1 138.4 ±16.4* 248.5 ± 38.7 202.1 ±40.4 A2 27.8 ± 102 143.6 ±37 J 102.5 ± 28.6 
B1 612.2 ±54.7 • 277.3 ± 19 J. 161.6 ±96.4 B2 147.3 ±44.4 317.8 ±65.7 234.6±40.6* 
CI 232.0 ±78.9' 197.8 ±492 309.4± 44.9' C2 168.0 ±20.9 391.1± 38.3* 162.4 ±29.1 
D1 175.7 ±64.9* 302.3 ±46.9 196.1 ±77.3 D2 174.0 ±34.3 480.6 ± 603' 197.3 ±21.5 
£1 53.2 ± 17.4 I47_3 ± 43^ 94.4 ±39.6 E2 70.6 ± 11.3 181.2 ± 43.6 80.1 ± 18.0 
TxBj (pg/tnl) 
A1 35.9 ±3.6 25.5 ±5.9 11.1± 1.7 A2 20.9 ± 9.8 345.9 ± 44.8 389.6±71.9* 
B1 48.1 ±5.5* 63.8 ±7.3 • 12.5 ±8.2 B2 5.0 ± 2.3 ' 61.5 ± 11.8" 41.6±8.8* 
CI 7.0 ± 5.5' 17.4 ±2.8 8.4 ±7.1 • C2 14.2 ±4.1 167.7 ± 25.1 29.1 ±8.3 • 
D1 33.3 ±9.7 71.9 ±9.6' 25.4 ± 9.3 D2 35.0 ± 16.2 88.6 ± 22.9 23.7 ±9.4* 
E 1 19.7 ±4.9 25.1 ±6.7 23.7 ±4.5 E2 18.6 ±7.4 170.6 ± 59.8 7.9 ±0.32 
LTQ (pg/tnl) 
A1 22.5 ± 1.1 * 70±3.7 19.0 ±2.4 A2 26.7 ± 2.7 • 77.0 ± 4.1 14.1 ±3.0 
B1 10.6 ± 1.4 78.6 ± 5.5 5.1 ±0.5* B2 14.5 ±5.7 56.7 ± 11.5 25.4 ±4.3 
CI 14.6 ±2.1 58.3 ± 12.8 26.9 ± 1.9 C2 13.7 ± 1.3 55.0 ± 11.5 27.2 ± 4.0 
D1 16.2 ± 1.0 48.8 ± 1.1 20.9 ± 2.5 D2 14.9 ±2.8 37.6 ± 3.4 18.7 ±3.2 
El 9.0 ±0.30 70.8 ± 8.1 22.1 ± 1.9 E2 9.3 ±2.5 66.8 ± 5.5 26.9 ±4.4 
* = SignificantK' different from controls at P<0.05. 
157 
Table 3. Mean plasma cx)ncentrations of eicosanoids associated with broachodilation. edema, and chemotaxis in 
vaccinated calves (A-E) after challenge with live, washed H. somnus alone (I) or with (MLV) BRSV (2). Results 
are expressed as the mean concentration ± standard error of the mean prior to challenge and 15- and 60 minutes 
post-challenge. Significant increases are shown in bold ^ e. 
Time relative to H. somnus Challenge 
Time Relative to H. somnus +BRSV 
Challenge 
0 15 60 0 15 60 
PGE^ (pg/ml) 
A1 10.8 ± 1.8 35.6 ± 6.9 29.2 ±8.1 A2 3.2 ±2.2" 25.1 ± 5.4 35.2 ±6.6 
B1 10.4 ±3.1 26.7 ±0.88 15.4 ±8.3 B2 7.8 ±3.2 21.5 ±2.7 19.1 ±2.3 
CI 6.5 ± 2.7 22.4 ± 6.5 32.2 ±4.4 C2 8.1 ±3.0 20.0 ±5.4 16.4 ± 2.3 
D1 13.4 ±4.5 46.2 ± 5.2 18.9 ±2.6 D2 19.5 ±9.6 48.8 ±8.4' 27.1 ±3.8 
El 6.3 ±3.7 20.0 ±3.6 25.3 ± 10.1 E2 11.1 ±2.2 18.1 ±3.4 20.2 ±3.3 
6-ketoPGF,J (pg/ml) 
A1 244.0 ±43.3 ' 32.3 ±6.3^ 19.3 ±9.6 A2 7.3 ±2.2' 45.0 ± 12-2 132 ±91.3* 
B1 19.4 ± 7.6 51.2 ± 11.5 16.0 ± 8_2 B2 219.8 ±36.9' 49.5 ± 12.9 23.4 ±6.8* 
CI 20.1 ±2.4 57.7 ± 11.2 • 28.7 ± 12.6 C2 10.2 ±3.9 59.3 ± 10.4 26.8 ±5.9" 
D1 20.8 ±5.1 38.0 ± 9.8 18.2 ±6.2 D2 28.1 ± 5.6 54.9 ± 9.7 28.1 ±3.5" 
El 13.7 ±6.9 21.1 ± 1.6 14.0 ± 7.6 E2 22.5 ±6.4 24.6 ± 2.9 8.5 ±3.4 
LTB^ (pgAnl) 
A1 47.5 ± 2.8 477.0±34.5 • 109.3 ±35.4 A2 55.4 ±5.6 331.0±43.6 14I.0±42.4 
HI 41.3 ±6.4 1883 ± 8.7 126.3 ± 20.7 B2 32.4 ± 1.8 125.0 ±21.1 138.3 ± 19.8 
CI 56.9 ± 14.7 241J ± 33.2 154.7 ±27.5' C2 49.3 ± 19.7 318.0 ± 89.6 166.7 ±41.7" 
D1 58.1 ± 17.1 385.0±147.8 164.0 ±28.4* D2 47.2 ± 3.4 474 ± 130.4 I84.8±18.2' 
El 31.9 ±3.9 188.7 ± 39.9 51.3 ± 1.9 E2 31.7±4.1 292.7 ±47.9 66.3 ± 9.0 
' = Statistically different from controls at P<0.05. 
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Table 4. Mean plasma concentrations of histamine and serotonin in vaccinated calves after challenge 
with hve. washed H. somnus with or without a modified live BRSV. Results are expressed as the mean 
concentration (ng/ml) = standard error of the mean pnor to challenge and 15- and 60 minutes post-
challenge. Sigmficant increases are shown m bold t\pe. 
Time Relative to Challenge Time Relative to Challenge 
0 15 60 0 15 60 
Histamine (ng/ml) 
A1 0 4.1 ±0.5 3.0 ±0.4 A2 0.43 ± 0.4 " 4.4 ± 0.8 3.1 ±0.6 
B1 2.9 ± 0.7 • 3.9 = 0.6 6.4 ±0.3 B2 2.1±0.3 3.3 ±0.5 5.4 ±0.1 
CI 1.9 = 0.3" 3.9 = 0.1 4.5 ± 0.3 C2 1.4 = 0.8 3.7 ± 0.3 4.8 ±0.7 
D1 1.3 ±0.6" 4.2 ± 0.5 4.4 = 0.4 D2 0.6 ± 0.4 4.2 ± 0.7 3.9 ± 0.6 
El 0 3.7 ±0.1 4.1 ±0.2 E2 1.2 = 0.6 4.9 ± 0.9 3.7 ±0.4 
Serotonin (ng/ml) 
A1 19.5 =1.8" 39.8 ± 8.9 40,4= 14.2" .A2 21.2 ±4.8 36.1 ± 11.6 32.9±10.3 " 
B1 75.1 =2.4 95.5=1.6 ' 83.4= 1.2 " 82 76.1=22.1 " 75.9± 14.2 " 46.2 ± 9.9 
CI 50.9 = 6 7 47.3=11.9 54.0 = 9.2 * C2 46.5=21.1 " 61.9± 10.4 " 45.4 = 7 7 
D1 41.3 = 6.4 49.9±12.2 42.6=16.4" D2 54.1 ±8.8 " 44.2 ± 22.6 47.4 ± 19. r 
El 48.2=11.9 27.1 = 1.8 6.9 = 7.3 E2 17.6 = 2.9 23.2= 10.3 96.6 ± 18.1 
•* = Significantly different from Controls at P<0.05 
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CHAPTER 7. HISTAMINE PRODUCTION BY 
HAEMOPHILUS SOMNUS 
A paper submitted to Veterinary Microbiology 
Kevin W. Ruby, Ronald W. Griffith, Merlin L. Kaeberle, and Elizabeth C. Lytle 
Abstract. We have recently demonstrated Haemophilus 50OTm/5-specific IgE antibody 
induced by various H. somnus bacterins. Pathogenesis of bovine respiratory disease caused 
by H. somnus may also involve the production of histamine molecules. Ten H. somnus and six 
Pasteurella multocida isolates, and various bacterial cultures from the Center for Veterinary 
Biologies Laboratory culture collection were grown on blood agar plates in 5% COo. 
Histamine concentrations were determined by a commercial ELISA. Four H. somnus isolates 
yielded histamine levels of 100 - 200 ng/ml; two isolates yielded 50 - 100 ng/ml; and four 
isolates yielded less than 50 ng/ml of histamine. Histamine levels of all P. multocida tested 
were less than 12 ng/ml. Bacterial challenge cultures with the highest histamine levels were 
H. somnus (120 ng/ml) and Bordetella bronchiseptica (105 ng/ml) followed by Erysipelothhx 
rhusiopathiae (65 ng/ml). Salmonella dublin and S. choleraesuis (65 ng/ml), and 
S. typhimjirium (72 ng/ml). The ability of H. somnus to secrete histamine was evaluated 
using two H. somnus strains (8025, 156A) and one isolate (156A NI, a recent respiratory 
isolate) cultured in liquid medium with sterile gauze plugs for 17-, 41-, 96-, and 120-hours in 
5%, 15% or 25% COt in air. After 17-h of incubation, there were no significant differences 
among histamine content of washed whole cells of either strain regardless of atmospheric 
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conditions. Maximal surface histamine levels were observed after 120 hours incubation; strain 
I56A at 5% CO, (160 ng/ml); strain 8025 at 15% CO, (180 ng/ml); and the 156A NI isolate 
at 15% CO2 (225 ng/ml). Supernatant histamine levels were higher compared to the histamine 
content on washed whole cells. Results of this study suggest that histamine produced by N. 
somms might contribute to inflammation and airway hyperresponsiveness in bovine 
respiratory disease. 
Introduction 
The etiology of bovine respiratory disease includes complex interactions between 
envirormiental stressors and various viruses and/or bacteria. Cattle undergoing 
naturally-induced respiratory disease exhibit clinical signs of respiratory disease such as a dry, 
hacking cough, dyspnea, tachypnea, and wheezing. Although Pasteurella hemolytica is the 
major bacterial species isolated from pneumonic lungs, Haemophilus sommis has been isolated 
with increasing frequency from affected calves over the past 2 decades. 
Certain bacteria readily produce histamine by decarboxylation of histidine.^' ~ ^ The 
synthesis of histamine by bacteria suggests the possibility that inflammatory reactions 
surrounding areas of infection might in part be due to the formation of histamine by the 
invading bacteria. Synthesis of histamine has previously been shown in a variety of bacterial 
species, mainly Gram- negative organisms. High histamine concentrations in tissues of fish 
probably account for the signs associated with the ingestion of spoiled Scombresocidae and 
Scombridae such as tuna and mackerel and possibly other species."*' ^ Other food-borne 
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bacteria that have been implicated include Proteus spp., Klebsiella pneumoniae, Enterobacter 
aerogenes, Clostridium perfiingens, and some species of Hqfhia, Vibrio. Providencia, 
Citrobacter, and Lactobacillus f' In a study of pathogenic and nonpathogenic respiratory 
bacterial species, three of the five pathogenic species studied, Branhamella catarrhalis, 
Haemophilus parainfluenzae, and Pseudomonas aeruginosa, produced clinically important 
histamine.^ Haemophilus influenzae has also been shown to produce significant quantities of 
histamine/ 
The effects of histamine on the lung are mediated primarily by histamine receptors (Hj 
and H,) and include constriction of smooth muscle, stimulation of vagal afferent nerve endings 
and mucus glands, and increased permeability of bronchial epithelium.®' ' Another class of 
histamine receptors (H3) are located within the brain and are involved with the somnolence 
associated with allergic responses.® We report here our findings for H. sommis and other 
bacterial pathogens. This is the first report of histamine production by H. somnus. 
Materials and Methods 
Bacterial Strains and Culture. 
In the first experiment, ten H sommis and six Pasteurella multocida isolates were 
obtained from the Iowa State University Veterinary Diagnostic Laboratory. Blood agar plates 
were inoculated with each isolate and incubated at 37°C for either 48- (H. sommis) or 
24-hours (P. multocida) in 5% CO,. 
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Various bacterial cultures from the Center for Veterinary Biolo^cs-Laboratoiy stock 
collection were also evaluated as control cultures. Bacterial cultures tested included 
Actinobacilluspleuropneumoniae (serotype 7), Bordetella bronchiseptica (strain B-133), 
Escherichia coli (K88 ac), Erysipelothrix rhusiopathiae (E1-6P), H. somnus (156A), 
Leptospira interrogans serovars canicola (Moulton), grippotyphosa (Oregon shrew), 
icterohaemorrhagiae (CFl), and pomona (MLS), Salmonella dublin (APHIS NVSL #82), S. 
choleraesuis (APHIS NVSL #76), and S. typhimurium (APHIS NVSL #102). Blood agar 
plates were inoculated with stock cultures of each of the above bacteria and incubated for 24 
or 48 hours. Leptospiral serovars were obtained from serovar-infected hamsters and were 
grown in P80-BA liquid medium^" at 31 °C for 7 days in capneic air. 
In the second experiment, the ability of H. somnus to secrete histamine was 
investigated using two H. somrms strains (156A and 8025) and isolate 156A NI. Strain 156A 
and isolate 156A NI were evaluated in the first experiment. Nine milliliters of 
brain-heart-infusion (BHI) broth (supplemented with 10% bovine serum) were inoculated with 
stock cultures of either 8025, 156A, or 156A NI (9 tubes per strain). Tubes were incubated 
at 37°C in 5%, 15% or 25% CO2 in air (3 tubes each atmosphere) for a total of 120 h. Sterile 
gauze plugs were utilized to allow difiusion of carbon dioxide. Two BHI broths that were not 
inoculated were incubated with each set of cultures and served as negative controls. 
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Bacterial Harvest. 
Growth from plate cultures was harvested with 3-ml of phosphate buffered saline 
(0.015 M PBS, pH 7.2), standardized to an OD595 of0.300, and used in the histamine ELISA. 
Leptospiral serovars and each of three tubes of H. somms broth cultures from each 
atmospheric condition were harvested at 17-, 41-, 96-, and 120-h of incubation. Cultures 
were centrifuged at 13,000 x g for 30 minutes and the supematants saved for histamine 
analysis. Cell pellets were resuspended in 50 ml sterile phosphate buffered saline (pH 7.2, 
PBS), and centrifuged. This procedure was repeated for a total of three washes. Prior to the 
last centrifligation, H. sommts cell pellets were standardized to an optical density (OD) of 
0.300 at 595 nm using PBS. Leptospiral cell pellets were standardized to a nephalometer 
reading of 20. To check for contamination and purity, blood agar plates were inoculated with 
0.1 ml of the culture and incubated at 37°C or room temperature (22-25 °C) for 24 h. 
Histamine determination. 
Histamine concentrations of standardized bacterial cell suspensions and culture 
supematants were determined by a commercial ELISA (Immunotech, Marseille, France) 
according to manufacturers' instructions. Uninoculated broth and plates washed with PBS 
served as negative controls for broth and plate cultures, respectively. Each sample was 
assayed in triplicate. 
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Results 
Experiment 1. 
Histamine concentrations of ten H. somrms and six P. multocida isolates grown on 
blood agar plates are listed in Table 1. Histamine concentrations of the P. multocida isolates 
(range, 4.3-12 ng/ml) were lower than those o^H. somrms isolates (range, 18.5-200 ng/mi). 
All H. somrms isolates tested had detectable amounts of surface histamine: four of the ten 
isolates had histamine concentrations ranging from 100-200 ng/ml (isolates 99 0772, McN, 
2645, and 8813); two isolates had surface histamine concentrations of 57.5 and 80 ng/ml 
(isolates 156 A and 2355); and four isolates had histamine concentrations of less than 
50 ng/ml (isolates 156ANI, S618, DF618, and 2718). 
Twelve bacterial plate cultures from the Center for Veterinary Biologies-Laboratory 
were also evaluated for the presence of surface histamine. Those bacteria with the highest 
surface histamine concentrations -WQXQH. somrms (120 ng/ml), B. bronchiseptica 
0(105 ng/ml), E. rhusiopathiae (65 ng/ml), S. dublin and S. choleraesids (65 ng/ml), and S. 
typhiumurium (72 ng/ml). Actinobacilluspleuropneumoniae, E. coli, and Leptospira 
interrogans serovars canicola, grippotyphosa, icterohaemorrhagiae, and pomona had 
histamine concentrations of less than 1.0 ng/ml. 
Experiment 2. 
Histamine concentrations on washed, whole cells and in medium supematants of 
H. somrms cultures at 17-, 41-, 96-, and 120-h of incubation at varying CO2 concentrations 
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are shown in Table 2. Washed whole cells 8025, 156A, and 156A NI had maximal histamine 
concentrations after 120 h incubation of 160 ng/ml (15%C02), 180 ng/ml (5% COt ), and 
225 ng/ml (15% CO,), respectively. There was an initial drop in surface histamine at 41 h for 
strains 8025 (32 ng/ml; 5% CO,) and 156A (32 ng/ml; 15% CO2 ). Strain 156A NI had 
minimal concentrations (40 ng/ml) after 17 h incubation under a 25% CO, atmosphere. 
Strains 8025 and 156A NI had maximal histamine concentrations in the medium supematants 
after 41 h incubation under a 25% CO, atmosphere. Medium supernatant from strain 156A 
had maximal concentrations after 96 h incubation under a 15% atmosphere. 
Discussion 
An immediate hypersensitivity component has been demonstrated for various etiologic 
agents of bovine respiratory disease. Plasma IgE levels specific for P. hemolytica have been 
demonstrated in infected calves." We recently demonstrated H. 5omwM5-specific IgE in 
calves vaccinated with commercial H. somrms bacterins.^" Histamine is ubiquitously 
distributed in mammalian tissues and is well-known as a mediator of immediate (Type I) 
hypersensitivity.'^- Histamine, 5-imidazole-ethylamine, (MW =111 daltons) is an 
intercellular mediator exerting potent effects on various target tissues. It is produced by 
decarboxylation of histidine. Histanoine is also an important mediator in the central nervous 
system and gastric mucosa'® and may play other roles via H,, Hj, or Hj receptors in the 
central nervous system.'® 
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Although the histamine content of media in the present study is similar to those 
described by Sheinman et al/, our approach differs in two important respects. First, Sheinman 
et al. estimated histamine via HPLC, which he verified by guinea pig ileal bioassay, whereas a 
commercial histamine ELISA detection kit which utilized monoclonal antibodies was used in 
the present study. The ELISA test is based on competition between the histamine to be 
assayed and its enzyme conjugate, histamine-aUcaline phosphatase, used as a tracer for binding 
to antibody coated to wells of a microtitration plate. Because the monoamine histamine is too 
small to completely occupy the binding site on the antibody, high afiBnity monoclonal 
antibodies directed against acylated histamine are utilized in this assay. Therefore, all samples 
must be acylated prior to use. Amines other than histamine may also react with the acylation 
reagent; material containing an amine at a concentration in excess of 10 nM interferes with the 
acylation of histamine. Low histamine concentrations would be expected in the presence of 
amine concentrations in excess of 10 nM. In the present study, acylated uninoculated control 
growth medium failed to react in the histamine assay. This suggests that histamine 
concentrations reported in this study reflect histamine concentration and not excess amines. 
Secondly, Sheinman et al. compared the relationship of estimated histamine content in culture 
medium with bacterial growth. Although we did not determine bacterial growth, all cultures 
were standardized to an OD595 of 0.300. In contrast to the work of Sheinman and co­
workers, the present study evaluated the histamine concentration on whole cells and in culture 
supernatant. 
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Results of this study demonstrate the ability of H. somnus to synthesize histamine 
(Table 1). Histamine is present on washed cells as well as in culture supernatant (Table 2). 
With the exception of strain 8025, both incubation time and the percent of CO, appear to 
enhance histamine synthesis. Isolate 156A NI yielded the highest levels of histamine. This 
strain was obtained from a calf experimentally infected with H. somnus (strain 156 A) grown in 
a 15% CO2 atmosphere. Clinical signs of respiratory disease were present in this calf. 
However, when a stock culture of strain 156A was tested, lower levels of histamine were 
associated with whole cells and culture supernatant. At least two other isolates (McN and 99 
0772) had similar levels of cell-associated histamine (105 and 162.5 ng/ml, respectively) 
(Table 1). These two isolates were also obtained from cattle undergoing a natural outbreak of 
respiratory disease due to H. somnus. 
It may be hypothesized that one of the early events that occur in the pathogenesis of 
the pneumonic form of H. somnus infections is increased synthesis and secretion of histamine. 
This study suggests a novel mechanism regarding the role of H. somrms in bovine respiratory 
disease. Histamine on the surface of H. somnus could bind to histamine receptors located on 
endothelial cells resulting in vasoconstriction, stimulation of vagal afferent nerves and mucus 
glands, and increased permeability of bronchial epithelium. In the presence of a subclinical 
viral infection (e.g., bovine respiratory syncytial virus, parainfluenza virus) additional host 
histamine receptors could be exposed in the submucosa due to epithelial desquamation from 
viral infection. After colonization of the respiratory tract, enhanced histamine synthesis and 
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secretion may occur. The relatively high pCOj in bronchiolar air may enhance the synthesis of 
histamine. 
These data also have implications for development of novel bacterins against 
pneumonic forms of H. somrms infections. The results suggest that H. somrms organisms can 
synthesize and secrete high levels of histamine molecules into the growth medium. If whole 
culture, including growth medium supernatant, are utilized in the formulation of a bacterin, 
bacterial histamine is also injected during vaccination. This could partially explain some of the 
adverse reactions seen at the injection site. Development of mutant strains of H. somrms 
lacking histamine may help prevent many adverse vaccine reactions that occur in calves. 
Prevention of histamine receptor binding, while maintaining protective immunogenic antigens 
would be beneficial. This study suggests that the ability of H. somrms to synthesize histamine 
may contribute to the pathogenesis of bovine respiratory disease and that histamine may be 
present in killed H. somrms bacterins. These results also raise issues for regulatory officials as 
to the safety of veterinary biologies. 
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Table 1. Histamine content (ng/ml) of various isolates of H. somnus and P. multocida as well as 
various bacteria from the Center for Veterinar\' Biologies-Laboratory (CVB-L) challenge culture 
collection. All bacteria were grown on blood agar plates. Results are expressed as the mean of 
triplicate wells. 
Isolate 
Histamine 
(ng/mi) Isolate 
Histamine 
(ng/ml) 
H. somnus CVB-L Cultures 
2355 80 A. pleuropneumoniae (Serotype 7) 3.1 
99 0772 162.5 B, bronchiseptica (B 133) 105 
156ANI 45 E. coli (K88 ac) 3.6 
156A 57.5 £1 rhusiopathiae (E1-6P) 65 
McN 105 H. somnus (156A) 120 
S618 18.5 L. canicola (Mouiton) 1.2 
DF618 35 L. grippotyphosa (Oregon shrew) 0.29 
2645 182.5 L. icterohaemorrhagiae9C \^) 0.17 
2718 45 L. pomona (MLS) 0.21 
8813 200 S. choleraesuis (APfflS NVSL #76) 65 
S. dublin (APfflS NVSL #82) 65 
P. multocida S. typhimurium (APfflS NVSL #102) 72 
2100 12 
2192 7.5 
1581 9 
1662 6 
1059 6.5 
2225 4.3 
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Table 2. Histamine content (ng/ml) of whole cells and culture mediiun of three H. sommis 
strains sampled 17-, 41-, 96-, and I20-h of incubation under differing atmospheric conditions. 
Results are expressed as the mean of triplicate wells. 
Whole Cells Supernatant 
8025 156A 156A NI • 8025 156A 156A NI • 
Time [CO,l 
5% 80 85 60 21 5 139 
17 h 15% 98 80 75 21 5 135 
25% 49 45 40 18 8 1.480 
5% 32 95 55 133 93 923 
41 h 15% 68 32 42 296 456 L226 
25% 45 49 85 971 191 L721 
5% 45 115 90 130 80 425 
96 h 15% 78 85 130 173 488 693 
25% 48 65 165 293 248 993 
5% 68 180 110 103 73 228 
120 h 15% 160 175 " 225 217 232 397 
25% 58 112 150 240 85 625 
® Isolate obtained fix)m a calf experimentalh' infected with H. somnus strain 156 A. 
173 
CHAPTER 8. GENERAL DISCUSSION 
General Discussion 
Discussion of Research 
While the induction of respiratory allergy has not been extensively studied in cattle, it 
has received considerable attention in children and laboratory animals ^ *• Bovine 
respiratory disease continues to be a major disease problem in all types of cattle operations 
Although there are vaccines against many of the etiological agents, Haemophilus somnus 
bacterins have not always provided adequate protection against the pneumonic manifestation 
due to infection with this organism. Anecdotal evidence suggests that occasionally more 
severe clinical disease occurs in calves vaccinated with H. somnus bacterins either alone or in 
combination with various viral vaccines. The possibility of disease enhancement by bacterins 
and vaccines or their synergistic effect must be evaluated. 
The purpose of the first two sets of experiments was to establish a positive control for 
bovine anaphylaxis. To this end, we first sensitized a small number of Holstein calves to 
Micropolyspora faeni and washed, live H. somnus organisms. Results of this study suggested 
that many Iowa calves may have pre-existing IgE and IgG antibody titers against M faeni. 
This is not suprizing given the high humidity climate in Iowa. The presence of anti-M faeni 
IgE antibodies may be a contributing factor in many of the respiratory distress seen in young 
calves. However, as these calves mature levels of anti-M faeni IgG antibodies increase, 
eflFectively desensitizing these animals to the effects ofM faeni antigen. 
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Young calves may have pre-exisiting anti-H. somnus IgE antibody. In the &st 
preliminary study, non-sensitized calves responded with tachypnea which lasted for 2 days 
after challenge with washed, live H. somnus organisms. In the second preliminanry study, a 
non-sensitized calf exhibited similar clinical signs of anaphylaxis following challenge with 
washed, live H. somnus organisms. These results should be not considered to be unusual 
since H. somnus is a normal commenssal of the nasopharyngeal area of cattle " . 
Aluminum-based adjuvnats are very eflBcient inducers of IgE antibody synthesis 
More severe clinical anaphylaxis was observed in a calf sensitized with ovalbumin 
suspended in aluminum hydroxide than the calf sensitized with ovalbumin alone. Similarly, H. 
somnus bacterins (adjuvanted with 20% aluminum hydroxide) vaccinated calves produced a 
more severe anaphylaxis than calves in the first preliminary study that were sensitized with H. 
somnus organisms alone. Generally, sensitization requires a chronic exposure to low levels of 
antigen. However, if the initial dose of antigen is extremely large or if the antigen persists in 
the body (as occurs with vaccination), hypersensitivity reactions may occur on first exposure 
to antigen'®. Since one purpose of adjuvants is to serve as a depot of antigen for chronic 
stimulation of the immune response, results of these preliminary studies support this 
hypothesis. 
One hallmark of allergic responses is the production of IgE type antibody. The third 
study extended our preliminary results and demonstrated that four licensed, monovalent, 
commercially available H. somnus bacterins can induce an IgE response. Each of the four 
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bacterins induced H. somnus-sp&a&c IgE that reacted with at least 7 antigens that were 
recognized by pooled sera obtained from cattle undergoing a natural respiratory disease due to 
H. somnus infection. This anti-H. somnus IgE antibody was detectable as early as the day of 
the booster injection (14 days after the primary injection) and as late as 45 days after the 
primary injection. This study also strongly suggests that H. somnus-spQciO^c IgE antibodies 
can be found in serum of some cattle, possibly induced by existing or previous sensitization. 
There is gradually accumulating evidence that bacterial infection can lead to specific IgE 
responses that may contribute to immediate hypersensitivity. Agents such as Bordetella 
pertussis, Pasteurella hemolytica, Escherichia coli. Salmonella enteritidis. Staphylococcus 
aeureus. Streptococcus spp.. Brucella abortus, Borrelia burgdorferi, zxid. Neisseria 
flavescens have been shown to induce IgE responses ~ . Bordetella pertussis and 
Neisseria flavescens have been associated with respiratory allergy The presence of IgE 
antibody specific for bacterial antigens has been reported in sera of human patients with 
various respiratory tract disease, especially those in which a chronic host-bacterium 
association exits Significant concentrations of IgE specific for Haemophilus 
influenzae were found in sera of human patients with chronic bronchitis High serum 
concentrations of bacteria-specific IgE were found in 97% of human patients with nasal 
polyps. Ubiquitous organisms, such as Proteus mirabilis, were the most frequently involved 
bacteria ". Children with cystic fibrosis were found to have serum IgE specific for 
Pseudomonas aeruginosa 
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Arachidonic acid metabolites (eicosanoids) have been implicated as regulators of 
bronchoconstriction and bronchodilation Viruses are recognized for their role in 
aflfecting IgE immunoregulation In children measles virus, rhinoviruses, influenza 
virus as well as peiramyxoviruses have been associated with asthmatic attacks Viral 
infections can predispose to development of an allergic state and can exacerbate the clinical 
response to other antigens. Therefore, establishment of a type-1 hypersensitivity to one 
allergen predisposes to induction of allergy to other agents. 
The fourth and fifth papers of my research investigated the effect of viral vaccination 
in the face of an existing hypersensitivity. Each of the four commercial H. sommis bacterins 
induced the production of eicosanoids associated with bronchoconstriction and edema 
formation. These increases were detected as early as the day of the booster injection (14 days 
after the primary injection). Together, these studies demonstrate that vaccination with 
H. sommis bacterins and BRSV (MLV) vaccines may adversely affect calves by enhancing 
higher concentrations of eicosanoids associated with development of a hypersensitized state 
and a late phase asthmatic-like bronchoconstriction. 
Haemophilus sommis may also participate in type-1 hypersensitiity reactions by 
producing virulence factors that contribute to the disease process. My research has 
demonstrated the ability of H. sommis to produce and release histamine in vitro into the 
surrounding envimment. Production of histamine by H. sommis in vitro may be influenced by 
CO2 concentration, length of incubation and strain differences. Greater production of 
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histamine by H. somnus may provide a survival advantage to the bacterium in the respiratory 
sub-mucosa where the partial pressure of CO, would be lower. The ability of H. somnus to 
produce histamine may also be a factor in the development of an IgE response. Kimata et al.^^ 
have demonstrated that histamine enhances IgE and IgG4 production by increasing 
endogenous interleuldn (IL)- 6 and EL-10 production via histamine Hj and H3 receptors, 
respectively. In a study of pathogenic and nonpathogenic respiratory bacterial species, 
Branhamella catarrhalis, Haemophilus parcdnfluenzae, Haemophilus influenzae, and 
Pseudomonas aeruginosa produced clinically important concentrations of histamine 
A Mechanism of Vaccine-Enhanced Disease 
This research strongly indicate vaccine-enhancement of bovine respiratory disease 
which involve a type-1 hypersensitivity component. Not only can individual biologicals induce 
a hypersensitivity but synergy can occur between bacterial and viral biologicals and be 
contributory to the disease process. The immune response is tipped in favor of an 
exaggerated humoral response (hypersensitive state) that is most likely ongoing at the time of 
vaccination. Therefore, it is desirable to develop H. somnus bacterins and BRSV vaccines 
that produce more of a Thj response as opposed to a Thj response. 
Based on this research, a novel mechanism of disease enhancement may be postulated. 
Concurrent viral infections, particularly BRSV, increase the susceptibility of cattle to 
H. somnus infection. Apparently healthy nonvaccinated young calves develop IgE antibody 
against H. somnus and BRSV due to chronic exposure to low levels of these agents. These 
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IgE antibodies bind to Fc receptors on immune cells, including basophils, mast cells, and 
eosinophils. Various cytokines and chemokines are also generated during this response, most 
notably IL-4 which stimulates the production of IgE antibodies. Thus, under normal 
conditions, calves are already sensitized to H. somrtus and BRSV antigens prior to 
vaccination. 
At the time of the vaccination with either H. somrtus or BRSV biologicals, the animal 
is most likely sensitized to these agents. Thus, vaccination serves as a catalyst to the 
sensitization process. Introduction of formalin-killed H. somrtus organisms suspended in 
aluminum hydroxide has the effect of enhancing anti-//. somrtus IgE antibody and eicosanoid 
production as well as providing an exogenous source of histamine. In the presence of IL-4, 
the aluminimi hydroxide adjuvant will stimulate enhnaced PGE, production resulting in the 
synthesis of more IgE antibody. 
Should the animal become infected with BRSV or H. sommts subsequent to 
vaccination, a more rapid response is likely to occur. During BRSV infection, cell damage 
and desquamation of respiratory epithelium occurs. Arachidonic acid, released from damaged 
cells, is metabolized by immune and non-immune cell types to generate eicosanoids which 
contribute or enhance the inflammation and cellular infiltration. Depending on the degree of 
epithelial desquamation, bronchial hyperreactivity may also occur. Infection with BRSV 
predisposes the animal to infection by H. somrms. Production of histamine by H. somrtus 
further enhances production of IgE antibodies and binds to histamine Hi and H, receptors 
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located on lymphocytes and bronchial smooth muscle. Clinical signs of respiratory distress are 
now evident. Without intervention, further insult and injury may result in death. Some 
animals may recover. 
The end result of H. somnus and BRSV vaccination of sensitized cattle is uncontrolled 
IgE production, production of eicosanoids associated with bronchoconstriction, edema 
formation, chemotaxis, and introduction of exogenous histaine to fuel the production of IgE 
antibody. Vaccination with modified live virus vaccines (especially BRSV) can compound this 
response further. 
Impact of Research Results 
This research has made a significant contribution toward understanding the role of 
H. somrms and type-1 hypersensitivity in bovine respiratory disease. Implications of this 
research have a broad impact on the veterinary biologies industry and the United States 
Department of Agriculture officials who regulate that industry. This research demonstrated 
vaccination with H. somnus and BRSV biologicals may result in induction of a sensitized state 
in cattle which may result in an increase in adverse hypersensitive events. Similar data has 
been generated for dogs by Frick ^ and Patterson ; no current data has been generated to 
evaluate this possibility in other host species. Therefore, better assessment of the safety of 
veterinary biologicals is needed in terms of their ability to induce a sensitized state and in 
evaluating the role of histamine in biologicals as it relates to adverse reactions. 
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The Center for Veterinary Biologies is charged with enforcing the Virus-Serum-Toxin 
Act. The purpose of this Act is to ensure that all veterinary biologicals are pure, safe, potent, 
and effective. Safety testing is required of all veterinary biologicals for partial fulfillment of 
licensure. Depending on the biologic, testing may be performed in the target host animal or in 
laboratory animal models. In these tests, animals are vaccinated with a specified volume of 
the biologic. Animals are then observed for a defined period of time, fi^equently 7-21 days, for 
adverse events that may be associated with the biologic. The safety test guidelines, however, 
are not designed to detect induction of hypersensitive states. Further evaluation of the ability 
of biologies to induce hypersensitive states and the consequences of that induction would 
provide data critical for regulatory agencies to evaluate the appropriate safety testing for such 
products. 
Additional studies should be undertaken to address concerns prior to consideration of 
additional Federal regulations. For example, what is an acceptable level of histamine 
concentration in biologicals? This research has demonstrated the ability of H. sommis to 
produce and secrete/release histamine into the surrounding environment. Bordetella 
bronchiseptica, Erysipelothrix rhusiopathiae. Salmonella choleraesitis, S. dublin, and 
S. typhimurium were also demonstrated to produce histamine. Most veterinary biologies 
(including H. somnus) are formulated with inactivated broth culture. Selective stimulation of 
bacterial L-histidine decarboxylase in response to available nutrients or pH in the surrounding 
medium may be a critical factor. Therefore, acceptable levels of histamine may be an 
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important factor for these biologies. 
What are the critical factors associated with IgE production following vaccination with 
specific biological products? Histamine has been shown to preferentially stimulate IgE 
production in mice . Development of genetically-engineered bacteria lacking the ability to 
produce histamine via deletion or modification of the bacterial L-histidine decarboxylase 
enzyme may be beneficial to elucidate the role of histamine in the induction of hypersensitive 
states. Presence of lipopolysaccharides or endotoxin may upregulate the expression of CD28, 
B7, CD40 and CD40L on host immune cells, and may be associated with production of IgE 
antibody. Use of adjuvants other than aluminum hydroxide may alleviate many of the 
undesirable IgE responses in these biologicals. Finally, relative percentages of T-suppressor 
cells and mature B-cells may be a critical factor in the development of a sensitized state. A 
low percentage of T-suppressor cells or a high percentage of B-cells at the time of vaccination 
may allow for uncontrolled IgE production. Therefore, the timing, route, and 
immunocompetent state of the vaccinate may be important. 
Despite many unanswered questions, regulatory ofiicals are not precluded fi-om being 
proactive. A working group could be established for the purpose of developing protocols to 
address the sensitizing capability of various veterinary biologicals in cattle, and subsequently 
in swine, dogs, and cats. Questions that could be addressed include validity of additional 
regulations on efficacy, safety testing, and possibly duration of immunity studies. Should 
vaccinated animals be challenged with the same disease agent(s) used in the formulation of the 
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biologic and, if so, when? What parameters of type-1 hypersensitivity should be monitored 
(i.e., agent-specific IgE vs IgG, plasma histamine and various eicosanoids, difierential white 
blood cell counts)? Does the use of a particular adjuvant enhance or minimize the 
development of a sensitized state? Does timing and route of vaccination make a difference? 
This data would provide a sound basis for development of regulations regarding the ability of 
veterinary biologicals to induce a sensitized state in the target host animal. 
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